---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description. Covers Product description and Place of product in therapy. 403 evidence topics quoted from 175 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; NDA submitted in the third quarter of 2026

> “During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program.”
> “Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

> “In the third quarter of 2026, the Company completed the darovasertib mUM new drug application (“NDA”) submission to the FDA.”
> “Under the license agreement with Novartis, the Company paid a $2.0 million milestone payment.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “NDA filing completed in Q3’26”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Commercial preparation for a potential U.S. launch

> “We presented the positive topline results at ASCO from our registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic uveal melanoma while continuing to advance our NDA submission and pre-commercial activities to support a possible commercial launch.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “General and administrative expenses increased by $23.7 million, or 53%, during the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 primarily due to increases of $15.2 million in personnel-related expenses, including salaries, benefits and stock-based compensation, $4.8 million in commercial preparation activities for darovasertib, $3.1 million in audit, tax, consulting and other external services for continued company growth, and $0.6 million in legal expenses, including contracting and patent support.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “Darovasertib commercial readiness activities advancing in the United States and globally with their partner, Servier”

Source: [IDEAYA Biosciences press release, 2026 corporate objectives (2026)](https://media.ideayabio.com/2026-01-11-IDEAYA-Biosciences-Provides-a-Business-Update-and-Outlines-2026-Corporate-Objectives-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference)

<a id="topic-2.1.1-4"></a>

##### Investigational status

> “Darovasertib is an investigational product and has not been approved by the FDA or any other regulatory authority.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

> “To date, none of the Company’s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-5"></a>

##### FDA agreement to review the NDA under the Real-Time Oncology Review program

> “In April 2026, IDEAYA announced the U.S. Food and Drug Administration (FDA) has agreed to review their new drug application (NDA) for darovasertib in combination with crizotinib under the Oncology Center of Excellence Real-time Oncology Review (RTOR) program.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “The RTOR program is designed to enable a more efficient NDA submission and review process to make safe and effective treatments available to patients as early as possible.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-6"></a>

##### FDA acceptance, priority review, and action date

No evidence found.

<a id="topic-2.1.1-7"></a>

##### Accelerated approval on progression-free survival with overall survival for full approval

> “Based on our discussions with the U.S. Food and Drug Administration (FDA), the PFS data from OptimUM-02 may enable an accelerated approval filing in the United States.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Overall survival data, when available, will be used to support a potential full approval in the United States and globally.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “IDEAYA plans to provide an update on the OS data as part of the pre-specified interim analysis expected in mid-2027.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.1.1-8"></a>

##### FDA orphan drug designation for uveal melanoma, April 2022

| Field | Quoted record |
| --- | --- |
| Generic name | “darovasertib” |
| Date designated | “04/27/2022” |
| Orphan designation | “Treatment of Uveal Melanoma” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “IDEAYA Biosciences Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=873322)

> “In April 2022, the FDA designated darovasertib as an Orphan Drug in UM, including primary and metastatic disease.”
> “If approved for one or more designated indications, darovasertib may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-9"></a>

##### Fast Track designation for darovasertib with crizotinib in metastatic uveal melanoma, November 2022

> “In November 2022, the FDA granted Fast Track designation to our development program investigating darovasertib in combination with crizotinib in adult patients being treated for mUM.”
> “The Fast Track designation makes our darovasertib and crizotinib development program eligible for various expedited regulatory review processes, including generally more frequent FDA interactions, such as meetings and written communications, potential eligibility for rolling review and priority review of an NDA.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IDEAYA's development program investigating darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor, for the treatment of adult patients with metastatic uveal melanoma.”

Source: [IDEAYA Biosciences press release, Fast Track designation (2022)](https://media.ideayabio.com/2022-12-05-IDEAYA-Biosciences-Receives-Fast-Track-Designation-for-Darovasertib-Combination-Therapy-with-Crizotinib-for-the-Treatment-of-Metastatic-Uveal-Melanoma)

<a id="topic-2.1.1-10"></a>

##### Breakthrough Therapy designation for neoadjuvant monotherapy in primary uveal melanoma, March 2025

> “In March 2025, the FDA granted Breakthrough Therapy designation (BTD) for darovasertib as a neoadjuvant treatment of adult patients with primary UM for whom enucleation has been recommended.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-11"></a>

##### FDA designations as summarized by the company, October 2026

> “The U.S. Food and Drug Administration (FDA) has also granted darovasertib Fast Track designation for the treatment of metastatic uveal melanoma, Orphan Drug designation in primary uveal melanoma and Breakthrough Therapy Designation as a neoadjuvant therapy for patients with primary uveal melanoma for whom enucleation has been recommended.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-2.1.1-12"></a>

##### European Union orphan designation for uveal melanoma, August 2025

> “This medicine was designated as an orphan medicine for the treatment of uveal melanoma in the European Union on 22 August 2025.”
> “The sponsorship was transferred to Les Laboratoires Servier.”

Source: [EMA orphan designation EU/3/25/3122 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3122)

<a id="topic-2.1.1-13"></a>

##### Origin at Novartis and the 2018 license to IDEAYA

> “Herein, we describe the discovery of darovasertib (NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity.”
> “LXS196 is being investigated in the clinic as a monotherapy and in combination with other agents for the treatment of uveal melanoma (UM), including primary UM and metastatic uveal melanoma (MUM).”

Source: [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)

> “In September 2018, the Company entered into a License Agreement with Novartis to develop and commercialize Novartis’ LXS196 (also known as IDE196), a Phase 1 protein kinase C (“PKC”) inhibitor, for the treatment of cancers with GNAQ and GNA11 mutations.”
> “Under the license agreement, Novartis granted to the Company a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively referred to as the licensed products, for any purpose.”
> “The Company paid Novartis an upfront payment of $2.5 million and issued 263,615 shares of its Series B redeemable convertible preferred stock concurrently with the execution of the license agreement.”
> “The Company will also pay mid to high single-digit tiered royalty payments based on annual worldwide net sales of licensed products”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-14"></a>

##### Servier license for rights outside the United States, August 2025

> “On August 29, 2025, IDEAYA Biosciences, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Les Laboratoires Servier (“Servier”) pursuant to which the Company granted to Servier an exclusive license under certain intellectual property rights controlled by the Company relating to darovasertib to develop and commercialize products in all countries worldwide except for the United States for all diagnostic, prophylactic and therapeutic uses in humans.”
> “Pursuant to the Agreement, Servier has agreed to provide the Company an upfront payment of $210 million.”
> “The Company is also eligible to receive development and regulatory milestone payments of up to an aggregate of $100 million, commercial milestone payments of up to an aggregate of $220 million, clinical trial cost sharing and clinical trial cost reimbursement, and royalties on net sales of products outside of the United States ranging from mid-teens to low-twenties percentages.”

Source: [IDEAYA Biosciences Form 8-K, Servier license agreement (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/d800731d8k.htm)

> “Servier will be responsible for the regulatory and commercial activities for darovasertib outside the United States.”
> “The Company and Servier will collaborate on the development of darovasertib and share the associated costs.”
> “The Company retains all rights to darovasertib in the United States.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.1-15"></a>

##### Patent protection for darovasertib

> “These solely owned or in-licensed patent applications, if granted, would expire between 2035 and 2045, without taking into account any applicable patent term adjustments or extensions.”
> “In addition, the PKC program portfolio includes two U.S. patent application, which are jointly owned with Pfizer directed to methods of treatment for certain combination treatments.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-16"></a>

##### Adjuvant setting: OptimUM-11 phase 3 trial of darovasertib with crizotinib, first participant dosed in September 2026

> “today announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary uveal melanoma who have completed local therapy and have an increased risk of developing metastatic disease.”
> “Patients will be eligible irrespective of HLA status and will be randomized 1:1 to receive darovasertib in combination with crizotinib for 12 months or observation.”
> “The primary endpoint of the trial is relapse-free survival.”
> “The companies will share the associated development costs of the trial.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

<a id="topic-2.1.1-17"></a>

##### Neoadjuvant setting: closure of the OptimUM-10 phase 3 trial

> “Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial.”
> “This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892.”
> “IDEAYA is committed to enabling patient access to neoadjuvant darovasertib and plans to submit published data from OptimUM-09 to support potential inclusion in clinical practice guidelines.”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

<a id="topic-2.1.1-18"></a>

##### Cash, cash runway, and financing

> “$1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

> “As of September 30, 2026, we had an accumulated deficit of $1,073.3 million.”
> “Based on our current business plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least the next 12 months from the issuance date of this Quarterly Report on Form 10-Q.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “In June, IDEAYA successfully completed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock, inclusive of the underwriters' full exercise of their option to purchase additional shares in the offering.”
> “Net proceeds from the offering were approximately $323.4 million, after deducting underwriting discounts, commissions and other expenses.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.1.1-19"></a>

##### OptimUM-02 topline results reported in April 2026

> “On April 13th, IDEAYA reported positive topline data from the Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib in 1L HLA*A2-negative mUM.”

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program)

<a id="topic-2.1.1-20"></a>

##### NDA submission in progress with completion expected in the second half of 2026, September and October 2026, superseded in November 2026

> “IDEAYA has initiated submission of a new drug application (NDA) for darovasertib in combination with crizotinib for patients with first line metastatic uveal melanoma (mUM) under the oncology center of excellence (OCE) real-time oncology review (RTOR) program and expects to complete the NDA submission in the second half of 2026.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

> “IDEAYA is submitting a new drug application (NDA) for darovasertib in combination with crizotinib for patients with first line metastatic uveal melanoma under the oncology center of excellence (OCE) real-time oncology review (RTOR) program and expects to complete the NDA submission in the second half of 2026.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-2.1.1-21"></a>

##### Rolling NDA submission under RTOR with completion expected in the second half of 2026, April to August 2026, superseded in November 2026

> “IDEAYA plans to initiate the RTOR submission process with the first pre-submission targeted for May, with completion of the NDA filing expected in the second half of 2026.”

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program)

> “IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2 2026”

Source: [IDEAYA Biosciences press release, first quarter 2026 results (2026)](https://media.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “IDEAYA completed its first pre-submission in May and expects to complete the NDA filing in the second half of 2026.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.1.1-22"></a>

##### NDA submission planned for the second half of 2026, April 2026, superseded in November 2026

> “NDA submission planned for H2'26 to support U.S. accelerated approval filing.”
> “Based on these data, the company will target to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-2.1.1-23"></a>

##### OptimUM-02 topline results expected in the first quarter of 2026, January to March 2026, superseded in April 2026

> “Topline results, including progression free survival (PFS) data, from ongoing registrational Phase 2/3 OptimUM-02 trial of the darovasertib and crizotinib combination in first line (1L) patients with HLA*A2-negative metastatic UM (mUM) are expected in Q1 '26”

Source: [IDEAYA Biosciences press release, 2026 corporate objectives (2026)](https://media.ideayabio.com/2026-01-11-IDEAYA-Biosciences-Provides-a-Business-Update-and-Outlines-2026-Corporate-Objectives-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference)

> “Topline results, including progression free survival (PFS) data, from ongoing registrational Phase 2/3 OptimUM-02 trial of the darovasertib and crizotinib combination in first line (1L) patients with HLA*A2-negative metastatic UM are expected by approximately the last week of March, pending completion of ongoing data collection, cleaning and analysis.”
> “Topline PFS results, if positive, are anticipated to enable a potential accelerated approval filing in the United States.”

Source: [IDEAYA Biosciences press release, fourth quarter and full year 2025 results (2026)](https://media.ideayabio.com/2026-02-17-IDEAYA-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update)

> “We expect to report topline data, including progression free survival (PFS) data, from this trial in the first quarter of 2026.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Updated Topline Results Guidance: The database lock is projected in the first half of April, followed by the topline data analysis thereafter”

Source: [IDEAYA Biosciences press release, updated OptimUM-02 topline guidance (2026)](https://media.ideayabio.com/2026-03-22-IDEAYA-Biosciences-Upcoming-Investor-Relations-Events-and-Updated-Darovasertib-Topline-Results-Guidance-from-Phase-2-3-OptimUM-02-Trial)

<a id="topic-2.1.1-24"></a>

##### Adjuvant setting: OptimUM-11 initiation planned for the first half of 2026 with a placebo comparator, February 2026, superseded in September 2026

> “We plan to initiate a global Phase 3 combination trial (OptimUM-11) of darovasertib and crizotinib in the adjuvant setting of primary UM in the first half of 2026.”
> “The trial is expected to enroll approximately 450 patients with high to medium-high risk of metastasis, randomized 1:1 to the combination of darovasertib and crizotinib or placebo.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.1-25"></a>

##### Neoadjuvant setting: OptimUM-10 enrollment planned for completion in 2027, February and May 2026, superseded in November 2026

> “In 2025, we initiated a randomized Phase 3 trial of darovasertib in the neoadjuvant setting (OptimUM-10), which will enroll approximately 450 patients across two cohorts of plaque brachytherapy-eligible (PB) and enucleation-eligible (EN) patients.”
> “We plan to complete enrollment in this trial by the first half of 2027.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Full enrollment in the trial is estimated to be complete by the end of 2027, revised from prior guidance of first half of 2027.”

Source: [IDEAYA Biosciences press release, first quarter 2026 results (2026)](https://media.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: IDEAYA Biosciences

> “IDEAYA retains regulatory and commercial rights to darovasertib in the United States, while Servier holds all such rights outside the United States.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

> “The Company owns or controls all commercial rights in its darovasertib program in UM in the United States, including in mUM and in primary UM, subject to certain economic obligations pursuant to its exclusive, worldwide license to darovasertib with Novartis.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name and development codes

> “The Company renamed Novartis’ LXS196 oncology asset as IDE196, which has a non-proprietary name of darovasertib.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

| Substance record field | Quoted record |
| --- | --- |
| Preferred substance name | “DAROVASERTIB” |
| United States Adopted Name | “DAROVASERTIB [USAN]” |
| International Nonproprietary Name | “darovasertib [INN]” |
| WHO Drug Dictionary name | “Darovasertib [WHO-DD]” |
| Development code synonyms | “IDE196”; “LXS196”; “NVP-LXS-196” |
| Molecular formula | “C22H23F3N8O” |

Source: [FDA UNII record E0YF0M8O09](https://precision.fda.gov/uniisearch/srs/unii/E0YF0M8O09)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class of darovasertib as described by the company

> “Darovasertib is an oral, potent and selective small molecule inhibitor of protein kinase C and our most advanced clinical program.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “Darovasertib is a potential first-in-class oral, small-molecule inhibitor of PKC.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

<a id="topic-2.1.2.1-4"></a>

###### Brand name of darovasertib

No evidence found.

<a id="topic-2.1.2.1-5"></a>

###### Combination partner: crizotinib (XALKORI), a kinase inhibitor marketed by Pfizer

> “XALKORI® (crizotinib) capsules, for oral use”
> “XALKORI® (crizotinib) oral pellets”
> “Initial U.S. Approval: 2011”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational darovasertib tablet and crizotinib capsule in the OptimUM-02 trial

| Product | Pharmaceutical form | Route | Maximum daily dose (mg) |
| --- | --- | --- | --- |
| Darovasertib | “IDE196 (LXS196)”; “TABLET” | “ORAL” | “600” |
| Crizotinib | “Crizotinib 200mg hard capsules”; “CAPSULE, HARD” | “ORAL” | “400” |

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.2-2"></a>

###### Earlier darovasertib powder-in-capsule formulation in the OptimUM-01 trial

> “For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib, allergy to mammalian meat products and gelatin”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-2.1.2.2-3"></a>

###### Darovasertib tablet strengths and commercial formulation

No evidence found.

<a id="topic-2.1.2.2-4"></a>

###### Crizotinib (XALKORI) dosage forms and strengths

> “Capsules: 200 mg, 250 mg”
> “Oral pellets: 20 mg, 50 mg, 150 mg”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.2-5"></a>

###### Crizotinib (XALKORI) capsule composition, including gelatin shells

> “XALKORI (crizotinib) capsules for oral administration are supplied as printed hard-shell capsules containing 250 mg or 200 mg of crizotinib together with colloidal silicon dioxide, microcrystalline cellulose, anhydrous dibasic calcium phosphate, sodium starch glycolate, magnesium stearate, and hard gelatin capsule shells as inactive ingredients.”
> “The pink opaque capsule shell components contain gelatin, titanium dioxide, and red iron oxide.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS patient medication information class of crizotinib

> “Crizotinib is in a class of medications called kinase inhibitors.”
> “AHFS® Patient Medication Information™. © Copyright, 2026.”

Source: [MedlinePlus crizotinib drug information (2022)](https://medlineplus.gov/druginfo/meds/a612018.html)

<a id="topic-2.1.2.4-2"></a>

###### Crizotinib established class in the prescribing information

> “Crizotinib is a kinase inhibitor.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.4-3"></a>

###### WHO Anatomical Therapeutic Chemical classification of crizotinib

| ATC code | Name | Defined daily dose | Unit | Route |
| --- | --- | --- | --- | --- |
| “L01ED01” | “crizotinib” | “0.5” | “g” | “O” |

Source: [WHO Collaborating Centre ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L01ED01)

> “L01ED Anaplastic lymphoma kinase (ALK) inhibitors”
> “Substances which are multi-targeted, but where ALK is considered the main target, are classified in this group.”

Source: [WHO Collaborating Centre ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L01ED01)

<a id="topic-2.1.2.4-4"></a>

###### NCI Drug Dictionary classification of darovasertib

> “An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities.”

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/darovasertib)

<a id="topic-2.1.2.4-5"></a>

###### AHFS and ATC classification of darovasertib

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Population of the NDA under Real-Time Oncology Review

> “today announced that the U.S. Food and Drug Administration (FDA) has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib (darovasertib combination) for patients with first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM) under the Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.”

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program)

<a id="topic-2.1.2.5-2"></a>

###### Indication pursued in the pivotal trial as described by the company

> “We are evaluating darovasertib in combination with crizotinib, Pfizer’s oral c-MET inhibitor (the darovasertib combination), in a potentially registration-enabling, Phase 2/3 trial (OptimUM-02) in patients with first line, human leukocyte antigen-A*02:01 negative (HLA*A2(-)) mUM.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.2.5-3"></a>

###### HLA-A∗02:01-positive OptimUM-01 data included in the NDA to support a broader labeled indication

> “Data from OptimUM-01 will be included as part of IDEAYA's NDA submission to the U.S. Food and Drug Administration (FDA) to support regulatory discussions that have the potential to expand the labeled indication of the darovasertib combination.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “NDA submitted, including data from OptimUM-02 + OptimUM-01”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

> “Data may support a potential future submission to the U.S. Food and Drug Administration (FDA) to expand the labeled use of darovasertib and/or a national comprehensive cancer network (NCCN)/compendia listing to enable use of the combination in these patients.”

Source: [IDEAYA Biosciences press release, fourth quarter and full year 2025 results (2026)](https://media.ideayabio.com/2026-02-17-IDEAYA-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update)

<a id="topic-2.1.2.5-4"></a>

###### Crizotinib (XALKORI) FDA-approved indications

> “XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test”
> “XALKORI is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.”
> “XALKORI is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Protein kinase C signaling downstream of mutant GNAQ and GNA11

> “A key downstream player of the constitutively active G-protein alpha subunits (GNAQ or GNA11) is the phospholipase C/protein kinase C (PKC) signalling pathway.”
> “PKC signalling is a key node in the maintenance of cellular homoeostasis; in UM cells, it results in phosphorylation and increased transcript expression of RasGrp3, a guanine nucleotide exchange factor that transduces signalling from GNAQ/GNA11 to the MAPK signalling pathway through PKC delta”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

> “One of the key downstream targets of the constitutively active Gq alpha subunits is the protein kinase C (PKC) signaling pathway.”

Source: [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)

> “We are developing darovasertib for uveal melanoma (UM), a rare, aggressive form of ocular cancer in which approximately 95% of patients harbor activating mutations in GNAQ/11 GTPase proteins that drive downstream PKC signaling and tumor cell growth.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Darovasertib: oral, selective inhibitor of classical and novel PKC isoforms

> “Darovasertib (previously known as IDE196 and LXS196) is an oral, potent, selective inhibitor of the classical (α, β) and novel (δ, ε, η, θ) PKC isoforms”
> “Consistent with its selective targeting of PKC, darovasertib potently inhibits the growth of UM cell lines containing mutant GNAQ or GNA11”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Our most advanced product candidate, darovasertib, is an oral, potent and selective PKC inhibitor currently in multiple clinical trials in both the metastatic and pre-metastatic settings of UM.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Darovasertib is an oral, selective inhibitor of PKC, the key oncogenic driver in >95% of patients”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.2.6.1-3"></a>

###### Second-generation PKC inhibitor with activity restricted to GNAQ- or GNA11-mutant uveal melanoma cell lines

> “LXS196 is a potent, second-generation, oral PKC inhibitor designed with improved pharmaceutical properties compared with AEB071.”
> “LXS196 has a highly selective kinase profile affording increased tolerability in preclinical studies, with cellular activity restricted to UM cell lines containing mutant GNAQ or GNA11 and no activity observed in skin-derived melanoma cell lines driven by mutant B-Raf or N-Ras”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.1-4"></a>

###### Rationale for combined PKC and MET inhibition: hepatocyte growth factor in the liver and MET overexpression

> “MET overexpression and resultant pathway activation has been associated with UM tumor metastasis and correlates with poor disease prognosis.”
> “Of relevance, overexpression of MET is observed in approximately 60%-86% of cases of mUM”
> “In preclinical studies, combined inhibition of PKC and c-MET resulted in greater antitumor activity than inhibition of either pathway alone”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “The liver microenvironment has high levels of HGF, and high MET receptor expression in UM is associated with metastatic progression.”
> “In order to identify combination partners for IDE196, we hypothesized that the rich growth factor microenvironment in the liver may prevent MUM tumor cells from responding to IDE196 and that a combination of IDE196 with a MET inhibitor may synergistically inhibit tumor cell proliferation.”

Source: [Wagle et al. (2021)](https://aacrjournals.org/cancerres/article/81/13_Supplement/1343/667196/Abstract-1343-Preclinical-evaluation-of-a-PKC-and)

> “In the adjuvant setting and in metastatic UM (mUM), darovasertib is combined with crizotinib, an oral inhibitor of the cMET pathway, which is believed to play a central role in metastatic spread”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.2.6.1-5"></a>

###### Crizotinib label: inhibition of ALK, c-Met, ROS1, and RON receptor tyrosine kinases

> “Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON).”
> “Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Reduction of pMARCKS and pPKC delta in tumor biopsies and peripheral blood mononuclear cells in the first-in-human study

> “LXS196 reduced pMARCKS and phosphorylated PKC delta (pPKC delta), suggesting target engagement in on-treatment tumour biopsies.”
> “Reduction in pPKC delta in PBMCs was observed within 6 h post-dose at all dose levels (Fig. 2a, b).”
> “The mean (range) reduction in percentage change from baseline to C1D15 (normalised ratio) for pPKC delta and pMARCKS was −68.1 (−91.4, −28.6) and −39.7 (−89.7, 199), respectively.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-2"></a>

###### No association between the extent of pMARCKS or pPKC delta suppression and dose group in the first-in-human study

> “A decrease in pMARCKS/MARCKS was observed by C1D15 in patient tumour samples; however, no clear associations were detected between the extent of pMARCKS suppression and LXS196 treatment group.”
> “Consistent with this, a decrease in pPKCd was observed by C1D15, but no correlation was seen between the extent of suppression and the LXS196 treatment group.”
> “The decrease in pPKCd was also observed in PBMCs, which are not expected to carry mutations in the GNAQ/GNA11 pathway.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-3"></a>

###### RasGRP3 and DUSP6 expression in the first-in-human study

> “RasGRP3 was decreased in some patients receiving LXS196 both QD and BID (Supplementary Fig. 2).”
> “Levels of RasGRP3 at screening and after treatment also correlate with the best percent change in tumour volume from baseline (Supplementary Fig. 2).”
> “MAPK pathway activity as measured by DUSP6 expression showed a trend towards suppression in the PR group (Supplementary Fig. 2).”
> “Exploratory analysis of RasGRP3 reveals a potential biomarker for predicting efficacy and evidence of a transcriptional regulatory feedback on RasGRP3 by PKC inhibition and warrants further investigation.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-4"></a>

###### Preclinical tumor regression in the 92.1 uveal melanoma xenograft model

> “When assessed in the 92.1 human UM mouse xenograft model, LXS196 dosed as a single agent leads to tumour regression at doses below its maximum tolerated dose (MTD), in contrast to AEB071, which achieves only stasis in this model”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-5"></a>

###### Preclinical synergy of darovasertib and crizotinib in the presence of hepatocyte growth factor

> “Addition of HGF alone significantly antagonized IDE196 activity at doses ≥1.23ng/ml.”
> “Crizotinib synergized strongly with IDE196 at clinically relevant doses (80nM) in MEL202 and MM28 in contrast to the 92.1 where mild or no synergy was observed.”
> “PD analysis showed that in the absence of HGF, IDE196 dose-dependently inhibited pERK, pMARCKS and pPKC-delta in all three cell lines.”
> “Addition of HGF dose-dependently induced pMET, pERK levels, pAkt and pPRAS40 levels in all cell lines which was not inhibited by IDE196.”
> “Addition of crizotinib alone or in combination with IDE196 strongly inhibited the activation of these pathways in these cell lines.”

Source: [Wagle et al. (2021)](https://aacrjournals.org/cancerres/article/81/13_Supplement/1343/667196/Abstract-1343-Preclinical-evaluation-of-a-PKC-and)

<a id="topic-2.1.2.6.2-6"></a>

###### Crizotinib label: QTcF change from baseline in an ECG substudy

> “In an ECG substudy conducted in 52 patients with ALK-positive NSCLC, the maximum mean QTcF (corrected QT by the Fridericia method) change from baseline was 12.3 ms (2-sided 90% upper CI: 19.5 ms) following administration of XALKORI 250 mg orally twice daily.”
> “An exposure-QT analysis suggested a crizotinib plasma concentration-dependent increase in QTcF”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption and terminal half-life of single-agent darovasertib under fasting conditions

> “During the dose escalation part of the study, following oral doses of 100–1000 mg QD and 200–400 mg BID, total plasma concentration profiles of LXS196 showed rapid absorption in fasting conditions with a Tmax of ~1 h after dose (median Tmax ranging from 0.483–2.00 h) and consistent terminal T1/2 across different doses (~11 h).”
> “The mean terminal half-life (T1/2) was consistent across tested dose groups ranging from 8.49–13.8 h.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.3-2"></a>

###### Accumulation, variability, and dose proportionality of single-agent darovasertib

> “Minimal or reduced accumulation was observed with repeated administration (mean Racc ranged from 0.718 to 1.27-fold).”
> “PK variability was moderate, as illustrated by the between-patient variability (CV%) for Cmax and for AUC0–t.”
> “Increase in exposure (AUC0–t and Cmax) on C1D1 and D15 was under-proportional to the increase in dose with both QD and BID schedules.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.3-3"></a>

###### Pharmacokinetic sampling and parameters in the first-in-human study

> “In the dose escalation part of the study, PK samples were collected at various pre- and post-dose time points on C1D1, D2, D3, D15 and D16.”
> “PK parameters included area under the curve (AUC0–12h), maximum concentration (Cmax) and time to Cmax (Tmax) on C1D1 and C1D15, and additionally, the accumulation ratio (Racc) of AUC0–t on C1D15 compared to that on C1D1.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.3-4"></a>

###### Absorption and tolerability in preclinical species

> “The lead series was optimized for kinase and off target selectivity to afford a compound that is rapidly absorbed and well tolerated in preclinical species.”

Source: [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)

<a id="topic-2.1.2.6.3-5"></a>

###### Pharmacokinetic endpoints in the OptimUM-02 EU trial record

> “Dose-exposure-response (S&E) relationship; Plasma concentration profiles and PK parameters”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.6.3-6"></a>

###### Darovasertib pharmacokinetics in combination with crizotinib

No evidence found.

<a id="topic-2.1.2.6.3-7"></a>

###### Crizotinib label: steady state, absorption, and effect of food

> “Following XALKORI 250 mg capsules twice daily, steady-state was reached within 15 days with a median accumulation ratio of 4.8.”
> “Steady-state minimum concentration (Cmin.ss) and AUC increased in a greater than dose-proportional manner over the dose range of 200 mg to 300 mg twice daily (0.8 to 1.2 times the approved recommended dosage).”
> “A single crizotinib capsule dose was absorbed with median time to achieve peak concentration (Tmax) of 4 to 6 hours, and the mean absolute bioavailability of 43% (range: 32% to 66%).”
> “A high-fat meal, reduced AUC0-INF and maximum plasma concentration (Cmax) of crizotinib each by 14% for the capsule formulation; reduced AUC0-INF and Cmax of crizotinib by 15% and 23%, respectively, for the pellet formulation as compared to those under fasted conditions.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.6.3-8"></a>

###### Crizotinib label: distribution, elimination, metabolism, and excretion

> “The geometric mean volume of distribution (Vss) of crizotinib was 1772 L following a single intravenous dose.”
> “Protein binding of crizotinib is 91% and is independent of drug concentration in vitro.”
> “The mean apparent plasma terminal half-life of crizotinib was 42 hours following single doses of crizotinib in patients.”
> “The mean apparent clearance (CL/F) of crizotinib was lower at steady-state (60 L/h) after 250 mg twice daily than after a single 250 mg oral dose (100 L/h).”
> “Crizotinib is predominantly metabolized by CYP3A.”
> “Following administration of a single oral 250 mg dose of radiolabeled crizotinib dose to healthy subjects, 63% (53% as unchanged) of the administered dose was recovered in feces and 22% (2.3% as unchanged) in urine.”
> “No clinically significant difference in crizotinib pharmacokinetics were observed based on age, sex, or ethnicity (Asian, non-Asian).”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information for darovasertib

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Crizotinib label: hepatotoxicity, with liver function monitoring every 2 weeks for the first 2 months

> “Drug-induced hepatotoxicity with fatal outcome occurred in 0.1% of the 1719 patients treated with XALKORI for NSCLC across clinical trials”
> “Concurrent elevations in ALT or AST ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in <1% of patients treated with XALKORI.”
> “Increased ALT or AST >5 times the ULN occurred in 11% and 6% of patients, respectively.”
> “One percent (1.0%) of patients required permanent discontinuation due to elevated transaminases.”
> “Increased transaminases generally occurred within the first 2 months of treatment.”
> “Monitor liver function tests, including ALT, AST, and total bilirubin, every 2 weeks during the first 2 months of treatment, then once a month, and as clinically indicated, with more frequent repeat testing for increased liver transaminases, alkaline phosphatase, or total bilirubin in patients who develop increased transaminases.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

| Adverse reaction | Severity | Dosage modification |
| --- | --- | --- |
| Hepatotoxicity | “Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times upper limit of normal (ULN) with total bilirubin less than or equal to 1.5 times ULN” | “Withhold until recovery to baseline or less than or equal to 3 times ULN, then resume at next lower dosage.” |
| Hepatotoxicity | “ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis)” | “Permanently discontinue.” |

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.7.1-3"></a>

###### Crizotinib label: interstitial lung disease and pneumonitis, with permanent discontinuation for drug-related disease

> “Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.”
> “Across clinical trials in patients with NSCLC (n=1719), 2.9% of XALKORI-treated patients had ILD of any grade, 1% had Grade 3 or 4 ILD, and 0.5% had fatal ILD”
> “Interstitial lung disease generally occurred within 3 months after the initiation of XALKORI.”
> “Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis. Exclude other potential causes of ILD/pneumonitis, and permanently discontinue XALKORI in patients diagnosed with drug-related ILD/pneumonitis”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.7.1-4"></a>

###### Crizotinib label: QT interval prolongation, with ECG and electrolyte monitoring

> “QTc prolongation can occur in patients treated with XALKORI.”
> “Across clinical trials in patients with NSCLC, 2.1% of 1616 patients had QTcF (corrected QT for heart rate by the Fridericia method) greater than or equal to 500 ms and 5% of 1582 patients had an increase from baseline QTcF greater than or equal to 60 ms by automated machine-read evaluation of ECGs.”
> “Avoid use of XALKORI in patients with congenital long QT syndrome.”
> “Monitor ECGs and electrolytes in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QT interval.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

| Adverse reaction | Severity | Dosage modification |
| --- | --- | --- |
| QT interval prolongation | “QT corrected for heart rate (QTc) greater than 500 ms on at least 2 separate electrocardiograms (ECGs)” | “Withhold until recovery to baseline or to a QTc less than 481 ms, then resume at next lower dosage.” |
| QT interval prolongation | “QTc greater than 500 ms or greater than or equal to 60 ms change from baseline with Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia” | “Permanently discontinue.” |

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.7.1-5"></a>

###### Crizotinib label: bradycardia, with heart rate and blood pressure monitoring and review of bradycardic and antihypertensive medications

> “Symptomatic bradycardia can occur in patients receiving XALKORI.”
> “Across clinical trials in patients with NSCLC, bradycardia occurred in 13% of 1719 patients treated with XALKORI.”
> “Grade 3 syncope occurred in 2.4% of XALKORI-treated patients and in 0.6% of the chemotherapy-treated patients”
> “Avoid using XALKORI in combination with other medications known to cause bradycardia (e.g., beta-blockers, nondihydropyridine-calcium channel blockers, clonidine, and digoxin) to the extent possible.”
> “Monitor heart rate and blood pressure regularly.”
> “If bradycardia occurs, re-evaluate for the use of concomitant medications known to cause bradycardia.”
> “Adult patients: Heart rate less than 60 beats per minute (bpm)”
> “Evaluate concomitant medications known to cause bradycardia, as well as antihypertensive medications.”
> “If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at previous dose upon recovery to asymptomatic bradycardia or to the age-specific heart rate provided above.”
> “If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose adjusted, resume at reduced dose upon recovery to asymptomatic bradycardia or to the age-specific heart rate provided above.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.7.1-6"></a>

###### Crizotinib label: severe visual loss and visual disorders, with monthly assessment of visual symptoms

> “Across all clinical trials in patients with NSCLC, the incidence of Grade 4 visual field defect with visual loss was 0.2% of 1719 patients”
> “Optic atrophy and optic nerve disorder have been reported as potential causes of visual loss.”
> “Assessment of visual symptoms for all patients is recommended monthly during treatment.”
> “Report new visual symptoms to an eye specialist.”
> “Permanently discontinue XALKORI for Grade 3 or 4 ocular disorders or severe visual loss (best corrected vision less than 20/200 in one or both eyes) unless another cause is identified”
> “There is insufficient information to characterize the risks of resumption of XALKORI in patients who develop visual symptoms or visual loss.”
> “Monitor symptoms and report any symptoms to an eye specialist.”
> “Consider dose reduction for Grade 2 visual disorders.”
> “Discontinue during evaluation of severe visual loss.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.7.1-7"></a>

###### Crizotinib label: gastrointestinal toxicity in pediatric and young adult patients with ALCL or IMT

> “XALKORI can cause severe gastrointestinal toxicities in pediatric and young adult patients with ALCL or pediatric patients with IMT”
> “In patients with ALCL (n=26), gastrointestinal toxicity occurred in 100% of patients; Grade 3 gastrointestinal toxicity occurred in 27% of patients and included diarrhea, nausea, vomiting, and stomatitis.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.7.1-8"></a>

###### Crizotinib label: embryo-fetal toxicity

> “Based on its mechanism of action, XALKORI can cause fetal harm when administered to a pregnant woman.”
> “In animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures similar to those observed with the maximum recommended human dose resulted in embryotoxicity and fetotoxicity.”
> “Advise pregnant women and females of reproductive potential of the potential risk to a fetus.”
> “Advise females of reproductive potential to use effective contraception during treatment with XALKORI and for 45 days following the last dose.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Crizotinib label: pregnancy

> “There are no available data on the use of XALKORI in pregnant women.”
> “Postimplantation loss was increased at doses ≥50 mg/kg/day (approximately 0.6 times the recommended human dose based on AUC) in rats.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Crizotinib label: lactation

> “There is no information regarding the presence of crizotinib or its metabolites in human milk, or the effects on the breastfed child or on milk production.”
> “Because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with XALKORI and for 45 days after the last dose.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Crizotinib label: pregnancy testing, contraception, and infertility

> “Verify the pregnancy status of females of reproductive potential prior to initiating XALKORI”
> “Advise females of reproductive potential to use effective contraception during treatment with XALKORI and for 45 days after the last dose.”
> “Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use condoms during treatment with XALKORI and for 90 days after the last dose”
> “Based on reproductive organ findings in animals, XALKORI may cause reduced fertility in females and males of reproductive potential.”
> “It is not known whether these effects on fertility are reversible”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Crizotinib label: geriatric use

> “Of the total number of patients with ALK-positive metastatic NSCLC in clinical studies of XALKORI (n=1669), 16% were 65 years or older and 3.8% were 75 years or older.”
> “No overall differences in safety or effectiveness were observed between these patients and younger patients.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Crizotinib label: hepatic impairment, with dose reduction for moderate or severe impairment

> “Reduce XALKORI dosage in patients with moderate or severe hepatic impairment”
> “No dose adjustment is recommended in patients with pre-existing mild hepatic impairment (AST > ULN and total bilirubin less than or equal to 1 times ULN or any AST and total bilirubin greater than 1 times ULN but less than or equal to1.5 times ULN).”
> “The recommended dose of XALKORI in patients with moderate hepatic impairment [any aspartate aminotransferase (AST) and total bilirubin greater than 1.5 times the upper limit of normal (ULN) and less than or equal to 3 times ULN] is the first dose reduction shown in Table 4 for adult patients with NSCLC or IMT”
> “The recommended dose of XALKORI in patients with severe hepatic impairment (any AST and total bilirubin greater than 3 times ULN) is the second dose reduction shown in Table 4 for adult patients with NSCLC or IMT”
> “Steady-state mean crizotinib AUC increased by 14% and Cmax increased by 9% in patients with moderate hepatic impairment (any AST and total bilirubin >1.5 times ULN and ≤3 times ULN) following XALKORI 200 mg orally twice daily compared with patients with normal hepatic function following XALKORI 250 mg orally twice daily.”
> “Mean crizotinib AUC decreased by 35% and Cmax decreased by 27% in patients with severe hepatic impairment (any AST and total bilirubin >3 times ULN) following XALKORI 250 mg orally once daily compared with patients with normal hepatic function following XALKORI 250 mg orally twice daily”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Crizotinib label: renal impairment, with dose reduction for severe impairment not requiring dialysis

> “Increased exposure to crizotinib occurred in patients with pre-existing severe renal impairment (CLcr less than 30 mL/min calculated using the modified Cockcroft-Gault equation for adult patients and the Schwartz equation for pediatric patients) not requiring dialysis, therefore reduce dosage of XALKORI in these patients”
> “No dose adjustment is recommended in patients with mild to moderate renal impairment (CLcr 30 to 89 mL/min).”
> “Following a single 250 mg dose, the mean AUC0-INF of crizotinib increased by 79% and the mean Cmax increased by 34% in patients with severe renal impairment (CLcr <30 mL/min) who did not require dialysis compared to those with normal renal function (CLcr ≥90 mL/min).”
> “Similar changes in AUC0-INF and Cmax were observed for the active metabolite of crizotinib”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

###### OptimUM-02 EU trial record: renal and hepatic function thresholds

> “Participants with creatinine clearance between 30 and 45 mL/min can be considered for trial enrollment, contingent upon consultation with the Medical Monitor to assess the need for dose modification, ensuring safe administration of the investigational agent.”
> “Total and direct bilirubin ≤ 1.5 × the upper limit of normal (ULN).”
> “For participants with documented Gilbert’s disease, total bilirubin ≤ 3.0 mg/dL is allowed.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.8-8"></a>

###### OptimUM-02 EU trial record: cardiac exclusions and heart rate threshold

> “A history or presence of ventricular tachyarrhythmia”
> “Has congestive heart failure requiring treatment. For New York Heart Association Class 1, inclusion can be considered with discussion and agreement with the Sponsor Medical Monitor”
> “In addition, participants with asymptomatic persistent heart rate < 55 bpm must be discussed with the Sponsor Medical Monitor for inclusion.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.8-9"></a>

###### OptimUM-02 EU trial record: contraception for 6 months in women and 3 months in men after the last dose

> “Women of child-bearing potential (WOCBP) who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective contraception during study treatment (see Appendix 5, Section 14.5), and must agree to continue using such precautions for 6 months after the final dose of study treatment; cessation of birth control after this point should be discussed with a responsible physician.”
> “Male participants must be surgically sterile or must agree to use double-barrier contraception methods from enrollment through treatment and for 3 months following administration of the last dose of study treatment.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.8-10"></a>

###### Darovasertib pharmacokinetics in hepatic or renal impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Darovasertib

<a id="topic-2.1.2.9.1-1"></a>

###### OptimUM-01 drug interaction cocktail substudy: CYP3A4/5 and P-gp inhibitors and CYP3A4/5 inducers prohibited before dosing

> “Moderate and strong inhibitors of CYP2A4/5 or P-gp are prohibited within 7 days, or within 5 half-lives, whichever is longer, of Cycle 1 Day -1.”
> “Intake of strong or moderate inducers of CYP3A4/5, CYP2B6, CYP2C9, CYP2C19, or OAT3 is prohibited during 15 days, or 5 half-lives, whichever is longer, prior to Cycle 1 Day -1.”
> “Intake of vitamin supplements containing Vitamin B6 (pyridoxine), grapefruit/grapefruit juice, or Seville orange juice within 7 days prior to Cycle 1 Day -1.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-2.1.2.9.1-2"></a>

###### Clinical drug interaction studies with darovasertib as the affected drug

No evidence found.

<a id="topic-2.1.2.9.1-3"></a>

###### Crizotinib label: strong and moderate CYP3A inhibitors and grapefruit

> “Concomitant use of crizotinib with strong CYP3A inhibitors increases crizotinib plasma concentrations”
> “Avoid concomitant use of strong CYP3A inhibitors.”
> “Avoid grapefruit or grapefruit juice”
> “Use caution with concomitant use of moderate CYP3A inhibitors.”
> “If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the dose of XALKORI to the second dose reduction shown in Table 4 for adult patients with NSCLC or IMT”
> “After discontinuation of a strong CYP3A inhibitor, resume the XALKORI dose used prior to initiating the strong CYP3A inhibitor.”
> “Coadministration of a single 150 mg oral dose of crizotinib with ketoconazole, a strong CYP3A inhibitor, increased crizotinib AUC0-INF by 216% and Cmax by 44% compared to crizotinib alone.”
> “Coadministration of XALKORI 250 mg orally once daily with itraconazole, a strong CYP3A inhibitor, increased crizotinib steady-state AUC by 57% and Cmax by 33% compared to crizotinib alone”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.9.1-4"></a>

###### Crizotinib label: strong CYP3A inducers

> “Concomitant use of crizotinib with strong CYP3A inducers decreases crizotinib plasma concentrations”
> “Avoid concomitant use of strong CYP3A inducers.”
> “Coadministration of XALKORI 250 mg orally twice daily with rifampin, a strong CYP3A inducer, decreased crizotinib steady-state AUC0-Tau by 84% and Cmax by 79%, compared to crizotinib alone”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.9.1-5"></a>

###### Crizotinib label: gastric acid reducing agents and P-glycoprotein

> “Gastric Acid Reducing Agents: No clinically significant differences in crizotinib pharmacokinetics were observed when used concomitantly with esomeprazole, a proton pump inhibitor.”
> “Crizotinib is a substrate for P-glycoprotein (P-gp) in vitro.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Darovasertib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### OptimUM-01 pravastatin and drug interaction cocktail substudies: planned pharmacokinetic outcome measures

> “Impact on pravastatin PK profile by IDE196 and Crizotinib combination”
> “PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-2.1.2.9.2-2"></a>

###### OptimUM-01 pravastatin and drug interaction cocktail substudies: exclusion of interacting drugs and probe substrates

> “Taken drugs that interfere with the absorption, metabolism, or elimination of pravastatin”
> “Treatment with bupropion, repaglinide, flurbiprofen, omeprazole, esomeprazole, midazolam, and dabigatran etexilate within 7 days prior to Cycle 1 Day -1.”
> “Intake of any strong or moderate inhibitor of CYP2B6, CYP2CI, CYP2C9, CYP2C10 and OAT3 is prohibited within 7 days or within 5 half-lives, whichever is longer, of Cycle 1 Day -1.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-2.1.2.9.2-3"></a>

###### Results of the pravastatin and drug interaction cocktail substudies

No evidence found.

<a id="topic-2.1.2.9.2-4"></a>

###### Overlapping adverse events of darovasertib and crizotinib in the OptimUM-01 first-line cohort

> “The AEs observed with darovasertib-crizotinib were in line with those seen with darovasertib monotherapy and those commonly seen with crizotinib monotherapy, including diarrhea, nausea, vomiting, edema, constipation, fatigue, decreased appetite, dizziness, and transaminase elevations”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-2.1.2.9.2-5"></a>

###### Crizotinib label: CYP3A substrates

> “Concomitant use of crizotinib increases plasma concentrations of CYP3A substrates”
> “Avoid concomitant use of XALKORI with CYP3A substrates where minimal concentration changes may lead to serious adverse reactions.”
> “If concomitant use of XALKORI is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling.”
> “CYP3A Substrates: Coadministration of XALKORI 250 mg orally twice daily for 28 days increased AUC0-INF of oral midazolam (CYP3A substrate) 3.7-fold compared to midazolam alone”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.9.2-6"></a>

###### Crizotinib label: drugs that prolong the QT interval or cause bradycardia

> “XALKORI can prolong the QT/QTc interval. Avoid concomitant use of XALKORI with drugs that prolong the QT interval”
> “XALKORI can cause bradycardia. Avoid concomitant use of XALKORI with drugs that cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin)”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.9.2-7"></a>

###### Crizotinib label: in vitro inhibition of CYP enzymes and transporters

> “CYP Enzymes: Crizotinib inhibits CYP2B6 in vitro. Crizotinib does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.”
> “Crizotinib does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A.”
> “Transporters: Crizotinib inhibits P-gp, organic cation transporter (OCT) 1, and OCT2.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### OptimUM-02 dose optimization arms and the selected combination dose in the registry record

> “Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.”
> “Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-2.1.2.10.1-2"></a>

###### OptimUM-02 randomized regimen: darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily

> “Eligible patients were randomized 2:1 to receive either darovasertib 300 mg BID + crizotinib 200 mg BID or investigator’s choice (pembrolizumab, ipilimumab + nivolumab, or dacarbazine)”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-2.1.2.10.1-3"></a>

###### OptimUM-01 first-line cohort: recommended phase 2 dose and delivered dose intensity

> “As of 28 May 2025, 44 pts with mUM and no prior systemic cancer therapy have received the recommended phase 2 dose of darovasertib 300 mg BID plus crizotinib 200 mg BID”

Source: [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf)

> “As observed in this patient population, with timely and appropriate management of these AEs, the mean delivered dose intensity of darovasertib-crizotinib was ≥80%.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-2.1.2.10.1-4"></a>

###### Crizotinib label: recommended dosage of 250 mg twice daily for adults with NSCLC

> “The recommended dosage for adult patients with ALK- or ROS1-positive metastatic NSCLC is XALKORI capsules 250 mg orally, twice daily, with or without food until disease progression or unacceptable toxicity occurs.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.10.1-5"></a>

###### Crizotinib label: dose reduction levels for adults, with 200 mg twice daily as the first reduction

| Dose reduction level for adult patients with NSCLC or IMT | Dose and schedule |
| --- | --- |
| First dose reduction | “200 mg twice daily” |
| Second dose reduction | “250 mg once daily” |

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

> “Permanently discontinue XALKORI capsules or pellets if unable to tolerate 250 mg taken once daily.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.10.1-6"></a>

###### Crizotinib label: dosage modification for hematologic toxicities in adults

| Severity of hematologic adverse reaction in adult patients with NSCLC or IMT | Dosage modification |
| --- | --- |
| Grade 3 | “Withhold until recovery to Grade 2 or less, then resume at the same dosage.” |
| Grade 4 | “Withhold until recovery to Grade 2 or less, then resume at next lower dosage.” |

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

> “Monitor complete blood counts including differential weekly for the first month of therapy and then at least monthly, with more frequent monitoring if Grade 3 or 4 abnormalities, fever, or infection occur”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Supportive measures for hypotension during initial dosing of darovasertib with crizotinib

> “Adequate hydration, initial withholding of blood pressure medications, and avoiding abrupt posture changes to prevent orthostatic hypotension during initial dosing periods are useful supportive measures noted in the previous study.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-2.1.2.10.2-2"></a>

###### Crizotinib label: administration with or without food, missed doses, and vomiting

> “Administer XALKORI capsules or pellets orally, twice daily, with or without food.”
> “If a dose of XALKORI capsules or pellets is missed, make up that dose unless the next dose is due within 6 hours.”
> “If vomiting occurs after taking a dose of XALKORI capsules or pellets, do not take an additional dose.”
> “Take the next dose at the regular scheduled time.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Crizotinib label: capsule handling

> “Swallow XALKORI capsules whole, with or without food twice daily.”
> “Do not chew, crush or split XALKORI capsules.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “Currently, participation in a clinical trial is the only way to receive any of IDEAYA’s investigational drugs.”
> “Until further safety and efficacy data become available, we will not be making these investigational drugs available in other ways.”

Source: [IDEAYA Biosciences clinical trials and expanded access policy](https://www.ideayabio.com/clinical-trials)

<a id="topic-2.1.2.11-2"></a>

###### U.S. commercialization plans and specialty sales force

> “However, we have initiated planning and preparation for potential commercial operations, including for sales, marketing and market access capabilities, subject to the results of our Phase 2/3 clinical trial for darovasertib (OptimUM-02) and required regulatory approvals.”
> “We believe a moderately sized specialty sales force, supported by effective marketing and sales management organizations, would enable us to reach healthcare professionals who specialize in the care of the patient populations for darovasertib and our other product candidates.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### Commercialization outside the United States by Servier

> “Under the Servier Licensing Agreement, Servier will be responsible for the commercialization of darovasertib outside of the U.S.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Manufacturing, packaging, and distribution through contract manufacturers

> “We have an agreement with STA Pharmaceutical Hong Kong Limited Pharmaceutical (STA Pharmaceutical), and Yuhan Corporation for the synthesis of the API for darovasertib, and agreements with STA Pharmaceutical and Patheon Inc. for formulation and manufacturing of darovasertib drug product.”
> “We have established arrangements with CMOs as well for packaging, labeling and distribution of darovasertib, IDE397, and IDE161.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Guideline and compendia listing as a route to payer coverage in HLA-A∗02:01-positive disease

> “IDEAYA also plans to publish data from OptimUM-01 for potential inclusion in the clinical practice guidelines to support the use of the combination in certain HLA*A2:01-positive mUM patients.”
> “Inclusion in the clinical practice guidelines, if achieved, is intended to provide healthcare professionals with an evidence-based rationale to consider use of darovasertib in appropriate patients and may support payer coverage for such patients.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “To seek inclusion in clinical practice guidelines and compendia”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.2.11-6"></a>

###### Specialty pharmacy distribution, pricing, and patient assistance

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Crizotinib supplied by Pfizer for the combination trials

> “Pursuant to the Second Pfizer Agreement, the Company is the sponsor of the combination trial and the Company will provide darovasertib and pay for the costs of the combination trial, and Pfizer will provide crizotinib for the planned combination trial at no cost to the Company for up to an agreed-upon number of mUM patients.”
> “The Company and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of darovasertib and crizotinib.”
> “Under Amendment No. 1 to the Second Pfizer Agreement, Pfizer will provide the Company with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.2.12-2"></a>

###### Concomitant medications excluded in the OptimUM-02 trial: CYP3A4/5, P-gp and BCRP substrates, and QT-prolonging drugs

> “Receives treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following (see Table 18):”
> “Other antineoplastic therapies (not including palliative radiotherapy) or investigational therapies other than IDE196”
> “Known risk for QT prolongation, except for the specific use of oral ondansetron for the management of nausea and vomiting (Note: intravenous [IV] formulations of ondansetron are to be used with caution.)”
> “Narrow therapeutic index sensitive substrates of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP)”
> “Known to be strong inducers or inhibitors of cytochrome P (CYP)3A4/5”
> “Known to be substrates of CYP3A4/5 with a narrow therapeutic index”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.12-3"></a>

###### Antihypertensive and other blood pressure-lowering medications in the single-agent LXS196 study

> “Active management of symptomatic hypotension was recommended per protocol and regular vital signs (including blood pressure and heart rate) and ECG monitoring were required throughout the study at regular study visits.”
> “Investigators were encouraged to temporarily withhold concomitant medications that may cause hypotension prior to the first dose of LXS196 and implement more frequent blood pressure monitoring throughout the study as deemed necessary per clinical need.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.12-4"></a>

###### Antidiarrheal prophylaxis with the darovasertib and crizotinib combination

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Darovasertib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Scope of the MIPS melanoma recurrence measure

> “Percentage of patients who had an excisional surgery for melanoma or melanoma in situ with initial American Joint Committee on Cancer (AJCC) staging of 0, I, or II, in the past 5 years in which the operating clinician examines and/or diagnoses the patient for recurrence of melanoma.”

Source: [CMS Quality ID 509 measure specification (2025)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_509_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

###### Product-specific effects on healthcare quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Competing products and development programs in uveal melanoma named by the sponsor

> “For darovasertib, we are not aware of other companies actively developing clinical-stage therapeutics directed to PKC as a target for solid tumors.”
> “Replimune has initiated a potentially registration-enabling trial for RP-2, an oncolytic immunotherapy. iOnctura has initiated a Phase 2 trial for Roginolisib, an allosteric PI3K delta inhibitor, in 2L+ mUM.”
> “Other programs in development for mUM include Novartis’ DYP688, an ADC, with a GNAQ-11 inhibitor payload in a Phase 1/2 clinical trial, and Immatics’ anzu-cel/IMA203, a PRAME-targeting TCR-based, T cell therapy.”
> “Additionally, Immunocore has commercialized Tebentafusp, also known under its branded name as Kimmtrak, for the treatment of adult patients with HLA*A2(+), unresectable or metastatic UM.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

###### Treatments used in practice for advanced uveal melanoma: NICE committee description

> “The clinical experts explained that the treatments used are those licensed for melanoma. These include pembrolizumab, nivolumab and ipilimumab immunotherapies, and dacarbazine chemotherapy. Most people with advanced uveal melanoma are offered pembrolizumab, and some people are offered ipilimumab with or without nivolumab. A small minority of people who cannot have immunotherapies are offered dacarbazine.”
> “A clinical expert noted that the nivolumab and ipilimumab combination has a higher toxicity profile than pembrolizumab or ipilimumab, so it is not used as often as other immunotherapies.”
> “The committee concluded that although pembrolizumab is the most common treatment option, there is no standard care for advanced uveal melanoma.”

Source: [NICE technology appraisal guidance TA1027, committee discussion (2025)](https://www.nice.org.uk/guidance/TA1027/chapter/committee-discussion)

<a id="topic-2.1.2.14-3"></a>

###### Treatments used in practice for metastatic uveal melanoma: CADTH description of off-label immunotherapy

> “The most prescribed systemic therapies in a first-line setting are immunotherapies (off-label), given as monotherapies (i.e., nivolumab, or pembrolizumab alone), or in combination (i.e., ipilimumab plus nivolumab).”
> “Systemic chemotherapies have a limited role in the treatment of mUM in Canada, due to toxicity and a low response rate.”
> “According to the clinical expert, while immunotherapy is a reasonable first-line option, the response to immunotherapy is considered poor, and therefore clinical trials are preferred for patients in first line and beyond.”

Source: [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1)

<a id="topic-2.1.2.14-4"></a>

###### Tebentafusp label: HLA-A∗02:01-positive indication and genotyping requirement

> “KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.”
> “Select patients for treatment of unresectable or metastatic uveal melanoma with KIMMTRAK based on a positive HLA-A*02:01 genotyping test of a whole blood sample [see Clinical Studies (14)].”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Tebentafusp label: weekly intravenous step-up dosing until progression

> “Recommended dosage: 20 mcg intravenously on Day 1, 30 mcg intravenously on Day 8, 68 mcg intravenously on Day 15, and 68 mcg intravenously once every week thereafter (2.2).”
> “Treat patients until unacceptable toxicity or disease progression occur.”
> “No dosage reduction for KIMMTRAK is recommended.”
> “Injection: 100 mcg/0.5 mL clear, colorless to slightly yellowish solution in a single-dose vial”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Tebentafusp label: administration setting, post-infusion monitoring, and two-step dilution

> “Administer the first three infusions of KIMMTRAK in an appropriate healthcare setting by intravenous infusion over 15-20 minutes. Monitor patients during the infusion and for at least 16 hours after the infusion is complete.”
> “If the patient does not experience Grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate ambulatory care setting, and monitor patients for a minimum of 30 minutes following each of these infusions [see Warnings and Precautions (5.1)].”
> “A 2-step dilution process is required for preparation of the final KIMMTRAK dose for infusion.”
> “Do not prepare more than one dose from the vial.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Tebentafusp label: boxed warning for cytokine release syndrome and its incidence in IMCgp100-202

> “Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated”
> “CRS (≥ Grade 2) occurred in 77% of patients in Study IMCgp100-202 who received KIMMTRAK [see Adverse Reactions (6.1)].”
> “Among patients who received KIMMTRAK, 23% received systemic corticosteroids for at least 1 infusion, 8% received supplemental oxygen during at least 1 infusion, and 0.8% received a vasopressor for at least 1 infusion.”
> “CRS led to permanent discontinuation in 1.2% of patients.”
> “The majority (84%) of episodes of CRS started the day of infusion. Among cases that resolved, the median time to resolution of CRS was 2 days.”
> “Ensure that healthcare providers administering KIMMTRAK have immediate access to medications and resuscitative equipment to manage CRS.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Tebentafusp label: skin reaction and liver enzyme warnings in IMCgp100-202

> “In study IMCgp100-202, skin reactions occurred in 91% of patients treated with KIMMTRAK, including Grade 2 (44%) and Grade 3 (21%) events.”
> “In Study IMC100-gp100-202, increases in alanine aminotransferase or aspartate aminotransferase were observed in 65% of patients treated with KIMMTRAK.”
> “Grade 3 or greater elevations in liver enzymes outside the setting of CRS occurred in approximately 8% of patients.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Tebentafusp label: IMCgp100-202 design and population of 378 participants

> “KIMMTRAK was evaluated in IMCgp100-202, a randomized, open-label, multicenter trial (NCT03070392) that enrolled patients with metastatic uveal melanoma (N=378).”
> “Patients were excluded if they received prior systemic therapy for metastatic or advanced uveal melanoma or localized liver-directed therapy.”
> “The major efficacy outcome was overall survival (OS). Additional efficacy outcomes were investigator-assessed progression free survival (PFS) and objective response rate (ORR) per RECIST 1.1.”
> “The median age was 64 years (range 23 to 92 years); 50% were female; 87% were White, and 12% were unreported or unknown race.”
> “Baseline ECOG performance status was 0 (73%), 1 (21%), or 2 (0.3%); 36% had elevated LDH level; and 94% had liver metastasis.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Tebentafusp label: IMCgp100-202 efficacy results versus investigator’s choice

| Outcome | KIMMTRAK (N=252) | Investigator’s choice of pembrolizumab, ipilimumab, or dacarbazine (N=126) |
| --- | --- | --- |
| Overall survival, number of deaths (%) | “87 (34.5%)” | “63 (50%)” |
| Overall survival, median in months (95% CI) | “21.7 (18.6, 28.6)” | “16 (9.7, 18.4)” |
| Progression-free survival, median in months (95% CI), final analysis | “3.3 (3, 5)” | “2.9 (2.8, 3)” |
| Objective response rate (95% CI), not formally tested | “9.1% (5.9, 13.4)” | “4.8% (1.8, 10.1)” |
| Complete response | “1 (0.4%)” | “0” |
| Partial response | “22 (8.7%)” | “6 (4.8%)” |

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

| Comparison, KIMMTRAK versus investigator’s choice | Hazard ratio (95% CI) |
| --- | --- |
| Overall survival, prespecified interim analysis, stratified by LDH status | “0.51 (0.37, 0.71)” |
| Progression-free survival, final analysis, stratified by LDH status | “0.73 (0.58, 0.94)” |

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Tebentafusp label: serious adverse reactions and discontinuation among patients who received KIMMTRAK in IMCgp100-202

> “Serious adverse reactions occurred in 28% of patients who received KIMMTRAK. Serious adverse reactions occurring in > 2% of patients were cytokine release syndrome (10%), rashes (4.5%), pyrexia (2.4%), and hypotension (2%). One patient (0.4%) experienced a fatal adverse reaction (pulmonary embolism).”
> “Adverse reactions led to permanent discontinuation in 3.3% of patients who received KIMMTRAK.”
> “The median duration of exposure was 5.3 months (range: 0.3 to 33 months) in patients treated with KIMMTRAK.”

Source: [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

###### Melphalan hepatic delivery system label: liver-directed indication restricted by hepatic tumor burden

> “HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

###### Melphalan hepatic delivery system label: intra-arterial dosing every 6 to 8 weeks for up to 6 infusions

> “HEPZATO, a component of the HEPZATO KIT, is administered by infusion into the hepatic artery (see IFU) every 6 to 8 weeks for up to 6 total infusions.”
> “The recommended HEPZATO dose is 3 mg/kg based on ideal body weight (IBW), as calculated per Table 1 below, with a maximum of 220 mg during a single treatment.”
> “Administer HEPZATO via the HEPZATO KIT Hepatic Delivery System only to patients weighing 35 kg or greater due to potential size limitations with respect to percutaneous catheterization.”
> “For injection: HEPZATO includes 50 mg freeze-dried (lyophilized) melphalan powder per vial in five (5) single dose vials, intended for reconstitution with the supplied diluents.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-14"></a>

###### Melphalan hepatic delivery system label: boxed warning, general anesthesia, and REMS-certified settings

> “Severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events may occur via hepatic intra-arterial administration of HEPZATO.”
> “Myelosuppression with resulting severe infection, bleeding, or symptomatic anemia may occur with HEPZATO.”
> “Administration of HEPZATO requires general anesthesia and extracorporeal bypass of circulation which may cause life threatening or fatal adverse effects.”
> “The HEPZATO KIT is only available through a restricted program under a REMS, because of the risk of severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events defined in the REMS.”
> “Healthcare settings that dispense and administer HEPZATO KIT must be enrolled, certified, and comply with the REMS requirements.”
> “Certified healthcare facilities must ensure that patients are assessed for severe peri-procedural complications during the procedure and for at least 72 hours following the procedure.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-15"></a>

###### Melphalan hepatic delivery system label: FOCUS single-arm efficacy in 91 treated participants

> “The efficacy of HEPZATO in hepatic-dominant metastatic uveal melanoma was based on the results from 91 patients who received HEPZATO via the HEPZATO KIT in the FOCUS Study (NCT02678572), a multicenter, open-label trial.”
> “The major efficacy outcome measures were objective response rate (ORR) and duration of response (DoR) using computed tomography (CT) or magnetic resonance imaging (MRI) assessed by an independent central review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.”
> “Forty-three percent (43%) of patients underwent prior therapy for metastatic disease, including systemic therapy (25%), other surgeries or procedures (14%), and radiation (11%).”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

| Outcome in the FOCUS trial | HEPZATO (N=91) |
| --- | --- |
| Objective response rate (95% CI) | “36.3% (26.4, 47.0)” |
| Complete response | “7.7%” |
| Partial response | “28.6%” |
| Number of responders | “n= 33” |
| Median duration of response, months (95% CI) | “14.0 (8.3, 17.7)” |

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-16"></a>

###### Melphalan hepatic delivery system label: serious and fatal adverse reactions and myelosuppression in FOCUS

> “Serious adverse reactions occurred in 45% of patients who received HEPZATO.”
> “Fatal adverse reactions occurred in 3 (3.2%) patients who were treated with HEPZATO; these included cardiac arrest, acute hepatic failure and bacterial peritonitis.”
> “HEPZATO was permanently discontinued due to adverse reactions in 18% of patients with neutropenia being the most common adverse reaction (3.2%) requiring permanent discontinuation.”
> “In the 95 patients who received HEPZATO in the FOCUS trial, 68% had Grade 3 or 4 myelosuppression.”

Source: [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)

<a id="topic-2.1.2.14-17"></a>

###### Nivolumab label: melanoma indication and dosing with ipilimumab

> “OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.”
> “Adult and pediatric patients weighing 40 kg or greater: 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)”

Source: [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)

<a id="topic-2.1.2.14-18"></a>

###### Nivolumab label: ocular melanoma excluded from the first-line CHECKMATE-066 trial

> “CHECKMATE-066 (NCT01721772) was a multicenter, double-blind, randomized (1:1) trial in 418 patients with BRAF V600 wild-type unresectable or metastatic melanoma.”
> “Key eligibility criteria included histologically confirmed, unresectable or metastatic, cutaneous, mucosal, or acral melanoma; no prior therapy for metastatic disease; completion of prior adjuvant or neoadjuvant therapy at least 6 weeks prior to randomization; ECOG performance status 0 or 1; absence of autoimmune disease; and absence of active brain or leptomeningeal metastases. The trial excluded patients with ocular melanoma.”

Source: [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)

<a id="topic-2.1.2.14-19"></a>

###### Nivolumab label: serious adverse reactions with nivolumab plus ipilimumab in CHECKMATE-067 and the immune-mediated adverse reaction warning

> “The most frequent (≥10%) serious adverse reactions in the OPDIVO and ipilimumab arm and the OPDIVO arm, respectively, were diarrhea (13% and 2.2%), colitis (10% and 1.9%), and pyrexia (10% and 1%).”
> “Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody.”

Source: [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)

<a id="topic-2.1.2.14-20"></a>

###### Ipilimumab label: melanoma indication and combination dosing with nivolumab

> “YERVOY, as a single agent or in combination with nivolumab, is indicated for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.”
> “YERVOY 3 mg/kg every 3 weeks for a maximum of 4 doses. (2.2)”
> “YERVOY 3 mg/kg immediately following nivolumab 1 mg/kg on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in the Full Prescribing Information for nivolumab. (2.2)”

Source: [Bristol-Myers Squibb YERVOY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125377s140lbl.pdf)

<a id="topic-2.1.2.14-21"></a>

###### Ipilimumab label: ocular melanoma excluded from CHECKMATE-067 and immune-mediated adverse reactions

> “CHECKMATE-067 (NCT01844505) was a multicenter, randomized (1:1:1), double-blind trial in which 945 patients with previously untreated, unresectable or metastatic melanoma were randomized to one of the following arms: YERVOY and nivolumab, nivolumab, or YERVOY.”
> “Patients were required to have completed adjuvant or neoadjuvant treatment at least 6 weeks prior to randomization and have no prior treatment with anti-CTLA-4 antibody and no evidence of active brain metastasis, ocular melanoma, autoimmune disease, or medical conditions requiring systemic immunosuppression.”
> “Immune-mediated adverse reactions can occur at any time after starting YERVOY.”

Source: [Bristol-Myers Squibb YERVOY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125377s140lbl.pdf)

<a id="topic-2.1.2.14-22"></a>

###### Pembrolizumab label: melanoma indication, dose, and uveal melanoma excluded from KEYNOTE-002

> “KEYTRUDA® is indicated for the treatment of patients with unresectable or metastatic melanoma.”
> “Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. (2.2)”
> “The efficacy of KEYTRUDA was investigated in KEYNOTE-002 (NCT01704287), a multicenter, randomized (1:1:1), active-controlled trial in 540 patients randomized to receive one of two doses of KEYTRUDA in a blinded fashion or investigator’s choice chemotherapy.”
> “The trial excluded patients with uveal melanoma and active brain metastasis.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s195lbl.pdf)

<a id="topic-2.1.2.14-23"></a>

###### Nivolumab and relatlimab label: melanoma indication, dose, and uveal melanoma excluded from RELATIVITY-047

> “OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.”
> “The recommended dosage of OPDUALAG for adult patients and pediatric patients 12 years of age or older who weigh at least 40 kg is 480 mg nivolumab and 160 mg relatlimab administered intravenously every 4 weeks until disease progression or unacceptable toxicity occurs.”
> “The efficacy of OPDUALAG was investigated in RELATIVITY-047 (NCT03470922), a randomized (1:1), double-blinded trial in 714 patients with previously untreated metastatic or unresectable Stage III or IV melanoma.”
> “The trial excluded patients with active autoimmune disease, medical conditions requiring systemic treatment with moderate or high dose corticosteroids or immunosuppressive medications, uveal melanoma, and active or untreated brain or leptomeningeal metastases.”

Source: [Bristol-Myers Squibb OPDUALAG prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761234s011lbl.pdf)

<a id="topic-2.1.2.14-24"></a>

###### Dacarbazine label: metastatic malignant melanoma indication, boxed warning, and intravenous dosing

> “Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma.”
> “Hemopoietic depression is the most common toxicity with dacarbazine (see WARNINGS ).”
> “Hepatic necrosis has been reported (see WARNINGS ).”
> “The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals.”
> “An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days. Treatment may be repeated every 3 weeks.”

Source: [Hikma Dacarbazine for Injection prescribing information (2020)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d81315c-7021-4091-b703-ad135390c936)

<a id="topic-2.1.2.14-25"></a>

###### Dacarbazine label: nausea and vomiting, myelosuppression, and administration setting

> “Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.”
> “Leukopenia and thrombocytopenia may be severe enough to cause death.”
> “Hospitalization is not always necessary but adequate laboratory study capability must be available. Extravasation of the drug subcutaneously during intravenous administration may result in tissue damage and severe pain.”

Source: [Hikma Dacarbazine for Injection prescribing information (2020)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d81315c-7021-4091-b703-ad135390c936)

<a id="topic-2.1.2.14-26"></a>

###### RP2 plus nivolumab versus nivolumab plus ipilimumab: phase 2/3 trial in immune checkpoint inhibitor-naive metastatic uveal melanoma

> “The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.”
> “Patients with confirmed diagnosis of metastatic Uveal melanoma not amenable to surgical resection.”
> “Any exposure to immune checkpoint inhibitor (ICIs) since the time of first being diagnosed with uveal melanoma.”

Source: [ClinicalTrials.gov NCT06581406](https://clinicaltrials.gov/study/NCT06581406)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of uveal melanoma and its sites of origin

> “Melanoma of the uveal tract (iris, ciliary body, and choroid) is rare, but it is the most common primary intraocular malignancy in adults.”
> “Uveal melanomas can arise in the anterior (iris) or the posterior (ciliary body or choroid) uveal tract.”
> “Most uveal tract melanomas originate in the choroid. The ciliary body is a less common site of origin, and the iris is the least common.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.1-2"></a>

###### Distribution of primary tumors by uveal site

> “UM appears as a pigmented or achromic mass arising from the choroid (90%), the ciliary body (6%) or the iris (4%)”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.1-3"></a>

###### Cell of origin and relation to cutaneous melanoma

> “Uveal melanoma (UM), which arises from melanocytes resident in the uveal tract, is the second most common melanoma subtype after cutaneous melanoma (CM)”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

<a id="topic-2.2.1.1-4"></a>

###### Ultraviolet light exposure and incidence trend

> “Unlike cutaneous melanoma, the incidence of UM has remained stable over time and is not linked to ultraviolet light exposure, except iris melanoma.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “In view of these susceptibility factors, numerous observational studies have explored the relationship between sunlight exposure and risk of uveal melanoma. These studies have found only weak associations or yielded contradictory results.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.1-5"></a>

###### Race, ethnicity, and iris color as risk factors

> “UM affects non-Hispanic white patients 18 times more frequently than black patients and 15 times more than Asian patients.”
> “Grey/blue-eyed coloured irises are at higher risk than brown-eyed coloured irises.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.1-6"></a>

###### Familial uveal melanoma and germline BAP1 and MBD4 variants

> “About 2%-5% of UMs are considered familial and are mainly associated with germline mutations in the tumour-suppressor gene BAP1 and less frequently with an MBD4 pathologic variant.”
> “Germline mutations in BAP1 have been identified as being responsible for the BAP1 tumour predisposition syndrome (BAP1-TPDS), which is associated with UM, mesothelioma, cutaneous melanoma and renal cell carcinoma.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.1-7"></a>

###### Risk factors: fair skin, light eye color, ocular melanocytosis, and BAP1 tumor predisposition syndrome

> “Risk factors include fair skin, light-coloured eyes, congenital ocular melanocytosis, ocular melanocytoma and the BAP1-tumour predisposition syndrome.”

Source: [Jager et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32273508/)

<a id="topic-2.2.1.1-8"></a>

###### Nevus of Ota as a risk factor

> “The nevus of Ota, a subtle intradermal proliferation of melanocytes resulting in bluish-gray hyperpigmentation in the sclera and periorbital dermis, is a risk factor for uveal melanoma.”

Source: [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)

<a id="topic-2.2.1.1-9"></a>

###### Progression of choroidal nevi to melanoma

> “In a large, retrospective, single-center series of 2,514 consecutive patients with choroidal nevi, the progression rate to melanoma was 8.6% at 5 years, 12.8% at 10 years, and 17.3% at 15 years.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Metastatic uveal melanoma

<a id="topic-2.2.1.2.1-1"></a>

###### U.S. age-adjusted incidence of uveal melanoma, SEER core registries, 1975 to 2020

> “The overall mean age-adjusted incidence of primary uveal melanoma in the US over the 45-year period from 1975 to 2020 was 5.6 per million population (95% CI: 5.5–5.7).”
> “As previously noted, a small but statistically significant (p < 0.05) annual percentage change of 0.5% was detected in whites.”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.2.1-2"></a>

###### Age-adjusted incidence of uveal melanoma by sex

> “Males had a significantly higher age-adjusted incidence of 6.3 per million population (95% CI: 6.1–6.6) compared to females with average age-adjusted incidence of 5.0 (95% CI: 4.8–5.2).”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence of uveal melanoma by race, ethnicity, sex, and age in 37,917 cases

> “A total of 37,917 UM cases were identified, with an overall AAIR of 5.54 per million (95% CI: 5.48-5.59), showing a stable but slightly increasing trend (AAPC = 0.06).”
> “Incidence was highest in non-Hispanic whites (6.87 ppm), men (6.25 ppm), and those aged 75-79 years.”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.2.1-4"></a>

###### Annual age-adjusted incidence of uveal melanoma by race and ethnicity

> “The annual age-adjusted incidence (per million population) of uveal melanoma was 0.31 (black), 0.38 (Asian), 1.67 (Hispanic), and 6.02 (non-Hispanic white).”

Source: [Hu et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16226513/)

<a id="topic-2.2.1.2.1-5"></a>

###### Race of uveal melanoma cases

> “A total of 98% of cases of uveal melanoma were in the white race, with only 0.6% of reported cases in the black population, and in the remaining 1.8%, race was unknown.”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.2.1-6"></a>

###### U.S. age-adjusted incidence of uveal melanoma and sex difference, NCI PDQ summary

> “The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people, with no clear variation by latitude. The incidence is higher in men (4.9 cases per million) than in women (3.7 cases per million).”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.2.1-7"></a>

###### Age at diagnosis of uveal melanoma

> “Median age at diagnosis was 63 years (range: 5–90 years).”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

> “Uveal melanoma is most often diagnosed in older individuals, with a progressively rising, age-specific incidence rate that peaks near age 70 years.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “UM occurs in patients of all ages; 1% of cases affect the paediatric population.”
> “Incidence increases with age, rising to >20 cases per million by the age of 70.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.2.1-8"></a>

###### Estimated U.S. new cases in 2026, all eye and orbit cancer

| Site, United States, 2026 | Estimated new cases, both sexes | Male | Female |
| --- | --- | --- | --- |
| Eye and orbit | “3200” | “1720” | “1480” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

> “About 3,200 new cancers (mainly melanomas) of the eye and orbit (eye socket) (1,720 in males and 1,480 in females)”

Source: [American Cancer Society key statistics for eye cancer (2026)](https://www.cancer.org/cancer/types/eye-cancer/about/key-statistics.html)

<a id="topic-2.2.1.2.1-9"></a>

###### Worldwide geographic variation in incidence

> “In a recent study, incidence that correlated with latitude was expressed as a north-to-south decreasing gradient, ranging from ≥8.0 cases per million person-years in Northern/Western Europe and Oceania, to 2.0-7.9 in North America, Eastern Europe and Southern Europe and <2.0 in South America, Asia and Africa.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.2.1-10"></a>

###### SEER stage at diagnosis of uveal melanoma

| SEER stage at diagnosis, uveal melanoma | N (%) |
| --- | --- |
| Localized | “6,126 (90.9)” |
| Regional | “506 (7.5)” |
| Distant | “109 (1.6)” |

Source: [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)

<a id="topic-2.2.1.2.1-11"></a>

###### Localized stage at diagnosis

> “Most tumors (81.3%) were localized at diagnosis”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.2.1-12"></a>

###### Detectable metastases at diagnosis of the primary tumor

> “Of 3610 patients with uveal melanoma, 69 (1.9%; 95% CI 1.5 to 2.4) presented with clinical metastasis (stage IV).”
> “Risk of synchronous metastases increased from 0.7% (T1) to 1.5% (T2), 2.6% (T3) and 7.9% (T4).”

Source: [Garg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8961763/)

> “Systemic metastases are evident in only 2% to 3% of patients at the time of diagnosis of the primary ocular melanoma.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “Most UMs are localised at diagnosis, with <2% presenting with detectable metastases.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.2.1-13"></a>

###### Proportion of patients who develop metastases after treatment of the primary tumor

> “Although local therapy is effective for local control in >90% of cases, up to 50% of patients will develop metastases, mainly in the liver (90%).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Unfortunately, up to 50% of patients with uveal melanoma will ultimately develop metastatic disease.”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Treatment of primary uveal melanoma with radiotherapy, enucleation or other modalities achieves local control in more than 90% of patients, although 40% or more ultimately develop distant metastases, most commonly in the liver.”

Source: [Carvajal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36600005/)

<a id="topic-2.2.1.2.1-14"></a>

###### Cumulative incidence of metastasis at 5 and 10 years, COMS trials

> “Seven hundred thirty-nine patients were diagnosed with at least 1 site of metastasis during follow-up after treatment for choroidal melanoma. Five- and 10-year cumulative metastasis rates were 25% (95% confidence interval, 23%-27%) and 34% (95% confidence interval, 32%-37%), respectively.”

Source: [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)

<a id="topic-2.2.1.2.1-15"></a>

###### Risk of metastasis by AJCC stage and tumor thickness

> “The AJCC Cancer Staging Manual is an anatomy-based system; tumour diameter and thickness, ciliary body involvement and extraocular extension are factors associated with the risk of metastasis at 10 years from 5% for stage I to 40% for stage III.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Small thickness UM (0-3 mm in thickness) was associated with a 5- and 10-year metastatic risk of 6% and 12%. The 5-/10-year metastatic risk of medium thickness (3.1-8 mm) and large tumors (>8 mm in thickness) was 14%/26% and 35%/49%, respectively”

Source: [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)

<a id="topic-2.2.1.2.1-16"></a>

###### Annual number of new U.S. cases of metastatic uveal melanoma

No evidence found.

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Metastatic uveal melanoma

<a id="topic-2.2.1.2.2-1"></a>

###### EU prevalence of uveal melanoma at orphan designation of tebentafusp

> “the condition was estimated to be affecting approximately 0.88 in 10,000 persons in the European Union, at the time the application was made.”
> “On average, UM incidence rate of 0.06 per 10,000 inhabitants is estimated for Europe.”
> “Based on this data, a current point prevalence of 0.88 per 10,000 EEA inhabitants was estimated.”

Source: [European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022)](https://www.ema.europa.eu/documents/orphan-maintenance-report/kimmtrak-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

<a id="topic-2.2.1.2.2-2"></a>

###### U.S. prevalence of uveal melanoma or of metastatic uveal melanoma

No evidence found.

<a id="topic-2.2.1.2.2-3"></a>

###### HLA-A∗02:01 positivity in U.S. and European populations

> “Despite showing unprecedented results, tebentafusp use is restricted to HLA-A*02:01-positivepatients. This accounts for 45% of people in the United States and Europe.”

Source: [de Melo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11299924/)

> “Unfortunately, only 40–50% of the European population express HLA-A*02:01, and eventually, almost all the patients treated with tebentafusp presented disease progression.”

Source: [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)

<a id="topic-2.2.1.2.2-4"></a>

###### HLA-A∗02:01 positivity by self-declared race among Brazilian bone marrow donors

> “Considering the race of the patients tested, 22.5% of white individuals, 17.5% of black, 22.8% of indigenous, 20.4% of yellow, and 20.2% of brown/mixed were HLA-A*02:01-positive.”
> “According to the presented data, the positiveness of HLA-A*02:01 in the Brazilian population is much lower when compared to the frequencies in North Americans and Europeans.”

Source: [de Melo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11299924/)

<a id="topic-2.2.1.2.2-5"></a>

###### HLA-A∗02011 share of HLA-A2 alleles in five U.S. population groups

> “The most frequently detected HLA-A2 allele in all groups was HLA-A*02011.”
> “Caucasian and Native American populations appear to be the most homogeneous exhibiting 95.7% and 94.3% A*02011, respectively.”
> “HLA-A*0202 (25.8%) and A*0205 (12.9%) were present in a large percentage of African-Americans.”

Source: [Ellis et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10689125/)

<a id="topic-2.2.1.2.2-6"></a>

###### HLA-A∗02:01 frequency in uveal melanoma cohorts compared with the general population

> “As a result, 10 haplotypes showed differences at a FDR of < 0.05 between uveal and population frequencies, of which nine showed higher frequency in uveal melanoma patients: HLA-A*01:01, HLA-A*02:01, HLA-B*08:01, HLA-B*15:01, HLA-B*18:01, HLA-B*44:02, HLA-C*01:02, HLA-C*05:01, HLA-C*07:01, HLA-C*12:03.”

Source: [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Five-year relative survival, all uveal melanoma, 1975 to 2016

> “The 5-year relative survival rate (82.8%) remained stable during the period from 1975 to 2016 (5-year follow-up data are not yet available for 2017–2020)”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.3-2"></a>

###### Five-year and ten-year relative survival, all uveal melanoma

> “5- and 10-year relative survival rates were 83.3% and 73.9%, respectively, with worse outcomes in metastatic disease.”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.3-3"></a>

###### U.S. five-year relative survival by SEER stage, eye melanoma diagnosed 2015 to 2021

> “These numbers are based on people diagnosed with melanoma of the eye (also known as ocular melanoma or intraocular melanoma) between 2015 and 2021.”

Source: [American Cancer Society eye cancer survival rates (2025)](https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html)

| SEER stage, eye melanoma | 5-year relative survival rate |
| --- | --- |
| Localized | “88%” |
| Regional | “65%” |
| Distant | “19%” |
| All SEER stages combined | “84%” |

Source: [American Cancer Society eye cancer survival rates (2025)](https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html)

<a id="topic-2.2.1.3-4"></a>

###### Estimated U.S. deaths in 2026, all eye and orbit cancer

| Site, United States, 2026 | Estimated deaths, both sexes | Male | Female |
| --- | --- | --- | --- |
| Eye and orbit | “530” | “280” | “250” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.3-5"></a>

###### Long-term metastasis-free survival and melanoma-related death

> “The KM estimates of MFS were 0.729 (0.719, 0.74), 0.648 (0.633, 0.663), and 0.616 (0.596, 0.636) at 10, 20, and 30 years, respectively. The cumulative probabilities of melanoma metastatic death at 10, 20 and 30 years were 0.241 (0.236, 0.245), 0.289 (0.283, 0.294), and 0.301 (0.295, 0.307).”
> “Death due to melanoma were rare beyond 20 years with normal life expectancy reached at 25 years after primary therapy.”

Source: [Radivoyevitch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8130945/)

<a id="topic-2.2.1.3-6"></a>

###### Uveal melanoma-related mortality over 35 years and late metastatic death

> “Uveal melanoma-related mortality was 31% (95% confidence interval [CI], 26-37) by 5 years, 45% (95% CI, 40-51) by 15 years, 49% (95% CI, 43-55) by 25 years, and 52% (95% CI, 45-58) by 35 years, according to cumulative incidence analysis.”
> “Of patients who died of uveal melanoma, 62%, 90%, 98%, and 100% did so within 5, 15, 25, and 35 years, respectively.”

Source: [Kujala et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14578381/)

<a id="topic-2.2.1.3-7"></a>

###### Time from treatment of the primary tumor to metastasis

> “The median time from the initial treatment of the tumor to metastasis was 3.45 years (interquartile range [IQR], 2.0-5.57).”

Source: [Lane et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6142974/)

<a id="topic-2.2.1.3-8"></a>

###### Micrometastatic dormancy and late liver metastasis

> “Metastatic liver disease is the overwhelming cause of death in uveal melanoma patients, with almost 50% of patients developing liver metastases up to 15 years after diagnosis.”
> “Most of these patients do not present with any evidence of overt metastasis at the time of initial diagnosis although it is assumed that they have undetectable micrometastases.”

Source: [Bakalian et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18281525/)

<a id="topic-2.2.1.3-9"></a>

###### Prognosis after extraocular extension, recurrence, or metastasis

> “Extraocular extension, recurrence, and metastasis are associated with an extremely poor prognosis, and long-term survival cannot be expected for patients with these features.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.3-10"></a>

###### Course after metastasis: liver involvement, survival beyond 5 years, and cure rate

> “Almost 50% of patients develop metastatic disease, which usually involves the liver, and is usually fatal within 1 year.”

Source: [Jager et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32273508/)

> “Meta-analyses confirm a median overall survival of 10-13 months, and a cure rate that approaches nil, although survival exceeding 5 years is possible, estimated 2% either with first-line treatment or with best supportive care.”

Source: [Rantala et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34999237/)

<a id="topic-2.2.1.3-11"></a>

###### Death rate after diagnosis of metastasis, COMS trials

> “The death rate following the report of melanoma metastasis was 80% at 1 year (95% confidence interval, 77%-83%) and 92% at 2 years (95% confidence interval, 89%-94%).”
> “Long-term survival after diagnosis of metastasis was uncommon; only 8 patients survived 5 or more years.”

Source: [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)

<a id="topic-2.2.1.3-12"></a>

###### Survival after diagnosis of metastasis with and without treatment

> “Overall, the median survival time was poor (3.9 months [IQR, 1.6-10.1]). Patients who received treatment fared better than those who did not receive treatment (median survival after metastasis diagnosis, 6.3 months [IQR, 2.96-14.41] vs 1.7 months [IQR, 0.66-3.5]).”

Source: [Lane et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6142974/)

<a id="topic-2.2.1.3-13"></a>

###### Pooled overall survival after metastasis, meta-analysis of 78 articles with 2494 participants

> “Individual-level data were obtained from 78 articles with 2494 patients. The median OS across all treatment modalities was 1.07 years (range: 0.59–2.50 years).”
> “Reported OS was unassociated with the decade of publication, but depended on the percentage of first-line treated patients.”

Source: [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)

<a id="topic-2.2.1.3-14"></a>

###### Progression-free and overall survival benchmarks

> “The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30).”
> “The median OS was 10.2 months (95% CI 9.5-11.0) and 1 year OS was 43% (95% CI 40-47).”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.1.3-15"></a>

###### One-year survival in a cohort with metastatic uveal melanoma

> “In our cohort, one-year survival for all patients with metastatic uveal melanoma is equal to 47.8% (95% CI 40.4–55.2), similar to that reported in known publications”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

<a id="topic-2.2.1.3-16"></a>

###### Overall survival with active treatment by working formulation stage

> “The median OS with active treatment was 18 (range, 0.7–162), 6.9 (range, 1.3–30) and 1.9 (range, 0.2–18) months in working formulation stage IVa, IVb and IVc, respectively.”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.3-17"></a>

###### Prognostic factors after metastasis: lactate dehydrogenase, alkaline phosphatase, and liver metastasis size

> “Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus <3 cm) to be substantially associated with shorter PFS.”
> “The most substantial prognostic factors for shorter OS by univariable and multivariable analysis were elevated LDH and elevated ALP.”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

> “The multivariable Cox analysis showed that slight to moderately elevated LDH (250–500 U/L) and high LDH level (>500 U/L) were a statistically significant factor associated with poor survival (p < 0.001), HR of 1.8 (95% CI 1.07–3.01) and 9.0 (95% CI 5.63–14.35) respectively. Also, the presence of liver metastases was negatively associated with survival, HR 2.09 (95% CI 1.07–4.08, p = 0.03).”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Different staging systems predict survival after metastatic disease appears, based on tumour burden, liver function tests, World Health Organization performance status (PS) and metastasis-free interval.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.3-18"></a>

###### AJCC distant metastasis categories by largest metastasis diameter

| AJCC M category | Definition |
| --- | --- |
| M1a | “Largest diameter of the largest metastasis ≤3.0 cm.” |
| M1b | “Largest diameter of the largest metastasis 3.1–8.0 cm.” |
| M1c | “Largest diameter of the largest metastasis ≥8.1 cm.” |

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.3-19"></a>

###### Distribution of AJCC M categories in a nationwide Finnish cohort

> “The largest metastasis was small (M1a) in 52%, medium-sized (M1b) in 31%, large (M1c) in 11%, and undetermined in 6% of patients.”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.3-20"></a>

###### Survival by mode of detection of metastasis

> “Cumulative rates of melanoma-related death were higher for patients in the symptomatic group vs the asymptomatic group (P < .001, log-rank test) owing to differences in mortality observed in the first year after diagnosis of metastasis (87.8% vs 68.5%).”
> “Presymptomatic detection of metastatic uveal melanoma by routine surveillance testing seems to confer a survival advantage only in the first year after diagnosis of metastasis, which is likely because of lead-time bias.”

Source: [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)

> “However, with multivariable analysis, the only variable that remained a significant risk of mortality was diagnosis by symptoms (HR 2.39 p < 0.017).”

Source: [Xu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6751472/)

<a id="topic-2.2.1.3-21"></a>

###### Delay before the effect of newer systemic therapies appears in SEER data

> “It will be several years before impact of newer systemic therapies for uveal melanoma is captured in SEER database”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Activating GNAQ and GNA11 mutations

> “Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.”
> “Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11.”

Source: [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)

<a id="topic-2.2.1.4-2"></a>

###### GNA11 and GNAQ Q209 mutations in primary tumors and metastases

> “The frequency of mutations in GNA11 at the codon encoding Q209 increased progressively from blue nevi (6.5%) to primary uveal melanomas (31.9%) to uveal melanoma metastases (56.5%), a pattern inverse to the distribution of Q209 mutations in GNAQ, which are most common in blue nevi (54.7%) and least common in uveal melanoma metastases (21.7%) (P<0.001)”

Source: [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)

> “In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients.”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

<a id="topic-2.2.1.4-3"></a>

###### Mutually exclusive G-protein pathway mutations: GNAQ, GNA11, CYSLTR2, and PLCB4

> “We found mutually exclusive somatic mutations in the G-protein pathway-associated GNAQ and/or GNA11 (92.5%), CYSLTR2 (4%), and PLCB4 (2.5%) genes”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

<a id="topic-2.2.1.4-4"></a>

###### CYSLTR2 mutation as a uveal melanoma oncogene

> “We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.”
> “The Leu129Gln CysLT2R mutant protein constitutively activates endogenous Gαq and is unresponsive to stimulation by leukotriene.”

Source: [Moore et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5032652/)

<a id="topic-2.2.1.4-5"></a>

###### PLCB4 mutation as the downstream effector of Gαq signaling

> “PLCB4 p.D630Y mutations are mutually exclusive with mutations in GNA11 and GNAQ, consistent with PLCB4 being the canonical downstream target of the former gene products.”

Source: [Johansson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4826231/)

<a id="topic-2.2.1.4-6"></a>

###### Protein kinase C and MAPK pathway activation downstream of GNAQ and GNA11

> “We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation.”
> “In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation, MAPK activation can be attributed to activated PKC.”

Source: [Chen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524511/)

<a id="topic-2.2.1.4-7"></a>

###### Second driver event: BAP1, SF3B1, or EIF1AX

> “After the GNAQ/GNA11 mutation, a second driver event is necessary for malignant transformation. The premalignant cells either present loss of function BAP1 or mutations in SF3B1 or EIF1AX. This second hit also occurs in a mutually exclusive fashion.”

Source: [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)

<a id="topic-2.2.1.4-8"></a>

###### BAP1 inactivation in metastasizing tumors and chromosome 3 loss

> “Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors”
> “One copy of chromosome 3 was missing in all 17 BAP1-mutant class 2 tumors for which cytogenetic data were available, consistent with chromosome 3 loss uncovering recessive BAP1 mutations”

Source: [Harbour et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3087380/)

<a id="topic-2.2.1.4-9"></a>

###### Four molecular subsets defined by chromosome 3 status, TCGA

> “Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM.”
> “EIF1AX and SF3B1 mutations in 27 of the 80 UM (34%) were nearly mutually exclusive”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

<a id="topic-2.2.1.4-10"></a>

###### Prognostic associations of BAP1, SF3B1, EIF1AX, MBD4, and PRAME

> “Biallelic BAP1 inactivation is associated with high risk of metastasis.”
> “Change-of-function SF3B1 mutations are associated with late metastasis.”
> “Mutations in EIF1AX are associated with a better prognosis.”
> “Mutations in MBD4 lead to a hypermutator phenotype, which has been correlated with improved response to immune checkpoint inhibitor (ICI) therapy.”
> “Expression of PRAME (preferentially expressed antigen of melanoma) is associated with a higher risk of metastases.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.4-11"></a>

###### Low tumor mutational burden and absence of BRAF, NRAS, KIT, and NF1 mutations

> “In WES data for matched tumor-blood pairs, the median somatic mutation density of 1.1 per Mb was markedly lower than in CM”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

> “Uveal melanomas are molecularly distinct from cutaneous melanomas and lack mutations in BRAF, NRAS, KIT, and NF1.”

Source: [Moore et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5032652/)

<a id="topic-2.2.1.4-12"></a>

###### Immunosuppressive tumor microenvironment

> “The UM microenvironment is characterised by high levels of tumour-promoting M2 macrophages, few active cytotoxic T cells and low programmed death-ligand 1 (PD-L1) expression.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.4-13"></a>

###### Hematogenous spread and liver tropism

> “Because the uveal tract is a vascular structure without lymphatic channels, tumor spread occurs principally by local extension and by dissemination through the bloodstream.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “UM is characterised by early seeding and years of dormancy of micrometastases; the liver constitutes a specific niche, as numerous molecules like chemokine ligand 12 and chemokine receptor 4 (CXCL12/CXCR4) are involved in UM liver homing.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.4-14"></a>

###### MET expression in primary tumors and liver metastases

> “Thirty-nine of 40 (98%) primary tumors and nine of 10 (90%) metastatic liver lesions expressed c-MET (H-score range 0-300).”
> “c-MET expression was significantly higher in metastatic compared with primary tumors (median H-score 190 vs. 30, P=0.022).”

Source: [Gardner et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25211165/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Clinical diagnosis of the primary ocular tumor

> “Careful examination by an experienced clinician remains the most important test to diagnose intraocular melanoma. A small uveal melanoma cannot be distinguished from a nevus. Small uveal lesions are observed for growth before making a diagnosis of melanoma.”
> “Ancillary diagnostic testing, including fluorescein angiography and ultrasonography, can be extremely valuable in establishing and confirming the diagnosis.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “Diagnosis is accurately established by clinical examination in over 99% cases.”

Source: [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)

<a id="topic-2.2.1.5-2"></a>

###### Guideline recommendations on ocular imaging and biopsy of the primary tumor

> “UM diagnosis is based on clinical examination by ophthalmoscopy, fundus photography and conventional ocular ultrasound (US) in patients presenting with blurred vision or other visual symptoms; however, 13%-30% are diagnosed during routine eye examinations.”
> “Biopsy is not mandatory for typical UM diagnosis, which is well characterised by ophthalmoscopy, fundus photography and conventional ocular US [II, D].”
> “A biopsy is recommended if the clinical diagnosis is uncertain and if it has been discussed with the patient due to the potential risks of the procedure and the uncertainty of a conclusive result [II, A].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-3"></a>

###### Staging and screening for distant metastases at diagnosis

> “UM should be staged according to the eighth edition of the AJCC Cancer Staging Manual.”
> “Patients should be screened for distant metastases [liver US or MRI with diffusion-weighted sequences, supplemented by positron emission tomography (PET)–computed tomography (CT) or thoraco-abdomino-pelvic CT for extrahepatic extension].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-4"></a>

###### Molecular prognostic testing of the primary tumor: methods and risk groups

> “The most commonly used prognostic tests are FISH, multiplex ligation-dependent probe amplification, microsatellite analysis, single-nucleotide polymorphism array, array comparative genomic hybridisation, targeted NGS and a 12-gene PCR assay based on gene expression profiling (GEP).”
> “A low risk of metastasis is associated with tumours that have normal chromosomes 3 and 8; these tumours often display 6p gain.”
> “Late but infrequent metastatic spread is associated with normal chromosome 3, one or more extra copies of (partial) chromosome 8, GEP class 1 status and with PRAME expression.”
> “A high risk of metastasis is associated with loss of one copy of chromosome 3 or isodisomy of this chromosome, polysomy of chromosome 8q, a GEP class 2 profile and inactivating mutations or deletions of the BAP1 gene located on chromosome 3.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-5"></a>

###### Gene expression profile class 1 and class 2: prospective multicenter validation

> “The GEP assay successfully classified 446/459 (97.2%) cases. The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%).”
> “Metastasis was detected in 3 (1.1%) class 1 cases and 44 (25.9%) class 2 cases”
> “Using multivariate Cox modeling, GEP class had a stronger independent association with metastasis than any other prognostic factor (P<0.0001).”

Source: [Onken et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3404209/)

<a id="topic-2.2.1.5-6"></a>

###### Recommended molecular work-up of primary and metastatic tumors

> “If sufficient tumour material is available, the molecular work-up of primary UM could include copy number assessment in chromosomes 3, 6 and 8, GEP, mutational status of BAP1, SF3B1, EIF1AX, and immunohistochemistry for BAP1 and PRAME expression [III, B].”
> “Assessment of mutational status of GNAQ, GNA11, SF3B1 and MBD4 may be recommended in the metastatic setting as results may impact treatment decisions [IV, C].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-7"></a>

###### Surveillance imaging of the liver after treatment of the primary tumor

> “There is no prospective evidence that imaging surveillance impacts the outcomes of patients with UM.”
> “Liver function tests have a low sensitivity and do not help detect early metastasis.”
> “Hepatic US has a sensitivity of 96% in detecting liver metastasis from UM but the positive predictive value (PPV) is only 45%.”
> “Gadolinium-enhanced liver MRI with diffusion-weighted sequences has demonstrated sensitivity of nearly 100% and specificity of 80%-99%, with a better ability to detect small lesions compared with US.”
> “Genetic and clinical factors should be used to guide surveillance, as there is no standard approach to detecting metastases in patients with UM [III, A].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-8"></a>

###### Sensitivity of hepatic ultrasonography and MRI for surveillance

> “Hepatic ultrasonography and magnetic resonance imaging as surveillance methods have a sensitivity of 95-100% and 83-100%, respectively, to detect metastases without radiation hazard according to prevailing evidence, but computed tomography is necessary for staging.”

Source: [Rantala et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34999237/)

<a id="topic-2.2.1.5-9"></a>

###### Liver function test screening for metastasis, COMS trials

> “Based on all patients with reported metastasis, the sensitivity, specificity, positive predictive value and negative predictive value associated with at least one abnormal LFT before first diagnosis of metastasis at any site was 14.7%, 92.3%, 45.7% and 71.0%, respectively.”

Source: [Diener-West et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15197206/)

<a id="topic-2.2.1.5-10"></a>

###### Detection of metastases by screening ultrasonography and liver function tests

> “Metastases were diagnosed in 74% of patients (95% confidence interval [95% CI], 59-86) at screening and in 26% (95% CI, 14-41) when the patient consulted a physician because of symptoms that developed before the next scheduled visit.”
> “US was diagnostic in 78% (95% CI, 64-89), at least 1 LFT test was abnormal in 70% of patients (95% CI, 54-82), and a chest X-ray was abnormal in 2% of patients (95% CI, 0-12).”

Source: [Eskelin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10091801/)

<a id="topic-2.2.1.5-11"></a>

###### Staging imaging and biopsy confirmation of metastatic disease

> “Staging of metastatic disease is based on total body CT scan and liver MRI; brain imaging is not required in the absence of central nervous system symptoms; the usefulness of fluorodeoxyglucose (FDG)–PET–CT is still debated.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Diagnosis of melanoma metastasis was confirmed by biopsy in 77.8% of the asymptomatic group and in 76.2% of the symptomatic group.”

Source: [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)

<a id="topic-2.2.1.5-12"></a>

###### HLA-A∗02:01 testing in the metastatic setting

> “HLA-A∗02:01 peripheral blood testing is mandatory in the metastatic setting [I, A] but can also be considered in the localised setting to facilitate access to adjuvant clinical trials [V, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-13"></a>

###### HLA-A∗02:01 companion diagnostic: specimen and sequencing method

> “The SeCore CDx HLA Sequencing System is intended for the detection of human leukocyte antigen A-locus (HLA-A) alleles using genomic DNA isolated from whole blood samples.”
> “The SeCore CDx HLA Sequencing System is a Sanger sequence-based method for molecular typing of HLA-A Locus alleles. Sequencing-based typing is a high-resolution method for the identification of HLA polymorphisms.”

Source: [FDA SeCore CDx HLA Sequencing System De Novo decision summary (2022)](https://www.fda.gov/media/163612/download)

<a id="topic-2.2.1.5-14"></a>

###### Turnaround of HLA-A∗02:01 testing in practice

> “However, faculty agreed that early testing is a low-burden step that can identify patients who would benefit from tebentafusp, as HLA results return in approximately 4 days, which is often faster than tumor biopsy results.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

Additional sources: [National Comprehensive Cancer Network Uveal Melanoma guideline](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Visual symptoms: blurred vision, visual field defect, and photopsia before diagnosis of the primary tumor

| Symptom before diagnosis, 159 Finnish patients | Patients, n | Patients, % |
| --- | --- | --- |
| Blurred vision | “78” | “49” |
| Visual field defect | “51” | “32” |
| Photopsia | “29” | “18” |
| Irritation and pain | “26” | “16” |
| Metamorphopsia | “10” | “6” |
| Floaters | “9” | “6” |
| Asymptomatic | “20” | “13” |

Source: [Eskelin et al. (2002)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1771030/)

<a id="topic-2.2.1.6-2"></a>

###### Visual symptoms by tumor location

> “Most uveal melanomas are initially completely asymptomatic. As the tumor enlarges, it may cause distortion of the pupil (iris melanoma), blurred vision (ciliary body melanoma), or markedly decreased visual acuity caused by secondary retinal detachment (choroidal melanoma).”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

###### Ocular signs: retinal detachment and secondary angle-closure glaucoma

> “Serous detachment of the retina may occur. If extensive detachment occurs, secondary angle-closure glaucoma occasionally develops.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.6-4"></a>

###### Asymptomatic primary tumors detected on routine examination

> “Although UM patients typically present with symptoms including blurred vision, visual field defect, metamorphopsia, or photopsia, 30% patients may be asymptomatic and upon routine eye examination, they are detected incidentally.”

Source: [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)

> “On referral, 30.2% of patients were asymptomatic.”

Source: [Damato et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22503229/)

<a id="topic-2.2.1.6-5"></a>

###### Ocular pain and vision loss in a case series of synchronous primary and metastatic disease

> “Seventeen patients (81%) had ophthalmic symptoms at diagnosis.”
> “Common symptoms were loss of vision (n=12), myodesopsia (n=4), photopsia (n=3) and eye pain (n=5).”

Source: [Steckler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8901542/)

<a id="topic-2.2.1.6-6"></a>

###### Hepatic and constitutional symptoms: abdominal pain, anorexia, weight loss, and nausea at detection of metastasis

> “Among the symptomatic group, metastasis was diagnosed in 259 patients (74.2%) after the onset of symptoms, such as anorexia or abdominal pain.”

Source: [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)

> “Ten patients were diagnosed after presenting with symptoms (weight loss, abdominal pain, nausea, back pain).”

Source: [Xu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6751472/)

<a id="topic-2.2.1.6-7"></a>

###### Asymptomatic metastatic disease at detection

> “Of all the patients, 59% (95% CI, 43-73) were asymptomatic, and 80% (95% CI, 66-91) had only hepatic metastases.”

Source: [Eskelin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10091801/)

<a id="topic-2.2.1.6-8"></a>

###### Physical signs of metastasis: hepatomegaly, lymphadenopathy, and subcutaneous nodules

> “In 1985, the Collaborative Ocular Melanoma Study (COMS) employed a combination of physical examination for hepatomegaly, enlarged lymph nodes and subcutaneous nodules as well as ancillary chest X-rays and liver function tests.”

Source: [Garg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8961763/)

<a id="topic-2.2.1.6-9"></a>

###### Laboratory signs: elevated lactate dehydrogenase and alkaline phosphatase at diagnosis of metastasis

> “Lactate dehydrogenase level (LDH) was elevated in 85 (48.6%) patients (Table 1).”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Serum or plasma alkaline phosphatase exceeded the upper normal limit (UNL) in 26% of 193 patients with available data.”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.6-10"></a>

###### Neurological symptoms: brain metastases

> “116/1,845 (6.3%) mUM patients were identified with BM.”
> “Brain imaging was obtained only upon onset of neurological symptoms in most cases of identified brain metastases and not for asymptomatic surveillance.”

Source: [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Metastatic uveal melanoma as the leading cause of death

> “The audited cause of death was uveal melanoma in 145 (61%) of them.”
> “Metastatic uveal melanoma was the leading single cause of death throughout the study.”

Source: [Kujala et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14578381/)

<a id="topic-2.2.1.7-2"></a>

###### Liver deterioration before death in metastatic disease

> “Patients with metastatic UM develop late symptoms leading to rapid deterioration in the liver and overall QoL before death.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.7-3"></a>

###### Disability attributed to the condition: vision impairment, enucleation, pain, and organ failure

> “the condition is life-threatening with a reduced survival in relapsed/refractory metastatic disease and chronically debilitating due to vision impairment (enucleation of the affected eye) and pain;”
> “The COMP concluded that the condition is life-threatening with a reduced survival in relapsed/refractory disease and chronically debilitating especially due to enucleation and in metastatic disease due to pain, organ failure, and treatment burden.”

Source: [European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022)](https://www.ema.europa.eu/documents/orphan-maintenance-report/kimmtrak-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

<a id="topic-2.2.1.7-4"></a>

###### Metastatic sites at death, COMS large tumor trial

> “A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sites were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis.”

Source: [Collaborative Ocular Melanoma Study Group (2001)](https://pubmed.ncbi.nlm.nih.gov/11346394/)

<a id="topic-2.2.1.7-5"></a>

###### Hepatic and extrahepatic metastatic sites during follow-up

> “Liver was the most common site (89%).”

Source: [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)

> “Systemic metastases are generally hematogenous in origin, and the first site identified is usually the liver.”
> “Lung, bone, and subcutaneous sites are also common.”
> “In the COMS trials, the liver was the only site of detectable metastasis in 46% of patients with metastases reported during follow-up or at the time of death; 43% had metastases diagnosed in the liver and other sites.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “The liver was the most affected site: 88% of patients having liver metastases. Other affected sites were the lungs (25.1%), lymph nodes (16%) and bones (15.4%)”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Ninety-two percent of patients had hepatic metastases with or without dissemination to other sites, and 70% had only hepatic metastases”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.7-6"></a>

###### Survival after symptomatic brain metastases

> “Following diagnosis of symptomatic BM, mOS was 7.6 months”

Source: [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)

<a id="topic-2.2.1.7-7"></a>

###### Second primary malignancies

> “27.4% of patients had another primary malignancy”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.7-8"></a>

###### Primary tumor treatment: surgery and radiation trends, 1975 to 2020

> “The previously reported declining trend in the number of patients treated with surgery alone (93% from 1975 to 1977 vs. 21% from 2017 to 2020) ensued, with ongoing corresponding increasing rates of radiation as the primary treatment (1% from 1975 to 1977 vs. 58% from 2017 to 2020).”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.7-9"></a>

###### Enucleation of the affected eye

> “A tumour with an extensive extraocular extension or that replaces >50% of the globe or leads to a blind and/or painful eye should be treated with enucleation or exenteration (30% of patients).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.7-10"></a>

###### Radiation-related ocular complications: maculopathy, optic neuropathy, neovascular glaucoma, and cataract

> “Any type of RT can lead to posterior complications such as maculopathy, optic neuropathy, neovascular glaucoma and retinopathy, which can have an impact on vision and eye preservation.”
> “In the anterior segment of the eye, cataract and dry eye are the most common side-effects.”
> “Signs of RT-induced maculopathy on fundus examination are detected in ≤66.5% of cases within 3 years of PBR.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.7-11"></a>

###### Visual acuity after iodine-125 brachytherapy, COMS medium tumor trial

> “Three years after I(125) brachytherapy, median visual acuity was 20/125, with 34% having 20/40 or better and 45% having 20/200 or worse visual acuity, including eyes that were enucleated within 3 years of treatment.”

Source: [Melia et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11158813/)

> “Eighty-five percent of the patients treated with 125I brachytherapy retained their eye for 5 years or more, and 37% of them had visual acuity better than 20/200 in the irradiated eye 5 years after treatment.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.7-12"></a>

###### Psychological morbidity: anxiety, depression, and worry about recurrence after prognostic testing

> “Compared to other groups, survivors with poor prognoses showed initially elevated anxiety and depression and consistently elevated worry about local or distant recurrence over 5 years.”

Source: [Brown et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8964647/)

> “The mean (SD) HADS anxiety score at baseline (7.4 [4.0]) was higher than at 3 months (5.4 [3.7]; P < .001) or 12 months (4.7 [3.4]; P < .001), and decreased with older age (coefficient estimate [SD], -0.06 [0.02]; P < .001).”

Source: [Schuermeyer et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26539659/)

<a id="topic-2.2.1.7-13"></a>

###### Psychological burden of surveillance and of eye loss

> “The discussion should include the emotional and organisational impact of this surveillance strategy as well as its frequency and duration.”
> “QoL is affected by specific concerns, including recurrence and loss of the eye or visual impairment. These need to be considered by ophthalmologists and oncologists, who should provide appropriate care, including psychological support, as depressive symptoms are common after ocular tumour treatment.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Metastatic uveal melanoma

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### EORTC QLQ-C30 global health status and EQ-5D visual analogue scale in the IMCgp100-202 tebentafusp trial, intent-to-treat analysis set

> “Global health status and quality of life was assessed using the EORTC QLQ-C30 questionnaire.”
> “EORTC QLQ-C30 was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.”
> “The EQ-5D VAS score records the participant's self-rated health on a vertical visual analogue scale, with 0 being the worst imaginable health state and 100 being the best imaginable health state.”
> “The Intent-to-treat (ITT) Analysis Set comprises all participants assigned to treatment analyzed by the treatment assignment whether or not the participant received the assigned treatment.”

Source: [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)

| EORTC QLQ-C30 global health status (score 0 to 100) | Tebentafusp: participants assessed | Tebentafusp: mean | Tebentafusp: SD | Investigator's choice: participants assessed | Investigator's choice: mean | Investigator's choice: SD |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline (cycle 1) | “173” | “76.108” | “20.233” | “65” | “74.872” | “20.439” |
| Change from baseline at cycle 3 | “105” | “0.952” | “16.274” | “35” | “-0.238” | “14.919” |
| Change from baseline at cycle 5 | “94” | “-1.152” | “20.797” | “22” | “-10.227” | “22.557” |
| Change from baseline at cycle 9 | “57” | “-2.193” | “19.577” | “13” | “-8.333” | “13.176” |
| Change from baseline at end of treatment | “76” | “-10.417” | “20.911” | “34” | “-10.539” | “23.148” |

Source: [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)

| EQ-5D visual analogue scale (score 0 to 100) | Tebentafusp: participants assessed | Tebentafusp: mean | Tebentafusp: SD | Investigator's choice: participants assessed | Investigator's choice: mean | Investigator's choice: SD |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline (cycle 1) | “194” | “81.0” | “16.36” | “78” | “80.4” | “18.31” |
| Change from baseline at cycle 3 | “136” | “0.4” | “14.69” | “45” | “-0.8” | “14.28” |
| Change from baseline at cycle 5 | “108” | “0.6” | “15.61” | “28” | “-0.7” | “14.38” |
| Change from baseline at cycle 9 | “71” | “-0.9” | “19.81” | “14” | “-3.3” | “13.30” |
| Change from baseline at end of treatment | “95” | “-10.1” | “22.53” | “45” | “-11.7” | “21.40” |

Source: [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)

<a id="topic-2.2.1.8.1-2"></a>

###### Health-related quality of life in a randomized phase 2 trial of selumetinib versus chemotherapy

> “Data from a phase II trial (clinicaltrials.gov identifier: NCT01143402) where patients with metastatic uveal melanoma were randomized to receive selumetinib, an oral MEK inhibitor, or chemotherapy were analyzed. Patients reported HRQoL at baseline, after 1 month, and end of treatment (n = 118), whereas physicians adjudicated AEs via CTCAE.”
> “Mean HRQoL scores did not significantly differ at each of the three time points.”

Source: [Atkinson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5303646/)

<a id="topic-2.2.1.8.1-3"></a>

###### Emotional impacts and treatment burden reported in qualitative interviews

> “Seventeen patients and 16 clinicians participated in the study. All patients were on anti-cancer treatment at the time of being interviewed, except for three who were deliberating treatment options.”
> “Most patients placed greater emphasis on the emotional, rather than physical, impacts of disease and treatment. Emotional concerns were centred on the existential threat posed by metastatic disease within the context of uncertainty about treatment access and effectiveness. More variably, patients were concerned with burden from treatment in the form of time commitment, travel, need for hospitalisation, and expense. Of the treatments received, immunotherapy – especially tebentafusp – conferred the heaviest inconvenience and symptom burden.”
> “Role functioning/well-being was impacted by symptoms and treatment burden, with several patients reducing or ceasing employment or more physically demanding leisure activities.”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

<a id="topic-2.2.1.8.1-4"></a>

###### Anxiety before and after surveillance and response scans

> “Fear of disease progression was most often manifest as a preoccupation with investigative tests as an indicator of treatment efficacy and the need to seek alternatives. Feelings of anxiety increased from a few days leading up to a test to when results were received. Patients’ experience of time waiting for results varied from 1 day to 3 weeks, depending on whether they needed to schedule an appointment.”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

> “Most participants were able to maintain everyday normalcy but struggled to discuss their illness and treatment with family and friends. Participants reported heightened anxiety in the lead-up to routine scans and while awaiting results.”

Source: [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)

<a id="topic-2.2.1.8.1-5"></a>

###### Distress trajectories and worry about recurrence in uveal melanoma survivors

> “In a closed cohort study, we used growth mixture modeling (GMM) to identify statistically optimal trajectories over 6-, 12-, 24-, 36-, 48-, 60-, 72-, and 84-month time point posttreatment in 475 patients.”
> “The majority scored consistently low, but 17.5% showed consistently elevated anxiety, 10.9% consistently elevated depression, and 19.4% consistently elevated FCR.”

Source: [Brown et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36848060/)

> “Non-randomized 5-year study of a consecutive series of 708 UM survivors (51.6% male, mean age 69.03, SD=12.12) with observations at 6, 12, 24, 36, 48 and 60 months.”
> “Generally, no prognostic groups reported anxiety, depression and WREC or QoL scores that exceeded general population norms.”

Source: [Brown et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8964647/)

<a id="topic-2.2.1.8.1-6"></a>

###### Quality of life after melphalan percutaneous hepatic perfusion

> “Twenty-four patients (14 males; median age 63.0 years) completed 96 questionnaires. Most scores on all scales declined on day 2/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores.”
> “Three variables were significantly worse on day 21 compared to baseline: fatigue (6–33; p = 0.002), physical functioning (100 vs 86.7; p = 0.003), and role functioning (100 vs 66.7; p = 0.001).”

Source: [Tong et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11164794/)

> “Retrospective analysis of the change in QoL using the Functional Assessment of Cancer Therapy-General (FACT-G) with mUM patients receiving M-PHP (n = 20).”
> “Baseline FACT-G median (IQR) scores were 101.8 (21.8). QoL scoring significantly decreased immediately after the procedure [day 1; 85 (27.5); P = 0.002] and gradually improved over time. By day 28, QoL almost returned to pre-procedure levels [100.3 (13.8); P = 0.31].”

Source: [Vigneswaran et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/)

<a id="topic-2.2.1.8.1-7"></a>

###### EQ-5D-3L health status and health utility after isolated hepatic perfusion, SCANDIUM trial

> “HRQOL was measured by the EuroQol 5-domains 3-levels (EQ-5D-3L) questionnaire over 12 months.”
> “Throughout the 12-month follow-up period, the VAS scores remained stable in the IHP group but there was a decrease in the control group at 6 months (83 vs. 64, P=0.002) and 12 months (86 vs. 63), P=0.002) (Fig. 4A).”
> “There were similar findings for health utility as measured by EQ-5D-3L, with a significant difference between IHP and controls at 6 months (0.87 vs. 0.70, P=0.019) and 12 months (0.88 vs. 0.66, P=0.005) (Fig. 4B). However, this difference was not significant when adjusting for baseline health utility scores with a mean change from baseline at 6 months of −0.02 versus −0.10 (P=0.36) and at 12 months −0.02 versus −0.08 (P=0.49).”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

Additional sources: [Campbell et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807618/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### All-cause healthcare costs and resource use in U.S. commercial, Medicare, and Medicaid claims

> “This study was conducted using the Merative MarketScan Commercial, Medicare, and Multi-State Medicaid Databases.”
> “In total 471 mUM patients were included; 47% Commercially-insured, 43% Medicare, and 10% Medicaid patients.”
> “Mean healthcare costs were $29,187 per patient per month (PPPM) (SD: $46,089) and included inpatient and outpatient medical costs, and outpatient pharmacy costs.”
> “Inpatient costs were $6,502 PPPM (SD: $28,591) overall, including $4,049 PPPM (SD: $23,619) for ICU admissions.”
> “Outpatient medical services (i.e., ER, office, labs, radiology, treatments) were $20,555 PPPM (SD $24,272).”
> “Outpatient pharmacy costs were $2,131 PPPM (SD $5,448).”
> “Most expenditures in mUM patients are associated with outpatient medical services; ICU admissions accounted for ≥60% of inpatient expenditures.”

Source: [Ott et al. (2026a)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/clinical-and-economic-burden-of-metastatic-uveal-melanoma-a-retrospective-analysis-of-commercially-insured-medicare-and-medicaid-patients-in-the-united-states)

<a id="topic-2.2.1.8.2-2"></a>

###### Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims

> “Costs were calculated from paid amounts on adjudicated claims, including insurer/health plan payments and patient out of pocket payments; actual costs (vs. imputed costs) were available for most patients.”
> “Healthcare costs were measured during the variable follow-up period in Commercial and Medicare patients.”
> “Mean PPPM all-cause costs were highest in patients treated with tebentafusp (Figure 3).”
> “Adverse event-related costs were highest among patients treated with tebentafusp but were the highest percentage of total costs in patients treated with chemotherapy (Figure 4).”
> “In this claims-based analysis, only half of mUM patients received any systemic treatment and 19% received liver directed therapy.”

Source: [Ott et al. (2026b)](https://www.ispor.org/docs/default-source/cti-meeting-21555-documents/38342afa-bde4-4633-bef6-da8a6d3fd1ee.pdf?sfvrsn=608231d6_0)

| Treatment group (Commercial and Medicare patients) | Mean all-cause healthcare costs per patient per month (2025 US$) | Mean adverse event-related costs per patient per month (2025 US$) | Adverse event-related costs as a percentage of all-cause costs |
| --- | --- | --- | --- |
| All patients (n=423) | “$28,859” | “$2,607” | “9.0%” |
| Chemotherapy (n=77) | “$30,682” | “$3,944” | “12.9%” |
| Checkpoint inhibitors (n=145) | “$36,056” | “$4,158” | “11.5%” |
| Tebentafusp (n=39) | “$93,805” | “$6,746” | “7.2%” |
| Liver directed therapy (n=80) | “$35,509” | “$3,078” | “8.7%” |

Source: [Ott et al. (2026b)](https://www.ispor.org/docs/default-source/cti-meeting-21555-documents/38342afa-bde4-4633-bef6-da8a6d3fd1ee.pdf?sfvrsn=608231d6_0)

<a id="topic-2.2.1.8.2-3"></a>

###### Hospital resource use and inpatient costs in NHS England

> “A cohort of UM (ICD-10 codes C693 or C694) patients that developed a subsequent cancer code (indicating metastasis), were identified within HES (observational period: Apr2012-Jun2016, follow-up until Jan2017).”
> “This analysis excluded costs not captured within HES (e.g. High Cost Drugs, Specialised Services, non-hospital palliative care).”
> “28% of patients were treated ≥40 km from home; and chemo-/immunotherapy was the most frequent medical procedure delivered (112 patients, 25%).”
> “Over the observed period, the cost to NHSE for mUM inpatient admissions was £2.5 million (mean: £6,084 per patient; range: £224-58,854). The cohort attended 3,618 outpatient appointments and had 669 A&E visits.”

Source: [Cheng et al. (2017)](https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-20th-annual-european-congress/quantifying-standard-of-care-soc-hospital-related-resource-utilisation-for-metastatic-uveal-melanoma-mum-patients-in-nhs-england-nhse-using-the-hospital-episodes-statistics-hes-dataset)

<a id="topic-2.2.1.8.2-4"></a>

###### Inpatient administration of tebentafusp during dose escalation in practice

> “We assessed MUM pts treated with TEBE at our center from Jun/2021-Nov/2022.”
> “We identified 36 pts.”
> “The median number of inpatient doses was 4 (3-18). In the OP setting, 19 pts (53%) were switched to q3 week visits after a median of 6 doses (6-39).”
> “Our data supports the reduction of OP visits and holding premedication after the resolution of AE.”

Source: [Ribeiro et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903102-2/fulltext)

> “Inpatient admission is recommended for the dose escalation for CRS monitoring and to provide appropriate supportive treatment.”
> “Fifteen patients received therapy, 47% (n=7) experienced CRS Grade 2 or above (Grade 2 n=5, 33%; Grade 3 n=2, 13%) versus 77% of patients in the trial setting.”
> “Future research should explore a larger real-world patient cohort to identify high-risk patients, removing the requirement for inpatient admission during dose escalation for low-risk patients.”

Source: [Roth et al. (2024)](https://cosa-2024.p.asnevents.com.au/days/2024-11-14/abstract/108393)

> “However, tebentafusp posed new challenges, requiring hospitalisation at commencement and long-distance travel for weekly infusions over an indeterminant period with no breaks”

Source: [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Metastatic uveal melanoma on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Practical and financial support from family members

> “About half of the patients described the support received from close family or friends as being important for emotional support, assisting in decision-making or practical support such as transport, finances, understanding of medical information, and support with activities of daily living when they were unwell. Of these patients, most specified their partner as their main source of support.”
> “However, some of them expressed regret for the emotional and practical burden their disease and treatment conferred to their family”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

<a id="topic-2.2.1.8.3-2"></a>

###### Travel and accommodation costs of treatment at specialist centers

> “Some treatments required patients to travel interstate or even overseas to access them, in two cases separating women from their family for long periods. In these instances, financial burden from travel and accommodation became a significant issue.”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

> “The survey was conducted on the SurveyMonkey platform, consisted of 22 questions, and was available in English from April 17th-May 17th, 2021.”
> “50% of participants similarly indicated that they require some level of assistance with travel costs.”
> “Therefore, while patients are willing to travel, it poses a significant financial hardship that is not always mitigated by provincial health insurance.”

Source: [Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021)](https://saveyourskin.ca/_files/ugd/e08cdc_41dfa819c12143e2a766b820f9cdeeab.pdf)

<a id="topic-2.2.1.8.3-3"></a>

###### Concern about the financial burden of self-funded treatment on the family

> “Aside from uncertainty, participant concerns focused largely on time, travel and financial burdens from new generation treatments, which were available only at specialist cancer centres and rarely subsidised by government schemes.”
> “Participants expressed worry about their ability to self-fund treatment and the potential they might have to decide whether to pursue expensive new treatments if their current one failed, especially the financial burden this might place on their family for increasingly uncertain gains with each new line of therapy”

Source: [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)

<a id="topic-2.2.1.8.3-4"></a>

###### Dependence on a spouse, partner, child, or caregiver

> “The majority of respondents at various risk for metastatic disease, and especially those with metastatic disease, also reported occasional dependence on a spouse, partner, child and/or caregiver.”

Source: [Haystack Project press release, uveal melanoma Patient Oriented Value report (2022)](https://haystackproject.org/s/Press-Release-UV-POV-vf.pdf)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Payment rates for HLA class I typing and uveal melanoma gene expression profiling on a 2026 state Medicaid laboratory fee schedule

> “This Fee Schedule is effective as of January 1, 2026.”
> “The appearance on this fee schedule of a code and rate is not an indication of coverage, nor a guarantee of payment.”

Source: [Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026)](https://www.chfs.ky.gov/agencies/dms/DMSFeeRateSchedules/2026ClinicalLabRates.pdf)

| Test | Code | Description | Rate |
| --- | --- | --- | --- |
| HLA class I typing, high resolution, one locus | “81380” | “HLA CLASS I TYPING HIGH RESOLUTION ONE LOCUS” | “$177.25” |
| HLA class I typing, high resolution, one allele or allele group | “81381” | “HLA CLASS I TYPING HIGH RESOLUTION ONE ALLELE OR ALLELE GROUP” | “$169.90” |
| Gene expression profiling of uveal melanoma, 15 genes | “81552” | “MRNA GENE EXPRESSION ANALYSIS OF 15 GENES IN EYE MELANOMA O TISSUE OR FINE NEEDLE ASPIRATE” | “$7,776.00” |

Source: [Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026)](https://www.chfs.ky.gov/agencies/dms/DMSFeeRateSchedules/2026ClinicalLabRates.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### HLA-A∗02:01 test at a U.S. reference laboratory: billing code, method, specimen, and turnaround

| Item | Labcorp test 167107, HLA A A∗02:01-Specific |
| --- | --- |
| CPT code | “81381” |
| Methodology | “Next Generation Sequencing (NGS), sequence-based typing (SBT) or other DNA methods as needed to achieve desired resolution” |
| Result turnaround time | “3 - 7 days” |
| Specimen | “Whole blood, buccal swabs, spot cards or extracted DNA” |
| Regulatory status | “This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.” |

Source: [Labcorp test 167107, HLA A A*02:01-Specific](https://www.labcorp.com/tests/167107/hla-a-a-02-01-specific)

<a id="topic-2.2.1.8.4-3"></a>

###### HLA-A∗02:01 status recorded in a U.S. real-world cohort

> “This retrospective study used the Tempus AI deidentified, multimodal database and included adults diagnosed with mUM from 2019-2025.”
> “Among 219 patients, median age at mUM diagnosis was 65 years; 52.5% were female.”
> “HLA-A*02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%.”

Source: [Salama et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/contemporary-real-world-patient-characteristics-treatment-patterns-and-clinical-outcomes-in-metastatic-uveal-melanoma-in-the-united-states)

<a id="topic-2.2.1.8.4-4"></a>

###### Medicare coverage of gene expression profiling of the primary tumor

> “This Medicare contractor will provide limited coverage for the DecisionDx-UM (Castle Bioscience, Inc.) test for the management of newly diagnosed uveal melanoma. This test is intended for the determination of metastatic risk, and to guide surveillance and referral to medical oncology (preferably an oncologist with expertise in melanoma) in patients who have a confirmed diagnosis of uveal melanoma (UM) and no evidence of metastatic disease.”
> “DecisionDx-UM is performed on tissue from a fresh-frozen fine needle aspirate biopsy (FNAB), formalin-fixed paraffin embedded (FFPE) sections from an enucleated tumor, or, in rare cases, fresh-frozen resection material. Results are reported as a 5-year risk classification for metastasis: low risk (Class 1A), intermediate risk (Class 1B), or high risk (Class 2).”

Source: [CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025)](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37130)

> “[C]overage for genetic or molecular prognostic testing may vary from payer to payer and require UM patients to go through multiple appeal processes to secure coverage. Medicare covers the DecisionDX-UM test but requires that billing providers utilize a registry and implies a level of oversight on subsequent care, including referrals and follow-up surveillance intensity, which could deter utilization.”

Source: [Haystack Project press release, uveal melanoma Patient Oriented Value report (2022)](https://haystackproject.org/s/Press-Release-UV-POV-vf.pdf)

<a id="topic-2.2.1.8.4-5"></a>

###### Medicare payment rate and annual volume of the DecisionDx-UM test

> “DecisionDx-UM tests are processed from our Phoenix laboratory and are covered under LCDs finalized by MAC administrators Palmetto and Noridian in July 2017. We estimate that a significant majority of the DecisionDx-UM tests performed for Medicare patients will meet the coverage criteria.”
> “Our rate for 2023 through 2025 was $7,776 per test and remains $7,776 per test for 2026.”
> “We estimate approximately 2,000 patients in the U.S. are diagnosed annually with UM, representing an estimated U.S. TAM of approximately $10 million.”

Source: [Castle Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm)

| DecisionDx-UM test reports delivered | Full year |
| --- | --- |
| Year ended December 31, 2025 | “1,769” |
| Year ended December 31, 2024 | “1,699” |

Source: [Castle Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm)

<a id="topic-2.2.1.8.4-6"></a>

###### Biopsy, prognostic genetic testing, and out-of-pocket payment reported in a Canadian patient and caregiver survey

> “30.56% of participants reported having a histopathology to confirm melanoma; 25% had a biopsy for monosomy 3; 19.44% had a biopsy for gene expression profiling; and 2.78% reported being unsure of how to answer the question.”
> “This question ascertained whether survey participants had undergone genetic testing to establish their level of metabolic risk.”
> “55.26% of participants responded that yes, they had; 39.47% responded that they had not; 2.63% were unsure; and 2.63% selected other and filled in more details surrounded the details of their genetic testing experience.”
> “53.85% of participants reported that they did not pay for their genetic testing and 46.15% did pay for their genetic testing.”
> “In multiple cases, participants stated that they declined genetic testing because of the cost.”

Source: [Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021)](https://saveyourskin.ca/_files/ugd/e08cdc_41dfa819c12143e2a766b820f9cdeeab.pdf)

<a id="topic-2.2.1.8.4-7"></a>

###### Surveillance intensity by metastatic risk class and modeled reduction in surveillance procedures

> “An accurate determination of metastatic risk at diagnosis allows for a risk-appropriate surveillance program.”
> “Patients with low metastatic risk can be removed from this traditional intensive surveillance and instead followed with a low intensity program, such as yearly exams, imaging, and LFTs.”
> “Strict compliance with DecisionDx-UM results was associated with a 50% reduction in the number of surveillance procedures performed at two years compared to the previous framework, and a 63% reduction at five years.”

Source: [CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025)](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37130)

<a id="topic-2.2.1.8.4-8"></a>

###### Liver surveillance imaging volume and modeled savings from risk-based screening in the United Kingdom

> “A total of 3854 liver scans were performed on the 615 patients, with a median of 6.2 scans per patient (range, 1–40). Liver MRI was the most performed modality, 2419 scans (63%).”

Source: [Rola et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9102800/)

> “Results showed that at 80% sensitivity, 87% of UM patients will avoid unnecessary radiological scans. This provides potential cost savings of between £46,000 and £97,000 per year to the National Health Service assuming 600 new cases per year.”

Source: [Eleuteri et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33516960/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Bispecific T-cell Receptor Therapy

<a id="topic-2.2.2.1.1-1"></a>

###### Tebentafusp: IMCgp100-202 primary analysis of overall survival in the intention-to-treat population of 378 participants

> “A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population.”
> “Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01).”
> “The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported.”

Source: [Nathan et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34551229/)

<a id="topic-2.2.2.1.1-2"></a>

###### Tebentafusp: IMCgp100-202 control arm composition and dosing

> “Of the 378 eligible HLA-A*02:01–positive patients, 252 were randomly assigned to the tebentafusp group and 126 to the control group; of the patients in the control group, 103 (82%), 16 (13%), and 7 (6%) were assigned to receive pembrolizumab, ipilimumab, and dacarbazine, respectively (Fig. S1 in the Supplementary Appendix).”
> “Pembrolizumab was given intravenously at a dose of 2 mg per kilogram of body weight (with a maximum of 200 mg per dose) on day 1 of each 21-day cycle. Ipilimumab was administered intravenously at a dose of 3 mg per kilogram on day 1 of each 21-day cycle for a maximum of four doses. Dacarbazine was given intravenously at a dose of 1000 mg per square meter of body-surface area on day 1 of each 21-day cycle.”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-3"></a>

###### Tebentafusp: IMCgp100-202 overall survival, progression-free survival, and response in the 3-year analysis

> “In this 3-year analysis, the overall survival benefit continued to favor tebentafusp, with a stratified hazard ratio for death of 0.68 (95% CI, 0.54 to 0.87) (Fig. 1A). Median overall survival was 21.6 months (95% CI, 19.0 to 24.3) in the tebentafusp group and 16.9 months (95% CI, 12.9 to 19.5) in the control group.”
> “The percentage of patients who were surviving at 1, 2, and 3 years among those treated with tebentafusp was 72%, 45%, and 27%, respectively, as compared with 60%, 30%, and 18% among the patients in the control group (Fig. 1A and Table S4).”
> “Median progression-free survival was 3.4 months (95% CI, 3.0 to 5.4) in the tebentafusp group and 2.9 months (95% CI, 2.8 to 3.0) in the control group (stratified hazard ratio for progression or death, 0.76; 95% CI, 0.60 to 0.97) (Fig. 1B and Table S4).”
> “With extended follow-up, the percentage of patients who had an objective response continued to be higher in the tebentafusp group than in the control group (11% vs. 5%), with five additional patients in the tebentafusp group having a partial response since the previous analysis (Table 1 and Fig. S5).”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-4"></a>

###### Tebentafusp: IMCgp100-202 treatment beyond progression, crossover, and survival with progressive disease as best response at 3 years

> “More than half the patients who received treatment in the tebentafusp group (139 of 245 [57%]) were treated beyond initial radiographic progression, as compared with a quarter of the patients in the control group (28 of 111 [25%]). Sixteen patients in the control group crossed over to receive tebentafusp after the primary analysis (Table S2).”
> “When this analysis was repeated with data from patients who crossed over to the tebentafusp group censored at the start of treatment with tebentafusp, the effect on the hazard ratio for death was minimal (0.70; 95% CI, 0.54 to 0.90).”
> “In a 100-day landmark analysis involving the patients who had a best overall response of progressive disease by day 100 after randomization, postlandmark overall survival was longer in the tebentafusp group than in the control group (Fig. 2, Table S6, and Figs. S8 and S9). The hazard ratio for death in this analysis was 0.62 (95% CI, 0.44 to 0.89) in favor of tebentafusp.”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-5"></a>

###### Tebentafusp: IMCgp100-202 cytokine release syndrome by ASTCT grade and treatment-related discontinuation at 3 years

> “cytokine release syndrome, which was graded post hoc, occurred in 89% of tebentafusp-treated patients and was most frequent in the first 4 weeks of treatment.”
> “Most of the patients who had cytokine release syndrome (88%) had grade 1 (12%) or 2 (76%) as the maximum grade, although some patients (1%) had a grade 3 event.”
> “Grade 3 or 4 treatment-related adverse events occurred in 116 patients (47%); the most common were rash (19%) and an elevation in the aspartate aminotransferase level (6%).”
> “No new treatment-related discontinuations were reported: during the trial, 2% of the patients in the tebentafusp group and 5% of those in the control group discontinued treatment because of adverse events that were related to treatment.”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-6"></a>

###### Tebentafusp: IMCgp100-202 final 5-year overall survival

> “Patients assigned to tebentafusp showed a continued overall survival advantage at 5 years, with median overall survival of 21.6 versus 16.9 months for the control group (hazard ratio 0.67, 95% CI 0.54-0.85, Figure 1). The 5-year survival rate was 16% (95% CI 11-21) in the tebentafusp group and 8% (95% CI 4-14) in the control group.”
> “As most deaths were related to disease progression (91%), melanoma-specific survival was highly similar to the overall population with a hazard ratio of 0.69 (95% CI 0.54-0.88).”
> “Of patients surviving at least 5 years, 44% (11 of 25) in the tebentafusp group were reported to have only received tebentafusp, whereas 6 of 7 patients in the control group had received subsequent tebentafusp”
> “Despite an 11% overall response rate, tebentafusp conferred a meaningful survival advantage not explained by subsequent therapies and evident across all RECIST categories.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.1-7"></a>

###### Tebentafusp: IMCgp100-202 survival with progression on tebentafusp and treatment beyond radiographic progression at 5 years

> “After adjusting for covariates, a post hoc analysis showed that patients who were treated with tebentafusp beyond radiographic progression had longer overall survival than those who discontinued treatment.”
> “Overall survival in patients with a best overall response of progressive disease by day 100 after randomization continued to be longer in the tebentafusp group than in the control group after a minimum duration of follow-up of 5-years [hazard ratio 0.61 (95% CI 0.43-0.88)”
> “Although the effect of TBP cannot be determined with certainty in this study, after adjusting for differences in these covariates, continued tebentafusp treatment was associated with improved postprogression survival [hazard ratio 0.61 (95% CI 0.44-0.83); Figure 5], with a similar trend of benefit among patients whose best overall response was progressive disease [hazard ratio 0.67 (95% CI 0.44-1.01)].”
> “Additionally, after rebaselining tumor burden at the point of initial disease progression, 27% (38/139) of tebentafusp patients treated beyond PD had subsequent tumor reduction compared with only 4% (1/28) of patients in the control group.”
> “Notably, 22% of patients in the control group received subsequent tebentafusp.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.1-8"></a>

###### HLA-A∗02:01 restriction: proportion of HLA-A∗02:01-negative patients at IMCgp100-202 prescreening

> “Furthermore, HLA-A∗02:01-negative patients continue to lack an established standard of care and comprised 49% of individuals prescreened, consistent with the rate observed in another ImmTAC study.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.1-9"></a>

###### Tebentafusp in previously treated disease: IMCgp100-102 response and survival

> “Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria.”
> “More than two-thirds of patients (n = 90) received prior immune checkpoint inhibition, of whom 68% had primary resistance to treatment with a prior best response of progressive disease, and 32% relapsed, with a prior best response of at least stable disease, following treatment.”

Source: [Carvajal et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9671803/)

<a id="topic-2.2.2.1.1-10"></a>

###### Tebentafusp in previously treated disease: IMCgp100-102 long-term survival in 146 treated participants

> “146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2. With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95% CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively.”

Source: [Sacco et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11163599/)

<a id="topic-2.2.2.1.1-11"></a>

###### Cytokine release syndrome: incidence, grade, and timing in a pooled analysis of 391 participants from IMCgp100-102 and IMCgp100-202

> “Across both studies, most patients experienced at least one episode of CRS (n = 344 of 391; 88%), the majority of which were mild (grade 1, 19%) or moderate (grade 2, 67%) in severity (Fig. 2A; Supplementary Table S4). Most grade 2 CRS events (92%) were due to hypotension, whereas 4.5% of events were attributed to hypoxia and 3.6% involved both conditions. Only a few patients (n = 7, 2%) had grade 3 (n = 6) or grade 4 (n = 1) CRS.”
> “There were no instances of immune effector cell-associated neurotoxicity syndrome reported, and no deaths occurred as a result of CRS.”
> “Most patients experienced CRS after each of the first three tebentafusp infusions, but both incidence and severity decreased with repeated dosing (Supplementary Fig. S3A).”

Source: [Sato et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12666308/)

<a id="topic-2.2.2.1.1-12"></a>

###### Cytokine release syndrome: management with antipyretics, fluids, and corticosteroids, and hospitalization in IMCgp100-202

> “Unlike other trials of T-cell engagers, none of the three tebentafusp trials mandated any premedications as primary prophylaxis for CRS. The medications most frequently used to treat CRS were antipyretics (88%), intravenous fluids (45%), and systemic corticosteroids (25%; Table 3); four (1%) patients received tocilizumab.”
> “Most patients with CRS (64%) received only a single dose of systemic corticosteroid to manage their CRS episodes, and in a post hoc propensity score analysis of IMCgp100-202, early corticosteroid use to manage AE did not negatively affect OS when adjusted for baseline prognostic factors (Fig. 3).”
> “In a retrospective analysis of hospitalizations, defined as either an extension of the mandated monitoring period during intra-patient dose escalation or an unplanned hospitalization at any time, in IMCgp100-202, a similar percentage of patients experienced an SAE-related hospitalization in the tebentafusp arm (24%) as in the investigator’s choice control arm (23%; Supplementary Table S8). In the tebentafusp group, most (65%) SAE-related hospitalizations occurred during the intra-patient dose-escalation period.”

Source: [Sato et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12666308/)

<a id="topic-2.2.2.1.1-13"></a>

###### Cytokine release syndrome: expert recommendations for post-dose monitoring and patient selection

> “Patients in good clinical condition and with a low tumour burden are good candidates for tebentafusp treatment, particularly if treated as early as possible after the diagnosis of metastatic disease.”
> “Postdose monitoring should thus focus on pyrexia and hypotension as the first symptoms of cytokine release. To minimise the risk of hypotension associated with CRS, patients should receive intravenous fluids before starting treatment.”

Source: [Hassel et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/37595494/)

<a id="topic-2.2.2.1.1-14"></a>

###### Tebentafusp: survival by line of therapy and inpatient stay during dose escalation in a treated cohort

> “71% of patients were treated in the first-line setting, with 94% having liver metastases. At a median follow-up of 12 months (range 0 to 34), mOS was 21 months (95% CI, 17 to NR), and mPFS was 2.76 months (95% CI, 2.53-3.22).”
> “First-line tebentafusp was associated with a longer mOS of 22 months (95% CI, 18 months to NR), compared to a mOS of 16 months (95% CI 10 months to NR) in the second-line and beyond (Figure S7).”
> “The required inpatient stay within the dose escalation phase was generally brief, with a median of 3 cumulative number of nights as an inpatient for doses 1 to 3.”
> “No ≥ grade 3 toxicity was observed beyond dose 5.”

Source: [Joseph et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13568816/)

<a id="topic-2.2.2.1.1-15"></a>

###### Tebentafusp in a cohort of 175 participants: toxicity, treatment beyond progression, and survival

> “175 patients were included: 127 received first-line tebentafusp, 48 had prior immune checkpoint inhibitors and/or chemotherapy.”
> “Thirty-two patients (18 %) developed transient grade 3-4 toxicity, mostly rash, 5 patients had grade 3 cytokine release syndrome.”
> “76 patients (43 %) were treated beyond progression; 1 was the CR, 1 PR and 30 SD. Median progression-free survival (PFS) was 4 months (95 % CI 2.7-5.3), median OS was 20 months (95 % CI 15.3-24.6).”

Source: [van der Kooij et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40680464/)

<a id="topic-2.2.2.1.1-16"></a>

###### Tebentafusp: retrospective comparison of sequencing with immune checkpoint inhibitors

> “Patients with HLA-A * 02:01 positive mUM, or metastatic GNA11/GNAQ mutant melanocytic tumors treated with tebentafusp followed by ICIs (group 1) or the inverse sequence (group 2) at any treatment line were retrospectively identified.”
> “Median OS was 22.4 months (95 % CI 19-24.8) in group 1 and 33.6 months (95 % CI 28.9-43) in group 2 (p = 0.004).”
> “This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.”

Source: [Dimitriou et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39647344/)

<a id="topic-2.2.2.1.1-17"></a>

###### Tebentafusp versus nivolumab plus ipilimumab: propensity score-weighted comparison of IMCgp100-202 and GEM1402

> “In the single-arm GEM1402 (N = 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%.”
> “The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I.”
> “IPTW analysis of pembrolizumab versus N+I showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06).”

Source: [Piulats et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38048850/)

<a id="topic-2.2.2.1.1-18"></a>

###### Tebentafusp: guideline recommendation for HLA-A∗02:01-positive metastatic disease

> “For HLA-A∗02:01-positive patients, tebentafusp should be standard of care in the first-line metastatic setting unless liver-directed treatment modalities are required first for tumour debulking [I, A; ESMO-Magnitude of Clinical Benefit (ESMO-MCBS) v2.0 score: 3].”
> “If these patients progress, liver-directed treatment modalities, anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.1-19"></a>

###### Tebentafusp: NICE recommendation and clinical findings

> “Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it according to the commercial arrangement.”
> “Clinical trial evidence suggests that tebentafusp could increase how long people live and how long they have before their cancer gets worse compared with usual treatment.”

Source: [NICE technology appraisal guidance TA1027, recommendations (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/1-Recommendations)

<a id="topic-2.2.2.1.1-20"></a>

###### Tebentafusp: CADTH recommendation, clinical findings, and inpatient monitoring for initial doses

> “The CADTH pCODR Expert Review Committee (pERC) recommends that tebentafusp be reimbursed for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the first-line setting”
> “Tebentafusp was associated with a risk of cytokine release syndrome and dermatological adverse events. pERC acknowledged that while not insignificant, these adverse events are transient and manageable with monitoring in an inpatient setting for initial doses, supportive care, and dose adjustment.”
> “According to the clinical expert consulted by CADTH, the first 3 to 4 infusions of tebentafusp are associated with a risk of cytokine release syndrome which requires inpatient monitoring in an experienced institution and management by a specialist physician experienced in the use of tebentafusp. Subsequent infusions may be performed in community clinic setting.”
> “pERC discussed the indirect treatment comparison (ITC) submitted by the sponsor: an unanchored matching-adjusted indirect comparison (MAIC) of tebentafusp relative to ipilimumab plus nivolumab. pERC noted that while a statistically significant improvement in OS and progression-free survival (PFS) for tebentafusp was demonstrated, the results of the ITCs stem from highly uncertain evidence due to limitations that impact the internal and external validity, despite the various adjustments.”
> “The preparation of tebentafusp is complex and intense and will require considerable Pharmacy resources to prepare each dose.”

Source: [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline recommendation on combination immunotherapy and patient selection

> “Given the lack of a clear survival advantage in metastatic UM associated with nivolumab–ipilimumab versus pembrolizumab and the increased toxicity associated with the former, only selected patients fit enough for the combination and with predominant extrahepatic disease should be considered for the combination immunotherapy.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-2"></a>

###### Guideline summary of anti-PD-1 monotherapy outcomes in uveal melanoma

> “Patients with metastatic UM have been excluded from most trials evaluating ICIs in cutaneous melanoma.”
> “Although the safety profile of PD-1 inhibitors was better in UM compared with cutaneous melanoma, efficacy was comparatively disappointing, showing <5% ORR, median PFS of 3 months and 1-year OS ∼50%, likely due to low tumour mutational burden, poor antigen processing and presentation and the immune-suppressive tumour microenvironment in UM.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-3"></a>

###### Guideline summary of phase 2 trials of nivolumab plus ipilimumab

> “In two phase II studies in 52 and 33 patients, respectively, nivolumab–ipilimumab was associated with ORR of 11% and 18%, median PFS of 3 and 5.5 months and median OS of 12 and 19 months, respectively, after a median follow-up of ∼13 months.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-4"></a>

###### Indirect comparison of tebentafusp, nivolumab plus ipilimumab, and pembrolizumab in first-line disease: guideline summary

> “In the absence of randomised comparative studies, indirect comparisons of ICIs with tebentafusp in first-line metastatic UM have been conducted.”
> “A propensity score analysis of two studies showed an OS benefit for tebentafusp versus nivolumab–ipilimumab (1-year OS rate of 73% versus 50%, respectively), independent of HLA status, and no significant difference in survival between pembrolizumab and nivolumab–ipilimumab (median OS and 1-year OS rate of 16.9 months and 60% versus 14.2 months and 52%, respectively).”
> “Toxicity rates were higher with nivolumab–ipilimumab compared with pembrolizumab (23% versus 2%-5% treatment-related discontinuations and two versus no treatment-related deaths).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.2-5"></a>

###### First-line nivolumab plus ipilimumab: single-arm phase 2 trial of the Spanish Multidisciplinary Melanoma Group, 52 participants

> “This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1).”
> “Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.”
> “A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.”
> “The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).”
> “The median OS and PFS were 12.7 months and 3.0 months, respectively.”
> “Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.”

Source: [Piulats et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33417511/)

<a id="topic-2.2.2.1.2-6"></a>

###### Nivolumab plus ipilimumab: single-arm phase 2 trial of 35 participants

> “This single-arm phase II study of nivolumab and ipilimumab in patients with metastatic uveal melanoma demonstrated an overall response rate (ORR) of 18%, a median progression-free survival of 5.5 months, and a median overall survival of 19.1 months.”
> “Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.”
> “The ORR was 18%, including one confirmed complete response and five confirmed partial responses.”
> “For the 35 patients included in the study, the median OS was 19.1 months (95% CI, 9.6 months to NR), and the 1-year OS was 56% (95% CI, 38% to 71%).”
> “The ORR in the 31 evaluable patients who were checkpoint naïve was 19%.”

Source: [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)

<a id="topic-2.2.2.1.2-7"></a>

###### Nivolumab plus ipilimumab in practice: multicenter retrospective study of 89 participants

> “We conducted a retrospective analysis of patients with metastatic UM (mUM) who received treatment with ipilimumab plus nivolumab across 14 academic medical centers.”
> “89 eligible patients were identified.”
> “Overall response rate was 11.6%.”
> “Median OS from treatment initiation was 15 months and median PFS was 2.7 months.”

Source: [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

<a id="topic-2.2.2.1.2-8"></a>

###### Ipilimumab plus a PD-1 inhibitor at 16 German skin cancer centers: 64 participants

> “The clinical data of 64 patients from 16 German skin cancer centers who met the inclusion criteria were investigated.”
> “The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete and partial response, respectively.”
> “The median PFS was 3.0 months (95% CI 2.4–3.6).”
> “The median OS was estimated to 16.1 months (95% CI 12.9–19.3).”

Source: [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/)

<a id="topic-2.2.2.1.2-9"></a>

###### First-line pembrolizumab: prospective observational cohort of 17 participants

> “In this prospective observational cohort single arm study, we investigated efficacy and safety of Pembrolizumab as first-line therapy for mUM.”
> “Seventeen patients were enrolled.”
> “Two patients achieved partial response (11.7%), 6 a disease stabilization (35.3%), whereas 9 (53%) had a progression.”
> “Toxicity was mild, without grade 3–4 side effects.”

Source: [Rossi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6584707/)

<a id="topic-2.2.2.1.2-10"></a>

###### PD-1 or PD-L1 antibody monotherapy: multicenter retrospective series of 56 participants

> “Safety and clinical efficacy outcomes including best overall response (BOR), progression-free survival (PFS), overall survival (OS) were determined retrospectively.”
> “we report clinical outcomes in a larger series of 56 patients treated at nine institutions with PD-1 (pembrolizumab or nivolumab) or PD-L1 (atezolizumab) antibodies.”
> “Objective tumor responses were observed in two patients for an overall response rate of 3.6% (95% CI 1.8-22.5%).”
> “The median PFS was 2.6 months (95% CI 2.4-2.8 months) and the median OS was 7.6 months (95% CI 0.7-14.6 months).”

Source: [Algazi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767160/)

<a id="topic-2.2.2.1.2-11"></a>

###### PD-1 inhibitor monotherapy at 20 German skin cancer centres: 86 participants

> “Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres.”
> “Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%.”
> “Median OS was 14 months for pembrolizumab-treated and 10 months for nivolumab-treated patients (p = 0.765).”

Source: [Heppt et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28648699/)

<a id="topic-2.2.2.1.2-12"></a>

###### Ipilimumab monotherapy: phase 2 DeCOG trial in pretreated and treatment-naïve participants

> “We performed an open-label, multicenter, single-arm phase II clinical trial (DeCOG-trial) to further evaluate the efficacy and safety of 3mg/kg ipilimumab in treatment-naïve and pretreated patients with advanced UM seen in daily routine in interdisciplinary skin cancer units in Germany.”
> “Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab.”
> “Median OS was 6.8 months (95% CI 3.7–8.1), median progression-free survival 2.8 months (95% CI 2.5–2.9).”
> “Sixteen patients had stable disease (47%), none experienced partial or complete response.”
> “Treatment-related AEs were observed in 35 patients (66%), including 19 grade 3–4 events (36%).”

Source: [Zimmer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4356548/)

<a id="topic-2.2.2.1.2-13"></a>

###### Ipilimumab monotherapy after prior treatment: expanded access program of 82 assessable participants

> “Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses.”
> “Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%.”
> “With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months.”

Source: [Maio et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24067719/)

<a id="topic-2.2.2.1.2-14"></a>

###### Meta-analysis of response and survival by checkpoint inhibitor class

> “Pooled ORR was 9.2% overall (95% CI 7.2-11.8) [4.1% for anti-CTLA4 (95% CI 2.1-7.7), 7.1% for anti-PD(L)1 (95% CI 4.5-10.9) and 13.5% for anti-CTLA4 plus anti-PD1 (95% CI 10.0-18.0)].”
> “Median OS was 11.5 months overall (95% CI 9.5-13.8) [8.0 months for anti-CTLA4 (95% CI 5.5-9.9), 11.7 months for anti-PD(L)1 (95% CI 9.0-14.0) and 16.0 months for ipilimumab plus anti-PD1 (95% CI 11.5-17.7) ( P < 0.001)].”
> “Median PFS was 3.0 months overall (95% CI 2.9-3.1).”

Source: [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Liver-directed Therapies

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline recommendations for surgical resection, thermal ablation, and stereotactic radiotherapy

> “Patients with oligometastatic UM with metastases confined to the liver can be considered for surgical resection and/or local liver-directed therapies (thermal ablation with radiofrequency, cryoablation or microwave ablation) [IV, B].”
> “SRT could be an alternative in patients not eligible for surgery or thermal ablation [IV, B].”
> “Preoperative MRI can be recommended as well as laparoscopy before or at the time of planned resection [IV, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-2"></a>

###### Guideline recommendations for regional hepatic perfusion

> “Patients with multifocal liver metastases confined to the liver should be considered for regional liver-directed therapies (PHP or IHP) [II, B].”
> “Patients with liver-dominant disease and a good general condition can be considered for regional treatment at any line of metastatic recurrence.”
> “The melphalan for Injection/Hepatic Delivery System, recently approved by the Food and Drug Administration (FDA), may be considered an option in patients with HLA-A∗02:01-negative UMLMs and limited tumour burden.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-3"></a>

###### Liver-directed options listed in the NCCN guidelines, as summarized by the FOCUS investigators

> “the National Comprehensive Cancer Network guidelines recommend for those patients, among other options, liver-directed therapies, including transarterial chemoembolization (TACE), radioembolization or immunoembolization, and thermal ablation, as well as locoregional perfusion procedures delivering high-dose chemotherapeutic agents, namely, intrahepatic perfusion (IHP), a surgical procedure, and percutaneous hepatic perfusion (PHP), a minimally invasive procedure.”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.3-4"></a>

###### Melphalan percutaneous hepatic perfusion: single-arm phase 3 FOCUS study, treated population of 91 participants

> “The multicenter, open-label, phase 3 FOCUS study was designed to evaluate the efficacy and safety of melphalan/HDS in patients with unresectable mUM.”
> “Due to slow enrollment, with patient reluctance to receive BAC treatment, the study design was amended to a single-arm study, after which all eligible patients received treatment with melphalan/HDS.”
> “Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.”
> “The study enrolled 102 patients with mUM.”
> “In the treated population ( n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44–47.01), including 7.7 % of patients with a complete response.”
> “The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.”
> “The median PFS was 9 months, with a PFS of 65 % at 6 months.”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.3-5"></a>

###### Selection criteria in the FOCUS study: liver involvement up to 50 percent

> “The study population included male and female patients 18 years of age or older with histologically verified mUM to the liver; liver tumor involvement of up to 50 %; at least one measurable liver lesion as assessed by contrast-enhanced computed tomography (CT) scans of the chest, abdomen, and pelvis as well as contrast-enhanced MRI of the liver (and brain and bone scans when indicated)”
> “The eligibility criteria were designed to minimize the risks associated with the procedure (e.g., exclusion of patients with moderate or severe liver cirrhosis, portal hypertension, or New York Heart Association [NYHA] II–IV status).”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.3-6"></a>

###### Melphalan percutaneous hepatic perfusion versus best alternative care: randomized portion of FOCUS, 85 participants

> “The multicenter, open-label, Phase 3 FOCUS study was designed to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable mUM in comparison to best alternative care (BAC).”
> “Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.”
> “The study enrolled 85 patients.”
> “Eligible patients were randomized to receive Melphalan/HDS ( n = 43) or BAC ( n = 42), and 72 patients received study treatment (Melphalan/HDS [ n = 40]; BAC [ n = 32]).”
> “Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%).”
> “Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients.”

Source: [Zager et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12130151/)

<a id="topic-2.2.2.1.3-7"></a>

###### Melphalan percutaneous hepatic perfusion versus best available care: earlier randomized phase 3 trial of 93 participants

> “A total of 93 patients were randomized to PHP-Mel ( n = 44) or BAC ( n = 49).”
> “This randomized, phase III study demonstrated the efficacy of the PHP-Mel procedure.”
> “hPFS was 7.0 months for PHP-Mel and 1.6 months for BAC ( p < 0.0001), while oPFS was 5.4 months for PHP-Mel and 1.6 months for BAC ( p < 0.0001).”
> “Median OS was not significantly different (PHP-Mel 10.6 months vs. BAC 10.0 months), likely due to crossover to PHP-Mel treatment (57.1 %) from the BAC arm, and the hOR was 36.4 % for PHP-Mel and 2.0 % for BAC ( p < 0.001).”

Source: [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/)

<a id="topic-2.2.2.1.3-8"></a>

###### Isolated hepatic perfusion versus best alternative care: randomized phase 3 trial, response and progression-free survival

> “In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group).”
> “Patients with histologically or cytologically confirmed liver metastases from uveal melanoma were eligible if they had measurable disease according to RECIST version 1.1 criteria, had received no previous therapy for melanoma metastases (ie, first-line therapy), and had no evidence of extrahepatic disease by positron emission tomography-computed tomography (CT).”
> “Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44).”
> “In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively ( P < .0001).”
> “The median PFS was 7.4 months versus 3.3 months ( P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months ( P < .0001), both favoring the IHP arm.”
> “There was one treatment-related death in the IHP group.”

Source: [Olofsson Bagge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414734/)

<a id="topic-2.2.2.1.3-9"></a>

###### Isolated hepatic perfusion versus best alternative care: SCANDIUM final overall survival

> “In this phase III randomized controlled multicenter trial (the SCANDIUM trial), patients with previously untreated isolated uveal melanoma liver metastases were included between 2013 and 2021, with at least 24 months of follow-up.”
> “The primary endpoint was the 24-month OS rate, with the hypothesis of a treatment effect leading to a 50% OS rate in the IHP group compared to 20% in the control group.”
> “The 24-month OS rate was 46.5% in the IHP group versus 29.5% in the control group ( P =0.12).”
> “The median OS was 21.7 months versus 17.6 months, with a hazard ratio of 0.64 (95% CI, 0.37–1.10).”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.3-10"></a>

###### Percutaneous hepatic perfusion with or without ipilimumab plus nivolumab: single-centre randomized phase 2 trial

> “In this investigator-initiated, single-centre, open-label, randomised, phase 2 trial, adults aged 18-80 years with unresectable liver-only or liver-dominant metastatic uveal melanoma, WHO performance status 0-1, and with no previous systemic therapy were randomly assigned (1:1) to receive percutaneous hepatic perfusion alone (perfusion group) or percutaneous hepatic perfusion combined with ipilimumab plus nivolumab (combination group).”
> “1-year progression-free survival was 54·7% (95% CI 36·8-69·5) with combination therapy versus 15·8% (5·8-30·1) with perfusion alone (adjusted hazard ratio 0·34 [95% CI 0·19-0·60]; p=0·0002).”
> “Grade 3-4 treatment-related adverse events occurred in 31 (82%) of 38 patients with combination therapy compared to 15 (41%) of 37 patients with perfusion alone, due to both a higher incidence of severe perfusion-related events and immunotherapy-related adverse events.”
> “One treatment-related death (due to triple M syndrome) occurred in the combination group.”

Source: [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/)

<a id="topic-2.2.2.1.3-11"></a>

###### Surgical resection of liver metastases: outcomes and selection criteria in the guideline

> “Retrospective cohorts have reported a median OS of 14-29 months after surgery of UMLMs.”
> “Median progression-free survival (PFS) and OS after resection with curative intent are 12 months and 26 months, respectively, with reported 5-year survival rates of ∼35% in highly selected patients.”
> “Surgery with curative intent (R0 resection) is the treatment of choice when the disease-free interval from primary tumour diagnosis to liver metastases is >24 months, and the number of metastases is ≤4 in the absence of miliary disease.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-12"></a>

###### Surgical resection of liver metastases: single-institution series of 255 resected participants

> “To review the evolving surgical management of this challenging condition at a single institution over a 16-year period.”
> “255 patients underwent surgical resection.”
> “The median overall postoperative survival was 14 months, but increased to 27 months when R0 resection was possible.”
> “With multivariate analysis, four variables were found to independently correlate with prolonged survival: an interval from primary tumour diagnosis to liver metastases >24 months, comprehensiveness of surgical resection (R0), number of metastases resected (< or = 4) and absence of miliary disease.”

Source: [Mariani et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19329272/)

<a id="topic-2.2.2.1.3-13"></a>

###### Surgical resection of metastases in highly selected patients

> “Surgical resection of metastases from ocular melanoma has been reported in case series of highly selected patients with occasional favorable outcomes.”
> “However, the favorable outcomes may be the result of strong patient-selection factors, and the role of resection in this setting is unclear.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.2.1.3-14"></a>

###### Thermal ablation compared with resection

> “Compared with liver resection, cryoablation, microwave or radiofrequency ablation is associated with lower complication rates, lower costs, shorter hospital stays and faster patient recovery.”
> “A retrospective study comparing resection and percutaneous ablation in 57 and 15 patients, respectively, found no difference in median OS (27 months versus 28 months).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-15"></a>

###### Hepatic arterial infusion, transarterial chemoembolization, and radioembolization: guideline summary

> “In hepatic arterial infusion (HAI), also known as intra-arterial or transarterial ChT, ChT is administered through a catheter placed in the hepatic artery.”
> “Many cytotoxic agents have been tested, with fotemustine being the most active.”
> “Studies investigating TACE in patients with UMLMs are limited to retrospective and small phase II trials and vary widely in the type of cytotoxic drugs and embolic agents used, the number of procedures per patient and patient selection criteria.”
> “The larger studies reported ORRs of 14%-46%, median PFS of 3-8 months and median OS of 5-29 months.”
> “In transarterial radioembolisation (TARE), microspheres labelled with yttrium-90 or holmium-166 have been studied in retrospective and small prospective series; median PFS was 5.4 months and median OS was 12.3 months.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-16"></a>

###### Immunoembolization with GM-CSF versus bland embolization: randomized phase 2 trial of 52 participants with liver-only metastases

> “To investigate the effects of immunoembolization with granulocyte–macrophage colony-stimulating factor (GM-CSF) in patients with uveal melanoma (UM) with liver-only metastasis.”
> “In this double-blind phase II clinical trial, patients were randomized to undergo immunoembolization or bland embolization (BE).”
> “Fifty-two patients (immunoembolization, n = 25; BE, n = 27) were enrolled.”
> “There were five partial responses in the immunoembolization group (ORR, 21.2%; 90% confidence interval [CI], 10.3%–30.5%) and three in the BE group (ORR, 16.7%; 90% CI, 6.3%–26.9%).”
> “OS times were 21.5 months (95% CI, 18.5–24.8 mo) with immunoembolization and 17.2 months (95% CI, 11.9–22.4 mo) with BE.”

Source: [Valsecchi et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4417549/)

<a id="topic-2.2.2.1.3-17"></a>

###### Yttrium-90 radioembolization: prospective phase 2 trial

> “In a prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastases, treatment-naïve participants (n = 24) achieved median overall survival of 18.5 months with a 1-year survival of approximately 61%.”
> “Participants treated with radioembolization in whom prior immunoembolization treatment failed (n = 23) achieved median overall survival of 19.2 months with a 1-year survival of approximately 70%.”

Source: [Gonsalves et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6776232/)

<a id="topic-2.2.2.1.3-18"></a>

###### Survival with liver-directed treatment in an individual-patient meta-analysis of 29 trials

> “Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016.”
> “Patients treated with liver directed treatments had statistically significant longer PFS and OS.”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.2.1.3-19"></a>

###### Pooled overall survival by treatment modality compared with conventional chemotherapy

> “Pooled OS reported after isolated hepatic perfusion [median OS: 1.34 years; hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.87–0.97, P = 0.0040], immunoembolization (median OS: 1.63; HR: 0.97, 95% CI: 0.95–1.00, P = 0.0080), and surgery (median OS: 1.43; HR: 0.94, 95% CI: 0.92–0.96, P < 0.0001) was longer, and after checkpoint inhibitor shorter (median OS: 0.59; HR: 1.13, 95% CI: 1.06–1.20, P < 0.0001) than after CHT (median OS: 0.91 years), but subject to identifiable confounding factors.”

Source: [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)

<a id="topic-2.2.2.1.3-20"></a>

###### Systematic review of liver-directed therapy: 55 studies of 2446 participants

> “55 studies were included in the study, with 2446 patients treated overall.”
> “Both surgery and liver-directed treatments were shown to have benefit in selected patients.”
> “Substantial variability in patient selection and study design makes comparison of data and formulation of recommendations challenging.”

Source: [Rowcroft et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31791894/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.4-1"></a>

###### Guideline summary of chemotherapy in metastatic uveal melanoma

> “Response rates are low (<10%) regardless of the cytotoxic agent tested and whether it was used as monotherapy or in combination.”
> “Drugs evaluated in this setting include dacarbazine, temozolomide, treosulfan, cisplatin and fotemustine”
> “with no demonstrated OS benefit over best supportive care.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.4-2"></a>

###### Pooled response to systemic treatment across 40 studies of 841 evaluable participants

> “Complete or partial remissions were observed in 39/841 patients (overall response rate [ORR] 4.6%; 95% confidence intervals [CI] 3.3–6.3%), no responses were observed in 22/40 studies.”
> “MUM is frequently treated with chemotherapeutics like dacarbazine, fotemustine, or gemcitabine/treosulfan although evidence for these regimens is limited.”

Source: [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/)

<a id="topic-2.2.2.1.4-3"></a>

###### Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib

> “Randomized open-label phase II clinical trial comparing selumetinib versus chemotherapy.”
> “101 patients were randomized on a 1:1 ratio to selumetinib 75 mg orally twice daily on a continual basis (n=50) or chemotherapy (temozolomide 150 mg/m2 orally daily for 5 of every 28 days or DTIC 1000 mg/m2 intravenously every 21 days; investigator choice; n=51) until disease progression, death, intolerable toxicity, or withdrawal of consent.”
> “Median progression-free survival for those randomized to chemotherapy and selumetinib was 7 (95% CI, 4.3 – 8.4; median treatment duration of 8 weeks (IQR, 4.3–16)) and 15.9 weeks (95% CI, 8.4 – 21.1; median treatment duration of 16.1 weeks (IQR, 8.1–25.3)), respectively (hazard ratio 0.46; 95% CI, 0.30 – 0.71; p < 0.001).”
> “Median overall survival was 9.1 (95% CI, 6.1 – 11.1) and 11.8 months (95% CI, 9.8 – 15.7) for those randomized to chemotherapy and selumetinib, respectively (hazard ratio 0.66; 95% CI, 0.41–1.06; p=0.09).”
> “No objective responses were observed with chemotherapy.”

Source: [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/)

<a id="topic-2.2.2.1.4-4"></a>

###### Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial

> “Alliance for Clinical Trials in Oncology A091201, a randomized phase II trial of the multiple TKI cabozantinib that also inhibits MET and VEGFR2 compared with temozolomide (TMZ) or dacarbazine (DTIC) in patients with metastatic UM.”
> “Patients with metastatic UM and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles.”
> “Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (p=0.35), respectively, with median PFS time of 60 and 59 days (p=0.964; HR=0.99).”
> “Median overall survival was 6.4 months and 7.3 months (p=0.580; HR=1.21), respectively.”
> “Grade 3–4 CTCAE adverse events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2 and 2X, respectively.”
> “MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic UM.”

Source: [Luke et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7055933/)

<a id="topic-2.2.2.1.4-5"></a>

###### Objective response with placebo plus dacarbazine compared with selumetinib plus dacarbazine

> “The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36).”

Source: [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/)

<a id="topic-2.2.2.1.4-6"></a>

###### Intravenous versus hepatic intra-arterial fotemustine: randomized phase 3 EORTC 18021 trial

> “The prospective randomized phase III trial (EORTC 18021) thus aimed to compare the efficacy and safety of HIA versus IV fotemustine in UM patients with metastases in liver only.”
> “Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis.”
> “HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79–1.50, log-rank P = 0.59.”
> “However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002).”
> “An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%).”
> “The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths.”

Source: [Leyvraz et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4433517/)

<a id="topic-2.2.2.1.4-7"></a>

###### Temozolomide: phase 2 trial of 14 participants with liver metastases

> “we conducted a phase II clinical trial of temozolomide in patients with uveal melanoma metastatic to the liver.”
> “Fourteen patients were enrolled in the trial.”
> “No complete or partial responses were observed.”
> “We conclude that, like DTIC, temozolomide at the dose and schedule studied in this trial is not effective for the control of metastatic melanoma of uveal origin.”

Source: [Bedikian et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12777987/)

<a id="topic-2.2.2.1.4-8"></a>

###### Temozolomide plus bevacizumab: noncomparative phase 2 study of 36 participants

> “This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m 2 on days 1–7 and 15–21) in 36 patients with metastatic uveal melanoma (MUM).”
> “Median PFS and OS were 12 weeks and 10 months, respectively.”
> “In patients with MUM, a combination of bevacizumab plus temozolomide achieved a 6-month PFR of 23%.”

Source: [Piperno-Neumann et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786360/)

<a id="topic-2.2.2.1.4-9"></a>

###### Cisplatin, dacarbazine, and vinblastine as first-line treatment for unresectable metastases: phase 2 study

> “In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type.”
> “Partial responses were observed in five (20%) patients, stable disease in 12 (48%) patients; disease control rate was 68%.”
> “Median OS of all the patients was 13 months, median progression free survival was 5.5 months.”
> “Five (20%) patients experienced grade 3-4 toxicity.”

Source: [Schinzari et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29076951/)

<a id="topic-2.2.2.1.4-10"></a>

###### Chemotherapy in the control group of a randomized trial of isolated hepatic perfusion

> “In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP.”
> “These disappointing outcomes reflect generally poor responses to systemic chemotherapy, which shows minimal efficacy and delivers no detectable survival benefit.”

Source: [Olofsson Bagge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414734/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Targeted Therapies and Clinical Trial Enrollment

<a id="topic-2.2.2.1.5-1"></a>

###### Guideline recommendation of clinical trial enrollment for HLA-A∗02:01-negative patients

> “For HLA-A∗02:01-negative patients, in the absence of a standard of care and depending on local resources, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.5-2"></a>

###### Guideline statements on referral and access to clinical trials

> “Patients should be referred for the recommendation of first-line locoregional or systemic treatment and discussion of UM clinical trials.”
> “Metastatic disease remains an area of high unmet need and requires ambitious research collaborations.”
> “Patients should have access to experimental treatments, including precision diagnostics and medicine and early-phase clinical trials for solid tumours.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.5-3"></a>

###### Clinical trials as an option in metastatic and recurrent intraocular melanoma

> “No effective method of systemic treatment has been identified for patients with metastatic ocular melanoma. Clinical trials are an option for these patients.”
> “Eligible patients should consider participation in clinical trials whenever possible.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.2.1.5-4"></a>

###### MEK inhibitor selumetinib compared with chemotherapy: response, adverse events, and survival

> “49% of patients treated with selumetinib achieved tumor regression, with 14% achieving an objective radiographic response to therapy.”
> “Treatment-related adverse events were observed in 97% patients treated with selumetinib, with 37% requiring at least one dose reduction.”
> “In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed.”

Source: [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/)

<a id="topic-2.2.2.1.5-5"></a>

###### Selumetinib plus dacarbazine versus placebo plus dacarbazine: phase 3 SUMIT trial of 129 participants

> “The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial”
> “patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine.”
> “A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).”
> “In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32).”
> “In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.”

Source: [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/)

<a id="topic-2.2.2.1.5-6"></a>

###### Selumetinib with or without paclitaxel: randomized SelPac trial of 77 participants

> “Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.”
> “The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).”
> “ORR was 14% and 4% in the combination and monotherapy arms respectively.”
> “SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.”
> “No improvement in OS was observed, and the modest improvement in PFS is not practice changing.”

Source: [Sacco et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38547774/)

<a id="topic-2.2.2.1.5-7"></a>

###### Systematic review of MEK inhibitors in metastatic uveal melanoma

> “The overall response rate was available in five studies and ranged from 0 to 14% with an average of 2.5%.”
> “The median progression-free survival ranged from 3.1 weeks to 16 weeks.”
> “UM is little responsive to MEK inhibition, regardless of the inhibiting agent and combination partner.”
> “Our results do not support the use of MEK inhibitors in UM.”

Source: [Steeb et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30205280/)

<a id="topic-2.2.2.1.5-8"></a>

###### Protein kinase C inhibitor AEB071 monotherapy: phase 1 study of 153 participants

> “Patients with metastatic UM (n = 153) were treated with AEB071 in a phase I, single-arm study.”
> “Preliminary clinical activity was observed, with 3% of patients achieving a partial response and 50% with stable disease (median duration 15 weeks).”
> “In conclusion, the protein kinase C inhibitor AEB071 was well tolerated, and modest clinical activity was observed in metastatic UM.”

Source: [Piperno-Neumann et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32029634/)

<a id="topic-2.2.2.1.5-9"></a>

###### Sotrastaurin plus the MEK inhibitor binimetinib: phase 1b trial of 38 participants

> “We therefore conducted this phase Ib study of the combination of sotrastaurin and binimetinib in patients with metastatic uveal melanoma”
> “Thirty-eight patients were treated across six dose levels.”
> “No patient achieved a radiographic response per RECIST v1.1.”
> “Stable disease was observed in 60.5% of patients treated.”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10288853/)

<a id="topic-2.2.2.1.5-10"></a>

###### Sotrastaurin plus the PI3K-alpha inhibitor alpelisib: phase 1b study

> “we conducted a phase Ib study to assess the safety of combined sotrastaurin, a PKC inhibitor, and alpelisib, a PI3K inhibitor.”
> “Patients with metastatic uveal melanoma (n = 24) or GNAQ/11 mutant cutaneous melanoma (n = 1) were enrolled on escalating dose levels of sotrastaurin (100–400 mg BID) and alpelisib (200–350 mg QD).”
> “Treatment-related adverse events (AE) occurred in 86% (any grade) and 29% (Grade 3).”
> “No objective responses were observed, and median progression-free survival was 8 weeks (range, 3–51 weeks).”

Source: [Shoushtari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8583628/)

<a id="topic-2.2.2.1.5-11"></a>

###### Kinase inhibitors compared with chemotherapy across published studies

> “Immunotherapy with ipilimumab, antiangiogenetic approaches, and kinase inhibitors have not yet proven to be superior to chemotherapy.”

Source: [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Limitations of Current Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Summary: HLA restriction of tebentafusp and absence of approved therapy for HLA-A∗02:01-negative disease

Tebentafusp, the only FDA-approved systemic therapy for metastatic uveal melanoma, is approved by the FDA and the EMA as first-line systemic treatment for HLA-A∗02:01-positive patients, and only approximately 45% of individuals in the United States and Europe are HLA-A∗02:01-positive. HLA-A∗02:01-negative patients “continue to lack an established standard of care” and comprised 49% of individuals prescreened in the tebentafusp trial. There is no consensus on first-line systemic therapy for HLA-A∗02:01-negative patients; their current options are immune checkpoint inhibitors, “which are not specifically approved for mUM”, and participation in clinical trials, and the National Cancer Institute states that no effective method of systemic treatment has been identified for metastatic ocular melanoma. Within its eligible population, tebentafusp produced a 5-year overall survival rate of 16% versus 8% in the control group with an 11% overall response rate, almost all treated patients eventually progressed, and Piperno-Neumann et al. state that “a high unmet need remains”. Tebentafusp requires weekly intravenous administration with observation periods at initiation and inpatient monitoring for the first 3 to 4 infusions because of the risk of cytokine release syndrome, which occurred in 89% of tebentafusp-treated patients.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext); [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802); [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/); [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq); [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/); [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1); [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.6-2"></a>

###### Summary: response, survival, and toxicity with immune checkpoint inhibitors

With PD-1 inhibitors in uveal melanoma, the objective response rate is below 5%, median progression-free survival 3 months, and 1-year overall survival approximately 50%. A meta-analysis reported a pooled objective response rate of 9.2% (4.1% for anti-CTLA4, 7.1% for anti-PD(L)1, and 13.5% for anti-CTLA4 plus anti-PD1) and a median overall survival of 11.5 months; a second meta-analysis of 1414 patients reported response rates of 3.4% with single-agent and 12.4% with dual checkpoint inhibition and median overall survival of 9.8 and 16.3 months. In two phase 2 trials of nivolumab plus ipilimumab, objective response rates were 11% and 18% and median overall survival 12 and 19 months. Pham et al. conclude that checkpoint inhibitors have limited efficacy in metastatic uveal melanoma. Dual checkpoint inhibition adds toxicity: in the 64 participants with metastatic uveal melanoma in CheckMate 401, 64% had grade 3-4 treatment-related adverse events and 30% discontinued; grade 3-4 treatment-related adverse events occurred in 40% of patients in one phase 2 trial and severe treatment-related adverse events in 39.1% of patients in a German series; 34 of 89 patients in a retrospective study across 14 academic medical centers discontinued for toxicity; and treatment-related discontinuation was 23% with nivolumab plus ipilimumab versus 2%-5% with pembrolizumab, without a clear survival advantage for the combination.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/); [Yamada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10991441/); [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/); [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/); [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

<a id="topic-2.2.2.1.6-3"></a>

###### Summary: scope and risks of liver-directed therapy

Liver-directed therapy treats liver metastases alone: percutaneous hepatic perfusion “does not address extrahepatic disease”. Most patients have multifocal and small liver metastases, and around 10% are eligible for local therapy, with perioperative mortality and morbidity after surgery of approximately 2% and 14%. The FOCUS study of melphalan percutaneous hepatic perfusion enrolled patients with liver tumor involvement of up to 50% and excluded those with moderate or severe cirrhosis, portal hypertension, or NYHA II-IV status; grade 3 and 4 treatment-emergent adverse events occurred in 81.1% of patients, including thrombocytopenia in 54.7%, and 17.9% discontinued treatment because of them. In an earlier randomized trial, four deaths were attributed to melphalan percutaneous hepatic perfusion, and median overall survival did not differ significantly between arms (10.6 versus 10.0 months). Isolated hepatic perfusion is non-repeatable and carries higher morbidity and mortality, and in the SCANDIUM trial the primary endpoint was not met (24-month overall survival 46.5% versus 29.5%, P=0.12). Adding ipilimumab plus nivolumab to percutaneous hepatic perfusion raised grade 3-4 treatment-related adverse events from 41% to 82%.

Source: [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/); [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/); [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/); [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.6-4"></a>

###### Summary: outcomes with chemotherapy and earlier targeted therapies

Response rates to chemotherapy are below 10% regardless of the cytotoxic agent, with no demonstrated overall survival benefit over best supportive care. Across 40 studies, complete or partial remissions occurred in 39 of 841 patients (4.6%), with no responses in 22 of the 40 studies. In randomized trials, no objective responses were observed with temozolomide or dacarbazine and median overall survival was 9.1 months, the objective response rate with placebo plus dacarbazine was 0%, and median overall survival with temozolomide or dacarbazine was 7.3 months in another trial. In a literature review, systemic treatment was associated with response rates below 10%, median progression-free survival of 1.8-7.2 months, and median overall survival of 5.2-19.0 months, and pooled survival fell from 52% at 1 year to 25% at 2 years and 13% at 3 years. Among earlier targeted agents, selumetinib plus dacarbazine did not significantly improve progression-free survival over placebo plus dacarbazine, the response rate to MEK inhibitors averaged 2.5% (range 0 to 14%), and 3% of 153 participants achieved a partial response with the protein kinase C inhibitor AEB071. A standard of care has not been defined despite numerous phase 2 studies.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/); [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/); [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/); [Luke et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7055933/); [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/); [Steeb et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30205280/); [Piperno-Neumann et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32029634/); [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.2.1.6-5"></a>

###### Response and survival with systemic treatment: guideline summary of a literature review

> “According to findings from a literature review, systemic treatment of metastatic UM was associated with low response rates (<10%), low median PFS (1.8-7.2 months) and OS (5.2-19.0 months).”
> “Few prospective studies have been published on this rare cancer, especially randomised controlled trials.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-6"></a>

###### No consensus on first-line systemic therapy for HLA-A∗02:01-negative disease

> “There is no consensus on first-line systemic therapy in HLA-A∗02:01-negative patients with metastatic UM.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-7"></a>

###### Unmet need and treatment options for HLA-A∗02:01-negative patients after the five-year tebentafusp analysis

> “Before tebentafusp, mUM lacked specifically approved therapies. Even with the progress reported in this study, a high unmet need remains.”
> “For these patients, current treatment options include immune checkpoint inhibitors, which are not specifically approved for mUM, and participation in clinical trials.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.6-8"></a>

###### Proportion of patients eligible for tebentafusp by HLA-A∗02:01 status

> “However, only ~45% of individuals in the United States and Europe are HLA-A*02:01–positive, making only a subset of patients potentially eligible for this treatment.”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.6-9"></a>

###### No defined standard of care after numerous phase 2 studies

> “Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM).”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.2.1.6-10"></a>

###### Decline in pooled overall survival from 1 to 3 years across treatment modalities

> “The median OS was 1.07 years (95% CI: 1.00–1.13), but the survival rate decreased rapidly from 52% (95% CI: 50–54) at 1 year to 25% (95% CI: 23–26) at 2 years, and 13% (95% CI: 12–15) at 3 years (Table 1 ).”

Source: [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)

<a id="topic-2.2.2.1.6-11"></a>

###### Limited efficacy of immune checkpoint inhibitors in meta-analysis

> “ICIs have limited efficacy in mUM and a recommendation for their use must consider the balance of benefit and risk for individual patients if no other options are available.”

Source: [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/)

<a id="topic-2.2.2.1.6-12"></a>

###### Pooled response and survival with immune checkpoint inhibitors in 1414 participants

> “A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included.”
> “Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8–5.1]; dual-agent: 12.4% [95% CI 8.0–16.9]; P < 0.001), DCR (single-agent: 29.3%, [95% CI 23.4–35.2]; dual-agent: 44.3% [95% CI 31.7–56.8]; P = 0.03), and OS (single-agent: 9.8 months [95% CI 8.0–12.2]; dual-agent: 16.3 months [95% CI 13.5–19.7]; P < 0.001).”

Source: [Yamada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10991441/)

<a id="topic-2.2.2.1.6-13"></a>

###### Toxicity of nivolumab plus ipilimumab in the uveal melanoma subgroup of CheckMate 401: guideline summary

> “In the subgroup of 64 patients with metastatic UM from CheckMate 401, ORR was 9% and median OS was 15 months; nivolumab–ipilimumab was associated with 64% grade 3-4 TRAEs, leading to discontinuation in 30% of patients.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-14"></a>

###### Grade 3 to 4 treatment-related adverse events with nivolumab plus ipilimumab

> “Forty percent of patients experienced a grade 3-4 treatment-related adverse event.”

Source: [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)

<a id="topic-2.2.2.1.6-15"></a>

###### Treatment discontinuation for toxicity with nivolumab plus ipilimumab

> “Overall, 82 (92%) of patients discontinued treatment, 34 due to toxicity and 27 due to progressive disease.”
> “Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM.”

Source: [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

<a id="topic-2.2.2.1.6-16"></a>

###### Severe treatment-related adverse events with combined checkpoint blockade

> “Regarding safety, 39.1% of treated patients experienced a severe, treatment-related adverse event according to the CTCAE criteria (grade 3: 37.5%; grade 4: 1.6%).”

Source: [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/)

<a id="topic-2.2.2.1.6-17"></a>

###### Liver-confined scope of percutaneous hepatic perfusion

> “Percutaneous hepatic perfusion can lead to meaningful hepatic tumour control in metastatic uveal melanoma, but its benefit is confined to liver metastases and does not address extrahepatic disease.”

Source: [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/)

<a id="topic-2.2.2.1.6-18"></a>

###### Procedural risks of hepatic perfusion: guideline statements

> “The expected benefit should be weighed against the risk of AEs (haematological complications mostly), but serious cardiovascular and thromboembolic complications may occasionally occur.”
> “The efficacy of IHP is similar to PHP, but IHP is non-repeatable and is associated with higher morbidity and mortality rates.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-19"></a>

###### Grade 3 to 4 adverse events and discontinuation with melphalan percutaneous hepatic perfusion, and morbidity of isolated hepatic perfusion

> “Grades 3 and 4 TEAEs were reported in 81.1 % of the patients including grade 3 or 4 thrombocytopenia (54.7 %), leukopenia (33.7 %), anemia (32.6 %), and neutropenia (29.5 %) (Table 3 ).”
> “Treatment was discontinued for 17.9 % of the patients due to TEAEs (Table 3 ).”
> “Although IHP treats the whole liver and has shown promising tumor response rates, its use is restricted by a high risk of morbidity and mortality due to its invasive nature.”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.6-20"></a>

###### Deaths attributed to melphalan percutaneous hepatic perfusion

> “Four deaths were attributed to PHP-Mel, three in the primary PHP-Mel group, and one post-crossover to PHP-Mel from BAC.”

Source: [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/)

<a id="topic-2.2.2.1.6-21"></a>

###### Overall survival primary endpoint not met with isolated hepatic perfusion

> “However, the primary endpoint of OS at 24 months was not met.”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.6-22"></a>

###### Eligibility for and morbidity of local treatment of liver metastases

> “Most patients with UMLMs have multifocal and small metastases.”
> “Around 10% of the patients are eligible for local therapy.”
> “Perioperative mortality and morbidity rates after surgery of UMLMs are ∼2% and ∼14%, respectively.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: target population

The FDA has agreed to review the new drug application for darovasertib in combination with crizotinib for patients with first-line HLA-A∗02:01-negative metastatic uveal melanoma under the Real-Time Oncology Review program, and the submission includes data from OptimUM-02 and OptimUM-01. OptimUM-02 enrolled adults 18 years and older with histologically or cytologically confirmed metastatic uveal melanoma that is HLA-A∗02:01 negative, no prior systemic therapy in the metastatic or advanced setting and no prior regional or liver-directed therapy (ablation or resection of oligometastatic disease and neoadjuvant or adjuvant therapy were allowed), measurable disease per RECIST 1.1, ECOG performance status 0 or 1, and a life expectancy of at least 3 months. Participants could be initially diagnosed with metastatic disease or have metastases after therapy for localized uveal melanoma. The trial excluded prior treatment with a PKC inhibitor or an inhibitor directly targeting MET, symptomatic or untreated CNS metastases, a high risk of syncope or falls, stroke within the last 6 months, and clinically significant cardiac disease. OptimUM-01 data, including the phase 2 expansion in 101 HLA-A∗02:01-positive participants, are intended to support discussions on expanding the labeled indication. Crizotinib is FDA approved for ALK- or ROS1-positive metastatic non-small cell lung cancer, ALK-positive anaplastic large cell lymphoma, and ALK-positive inflammatory myofibroblastic tumor. Identifying the population requires HLA-A∗02:01 typing, which a reference laboratory reports in 3 to 7 days; in a deidentified database of 219 patients, HLA-A∗02:01 status was negative in 42.9% and unknown in 15.1%.

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program); [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf); [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm); [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332); [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01); [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update); [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update); [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf); [Labcorp test 167107, HLA A A*02:01-Specific](https://www.labcorp.com/tests/167107/hla-a-a-02-01-specific); [Salama et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/contemporary-real-world-patient-characteristics-treatment-patterns-and-clinical-outcomes-in-metastatic-uveal-melanoma-in-the-united-states)

<a id="topic-2.2.2.2-2"></a>

###### Summary: position relative to current first-line therapy by HLA status and disease distribution

For HLA-A∗02:01-positive patients, tebentafusp is approved by the FDA and the EMA as first-line systemic treatment and is recommended as standard of care in the first-line metastatic setting unless liver-directed treatment is required first for tumour debulking. For HLA-A∗02:01-negative patients, in the absence of a standard of care, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies, and clinical trial enrolment are the preferred options; patients with extensive disease are encouraged to enter a clinical trial, with percutaneous hepatic perfusion or checkpoint inhibitors alone or in combination as alternatives, and local therapies are proposed for limited hepatic metastases. By disease distribution, oligometastatic disease confined to the liver can be considered for resection or thermal ablation, and multifocal metastases confined to the liver for regional perfusion.

Darovasertib plus crizotinib would enter first-line treatment of HLA-A∗02:01-negative disease. In 313 participants of the phase 2b/3 portion of OptimUM-02, the combination reduced the risk of progression by blinded independent central review by 58% (hazard ratio 0.42; 95% CI 0.30 to 0.59) compared with investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine, with median progression-free survival of 6.9 versus 3.1 months. Dr. Lutzky stated that tebentafusp remains the preferred first-line therapy for HLA-A∗02:01-positive disease, that darovasertib plus crizotinib may become an alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, and the same report states that darovasertib plus crizotinib “appears likely to become the preferred systemic first-line option”; percutaneous hepatic perfusion remains important for liver-dominant disease with preserved hepatic function. Faculty in an OncLive report did not support combining darovasertib plus crizotinib with tebentafusp upfront because of overlapping toxicity, or frontline dual checkpoint inhibition outside a clinical trial. The ESMO 2026 poster authors describe the combination as a potential “new oral standard of care” in this setting, and IDEAYA cites OptimUM-01 in support of its potential for patients irrespective of HLA-A∗02:01 status and line of therapy. The progression-free survival data may enable an accelerated approval filing, with overall survival from a prespecified interim analysis expected in mid-2027 to support full approval.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/); [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma); [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/); [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape); [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma); [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm); [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO); [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.2.2.2-3"></a>

###### Summary: anticipated use and care setting

The combination is taken orally: participants received darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, the recommended phase 2 dose, whereas the crizotinib label recommends 250 mg twice daily for NSCLC and lists 200 mg twice daily as its first dose reduction; crizotinib capsules are taken with or without food. The sponsor states that “A daily oral targeted regimen has the potential to improve compliance”. Tebentafusp, by comparison, requires weekly intravenous administration with observation at initiation, inpatient monitoring for the first 3 to 4 infusions in an experienced institution before subsequent infusions in a community clinic, and considerable pharmacy resources to prepare each dose.

Expert panelists noted that an oral regimen “removes the referral-forcing function that intravenous therapies create”, while the combination carries nausea, vomiting, diarrhea, and edema that low-volume community centers may not be able to manage; one panelist proposed a mandatory link to an expert center with community physicians managing maintenance. The short half-life of the combination typically makes brief holds and dose reductions, with dietary counseling, sufficient to keep patients on therapy, and the mean delivered dose intensity was 80% or more. Supportive measures for orthostatic hypotension during initial dosing include adequate hydration, initial withholding of blood pressure medications, and avoiding abrupt posture changes. The crizotinib label calls for liver function tests every 2 weeks during the first 2 months and then monthly, and ECG and electrolyte monitoring in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or QT-prolonging medications; OptimUM-02 excluded strong CYP3A4/5 inducers or inhibitors and narrow therapeutic index CYP3A4/5 substrates. A 2026 guideline recommends discussing therapeutic options at an oncology or molecular tumour board in reference centres with expertise in uveal melanoma, and a community oncology practice reports treating metastatic uveal melanoma in most of its clinic locations, a disease a general oncologist may see only once every several years. Darovasertib is currently available only through clinical trials; IDEAYA has initiated planning for potential commercial operations and expects a moderately sized specialty sales force to reach the relevant specialists, and Servier will be responsible for commercialization outside the U.S.

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf); [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf); [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf); [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802); [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1); [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape); [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01); [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma); [IDEAYA Biosciences clinical trials and expanded access policy](https://www.ideayabio.com/clinical-trials); [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.2.2.2-4"></a>

###### Darovasertib plus crizotinib in the targeted agents section of the guideline

> “An interim analysis of a phase II trial ( NCT03947385 ) evaluating darovasertib in combination with the mesenchymal-epithelial transition factor (c-MET) inhibitor crizotinib showed ORR of 31% in the first 35 assessable patients.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.2-5"></a>

###### Tebentafusp as the approved first-line systemic treatment for HLA-A∗02:01-positive disease

> “In 2021, tebentafusp demonstrated OS benefit in the HLA-A∗02:01-positive first-line population; 23 the first time a systemic treatment showed a survival benefit in metastatic UM.”
> “Tebentafusp has been approved by the FDA and the European Medicines Agency (EMA) as first-line systemic treatment in HLA-A∗02:01-positive patients with metastatic UM.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.2-6"></a>

###### Sequencing by HLA-A∗02:01 status in the French expert consensus guidelines

> “Systemic therapy with tebentafusp is the standard of care for HLA-A*02:01-positive patients.”
> “For HLA-A*02:01-negative patients with extensive disease, treatment options are limited.”
> “They are encouraged to participate in a clinical trial, alternatively, percutaneous hepatic perfusion, ICI alone or in combination can be proposed.”
> “Local therapies are proposed for patients with limited hepatic metastases, from liver surgery to isolated hepatic perfusion and chemoembolisation for patients with more extensive hepatic involvement.”

Source: [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/)

<a id="topic-2.2.2.2-7"></a>

###### Clinical trials for HLA-A∗02:01-negative patients and combination of tebentafusp with locoregional therapy in a 2026 review

> “The first-line treatment for HLA-A*02:01-positive MUM patients of tebentafusp can be combined with locoregional therapies upfront or in case of oligoprogression on tebentafusp following multidisciplinary tumor board (MTB) discussion.”
> “HLA-A*02:01-negative MUM patients should be offered participation in clinical trials.”
> “Innovative drugs, such as DYP688 or the combination of darovasertib and crizotinib, are promising.”

Source: [Piperno-Neumann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12962742/)

<a id="topic-2.2.2.2-8"></a>

###### Discussant view of first-line sequencing by HLA-A∗02:01 status after the OptimUM-02 presentation

> “For HLA-A*02:01–positive metastatic uveal melanoma, Dr. Lutzky said tebentafusp remains the preferred first-line therapy because of its proven survival benefit.”
> “However, he said darovasertib plus crizotinib may become an attractive alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, once available and as additional data emerge.”
> “Darovasertib plus crizotinib appears likely to become the preferred systemic first-line option.”
> “He added that liver-directed therapies remain important, particularly percutaneous hepatic perfusion for appropriate patients with liver-dominant disease and preserved hepatic function.”
> “Clinical trials also remain vital across HLA groups and lines of therapy, he said, because metastatic uveal melanoma is still not curable for most patients.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-2.2.2.2-9"></a>

###### Discussant statement that the question has shifted to sequencing

> “Nonetheless, the efficacy signal is sufficiently strong that I believe the burden of proof has now shifted away from demonstrating activity and toward defining optimal sequencing,”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-2.2.2.2-10"></a>

###### Expert workshop positions on darovasertib plus crizotinib, combination with tebentafusp, and first-line dual checkpoint inhibition

> “Results from OptimUM-02 established a meaningful ORR for darovasertib plus crizotinib in HLA-A*02:01–negative metastatic uveal melanoma.”
> “Faculty largely closed the door on combining darovasertib/crizotinib with tebentafusp upfront due to overlapping toxicity concerns.”
> “Faculty aligned on not using dual immune checkpoint inhibitor (ICI) therapy frontline outside a clinical trial and sequencing ICIs thoughtfully relative to liver-directed therapy and cell-based approaches.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.2-11"></a>

###### Oral administration, community management, and linkage to expert centers

> “Its oral route raises concerns about community misuse; proactive toxicity education and expert-center linkage are essential.”
> “However, the panelists warned that although an oral regimen removes the referral-forcing function that intravenous therapies create, the combination carries toxicities such as nausea, vomiting, diarrhea, and edema.”
> “These toxicities often require sophisticated management, which low-volume community centers may not be able to provide, Chmielowski said.”
> “To address this, Orloff proposed a mandatory link to an expert center with a prebuilt contingency plan, with community physicians managing maintenance.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.2-12"></a>

###### Daily oral regimen described by the sponsor

> “A daily oral targeted regimen has the potential to improve compliance, treatment outcomes and quality of life for UM patients”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.2.2.2-13"></a>

###### Weekly intravenous tebentafusp with observation at initiation, as contrasted by the OptimUM-01 investigators

> “Tebentafusp, the only (US) Food and Drug Administration (FDA)–approved systemic therapy, is restricted to a subset of human leukocyte antigen (HLA)-A*02:01–positive patients”
> “Additionally, this therapy requires weekly intravenous administration with observation periods at initiation.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-2.2.2.2-14"></a>

###### Inpatient and outpatient initiation of tebentafusp in practice

> “However, several faculty noted they still prefer inpatient monitoring for the initial doses, particularly in older patients with high disease burden.”
> “This is one of the last treatments with a mandatory observation requirement.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

> “Despite the lack of ICANS and low rate of grade 3 or 4 CRS, our practice has not yet begun to initiate tebentafusp patients in the outpatient setting like we have for all other BiTEs.”
> “However, to reduce barriers to access, we look forward to developing a model that will allow us to initiate newly identified patients on tebentafusp in an all-outpatient setting.”

Source: [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)

<a id="topic-2.2.2.2-15"></a>

###### Treatment in community oncology practice and clinical pathways for a rare disease

> “Whether through its collaboration with regional academic medical centers or by local diagnosis, NECS has treated patients with metastatic uveal melanoma in most of its clinic locations.”
> “Clinical pathways assist in appropriate patient treatment selection, especially for rare disease states that a general oncologist in the community setting may see only once every several years.”

Source: [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)

<a id="topic-2.2.2.2-16"></a>

###### Tumor board discussion in reference centers and access to expert centers

> “Therapeutic options should be discussed at an oncology or molecular tumour board (MTB) in reference centres with expertise in UM.”
> “The MTB should at minimum include ophthalmologists (optionally), pathologists, interventional radiologists, liver surgeons, radiation and medical oncologists.”
> “National networks and patient advocacy groups may help facilitate patient access to expert centres and organise local patient care.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.2-17"></a>

###### Sponsor and investigator positioning as a first-line standard for HLA-A∗02:01-negative disease

> “OptimUM-02 is the first randomized study to demonstrate a statistically significant and clinically meaningful benefit in PFS in the clinical setting of first-line HLA-A*02:01-negative metastatic uveal melanoma.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

> “Collectively, these findings further support the potential of with darova+criz as a new oral standard of care for patients with HLA-A*02:01-negative mUM in the first-line setting”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-2.2.2.2-18"></a>

###### Sponsor and investigator positioning across HLA-A∗02:01 status and lines of therapy

> “The randomized OptimUM-02 results demonstrate the potential for darovasertib plus crizotinib to establish a new first line standard for patients with HLA-A*02:01-negative disease, while the OptimUM-01 findings reinforce its potential to become a new standard of care for the broader population of patients irrespective of HLA-A*02:01 status and line of therapy.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

> “The OptimUM-01 update focused on the Phase 2 expansion results in 101 HLA-A*02:01-positive patients, including both treatment naïve and 2L patients who received prior tebentafusp.”
> “Collectively, the data support the broad potential of the darovasertib combination to drive meaningful clinical benefits for patients with mUM, irrespective of HLA-A*02:01 allele status or line of therapy.”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

Additional sources: [National Comprehensive Cancer Network Uveal Melanoma guideline](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### HLA-A∗02:01 status: confirmed response in first-line and any-line participants of OptimUM-01, August 2023

> “Clinical efficacy was observed in both human leukocyte antigen (HLA)-A2 positive (HLA-A2(+)) and HLA-A2 negative (HLA-A2(-)) patients.”
> “There were 50 all-line MUM patients with known HLA-A2 status among the 63 patients evaluable for efficacy, with 31 of these being HLA-A2(-) and 19 being HLA-A2(+).”
> “For HLA-A2(-) MUM patients, confirmed PRs were observed in 9 of 31 (29% overall response rate (ORR)) any-line and in 5 of 12 (42% ORR) first-line patients.”
> “For HLA-A2(+) MUM patients, confirmed PRs were also observed in 6 of 19 (32% ORR) any-line and in 3 of 5 (60% ORR) first-line patients.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-2.2.2.3-2"></a>

###### HLA-A∗02:01 status: sponsor summary of first-line activity in the pooled OptimUM-01 population

> “Strong Clinical Activity in First-line Patients Regardless of HLA-A*02:01 Status”
> “Darovasertib plus crizotinib demonstrated durable outcomes in a pooled first-line population that included both HLA-A*02:01-positive and HLA-A*02:01-negative patients (n=44)”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.2.2.3-3"></a>

###### Line of therapy and hepatic-only disease: OptimUM-01 per-protocol efficacy population, March 2023 data cutoff

> “In the PPEP, 30% had a confirmed partial response (cPR) with 92% of patients having tumor shrinkage.”
> “First-line (1L) pts (n=20) had a cPR of 45% with 95% of patients having tumor shrinkage.”
> “Median PFS (mPFS) in both PPEP and 1L pts was ∼7 months.”
> “In pts with hepatic only disease (n=20 pts, 1L and pretreated), an ORR of 35% and mPFS was 11 months.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-2.2.2.3-4"></a>

###### MET pathway activity and response to darovasertib monotherapy

> “These data also validate the company's translational research discovery that Phase 1 clinical response to darovasertib monotherapy associated with low cMETactivity, as measured by gene signature score.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="topic-2.2.2.3-5"></a>

###### GNAQ and GNA11 mutations as the shared target population of PKC inhibition

> “Uveal melanoma (UM) is a rare, aggressive form of ocular cancer in which approximately 95% of patients have activating mutations in GNAQ/11 GTPase proteins that drive downstream PKC signaling and tumor growth.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-2.2.2.3-6"></a>

###### Tebentafusp: overall survival in prespecified and exploratory subgroups with extended follow-up

> “Tebentafusp improved survival even in poor-prognosis groups, such as patients with baseline tumors ≥10 cm or those whose best RECISTv1.1 response was progressive disease, including cases where target tumor growth exceeded 20%.”
> “The treatment effect persisted across most prespecified subgroups with extended follow-up (Figure 2A).”
> “Additional exploratory subgroup analyses also showed a survival advantage associated with tebentafusp regardless of metastasis location (hepatic only or hepatic and extrahepatic) or baseline tumor burden, as measured by the sum of target lesion diameters (Figure 2B).”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-7"></a>

###### Tebentafusp: baseline factors associated with longer overall survival and with survival of at least 5 years

> “The baseline factors that were most associated with longer overall survival during treatment with tebentafusp included an ECOG performance-status score of 0, levels of LDH and alkaline phosphatase in the normal range, a largest metastatic lesion that was less than 8 cm in diameter, and a longer time since primary diagnosis (Table S5).”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

> “Accordingly, although tebentafusp-treated patients who survived at least 5 years included a mix of ages, genders, and tumor locations, all but one were ECOG 0 at baseline and typically presented with normal LDH and alkaline phosphatase levels as well as small metastatic lesions”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-8"></a>

###### Tebentafusp: disease volume and line of therapy as modifiers of benefit in expert discussion

> “Disease volume and line of therapy were identified as underrecognized modifiers of tebentafusp benefit, with faculty reporting better responses in frontline, lower-volume disease.”
> “This is consistent with trial data showing stronger responses in patients with liver lesions smaller than 3 cm and minimal benefit in heavily pretreated, high-volume settings.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.3-9"></a>

###### Tebentafusp: circulating tumor DNA reduction at week 9 and overall survival, 3-year analysis

> “In an exploratory analysis, 202 of the 252 patients in the tebentafusp group had baseline and week 9 serum samples that were obtained during treatment and were available for ctDNA analysis; 123 of the patients with a sample (61%) had at least one detectable uveal mutation at baseline.”
> “Likewise, patients who had clearance of ctDNA by week 9 had longer overall survival than those without clearance (median overall survival, 29.6 months vs. 10.2 months) (Fig. 3B).”
> “Overall survival among the 99 patients who had a reduction of at least 50% in the ctDNA level was longer than that among the 24 patients who had a reduction of less than 50%, no change, or an increase in the ctDNA level (hazard ratio for death, 0.41; 95% CI, 0.25 to 0.67) (Fig. 3C).”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.3-10"></a>

###### Tebentafusp: circulating tumor DNA reduction by best response and baseline tumor burden, 5-year analysis

> “Nearly half of evaluable patients with progressive disease (35 of 73 [48%]) experienced at least a 50% reduction in ctDNA levels, and 20 (27%) achieved complete ctDNA clearance (Table 1).”
> “A ctDNA reduction of 50% or greater occurred in 9 of 12 (75%) patients with baseline tumor size ≥8.1 cm, 43 of 53 (81%) with tumors of 3.1 to 8.0 cm, and 47 of 58 (81%) with tumors of ≤3.0 cm.”
> “Patients with undetectable baseline ctDNA had a median and estimated 5-year overall survival of 27.3 months (95% CI 24.1-34.3) and 27% (95% CI 17-38), similar to those who cleared ctDNA by week 9 [median 29.6 (95% CI 23-37) months and 19% (95% CI 9-33) at 5 years; Figure 3A and B].”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-11"></a>

###### Tebentafusp: BAP1 loss in the control group

> “Furthermore, in an exploratory analysis of a subset of patients with available tumor sequencing data, any loss of BAP1 was associated with a trend toward shorter overall survival in the control group compared to those with wild-type BAP1”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-12"></a>

###### Tebentafusp: early rash as a predictor of overall survival

> “rash within 1 week was not an independent predictor of overall survival”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

> “Although the development of early cutaneous toxicity has repeatedly been linked to better survival outcomes, this relationship does not appear to be independent of established prognostic variables.”

Source: [Koumprentziotis et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13664555/)

<a id="topic-2.2.2.3-13"></a>

###### Immune checkpoint inhibitors: MBD4-deficient hypermutated tumors

> “Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor.”
> “In our series of 42 metastatic UM patients treated with PD1inh, only one (UVM_IC) achieved a tumor response (details in Methods)”

Source: [Rodrigues et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951831/)

> “Among the 12 patients who received ICIs, nine received pembrolizumab, two ipilimumab plus nivolumab followed by nivolumab, and one pembrolizumab plus lenvatinib within the frame of the PLUME phase 2 trial (NCT05282901).”
> “The overall response rate was 50% (two complete, four partial) with a disease control rate of 83%.”
> “At 12 months, 73% of patients were progression free, and the estimated 2-year OS was 86%.”
> “Our findings support further evaluation of MBD4 mutation as a predictive biomarker and suggest that ICIs should be considered as a preferred first-line option in MBD4-mutated mUM.”

Source: [Honoré et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13641210/)

<a id="topic-2.2.2.3-14"></a>

###### Immune checkpoint inhibitors: low tumor mutational burden in GNAQ- or GNA11-mutant tumors

> “In addition, GNAQ/11 mutation patients are known to have low tumor mutational burden making these patients less likely to benefit from immune checkpoint inhibitor therapies.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

> “Lack of mutation burden and T cell infiltration, and MYC overexpression may be factors limiting therapeutic responses.”

Source: [Johnson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8063157/)

<a id="topic-2.2.2.3-15"></a>

###### Immune checkpoint inhibitors: liver metastasis volume and extrahepatic-only disease

> “Notably, the patients who benefited either had no liver metastases or small volume disease whereas rapidly progressing patients had bulky liver involvement.”

Source: [Johnson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8063157/)

> “(A) PFS for patients with extrahepatic-only sites of metastases versus liver metastases was 12.0 months versus 5.5 months (P = .0918).”
> “Twenty-seven evaluable patients had liver metastases, of whom five (19%) had a PR and three (11%) had stable disease for 6 months or longer.”

Source: [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)

> “Patients with extrahepatic metastases only and treated with ipilimumab-nivolumab combination seem to have a better prognostic, the expected survival was 3.2 times higher than with any other systemic treatment (HR 0.28, 95% CI: 0.11–0.69).”

Source: [Piperno-Neumann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12962742/)

<a id="topic-2.2.2.3-16"></a>

###### Immune checkpoint inhibitors: lactate dehydrogenase level and outcomes

> “Normal LDH was associated with improved OS (p=0.026)”
> “However, elevated LDH was not associated with significantly worse PFS.”

Source: [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

> “PFS was influenced by higher LDH values.”

Source: [Piulats et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33417511/)

<a id="topic-2.2.2.3-17"></a>

###### Lactate dehydrogenase and alkaline phosphatase as prognostic factors in the guideline

> “Elevated lactate dehydrogenase and alkaline phosphatase levels were the most significant prognostic factors for 6-month PFS and 1-year OS rates in a multivariate analysis.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Management of darovasertib plus crizotinib toxicities through dose holds, dose reductions, dietary counseling, and expert-center linkage

> “Meredith McKean, MD, MPH, the director of the Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute in Nashville, Tennessee, highlighted that the short half-life of darovasertib/crizotinib typically makes brief holds and dose reductions sufficient to keep patients on therapy when paired with dietary counseling.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.4-2"></a>

###### Crizotinib label: patient counseling on hepatotoxicity, bradycardia, and blood pressure medications

> “Inform patients to immediately report symptoms of hepatotoxicity [see Warnings and Precautions (5.1)].”
> “Advise patients to report any symptoms of bradycardia and to inform their healthcare provider about the use of any heart or blood pressure medications [see Warnings and Precautions (5.4)].”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.2.2.4-3"></a>

###### Crizotinib label: patient counseling on vision disorders, drug interactions, and photosensitivity

> “Inform patients of the potential risk of severe visual loss and to immediately contact their healthcare provider if they develop severe visual loss.”
> “Inform patients that visual changes such as perceived flashes of light, blurry vision, light sensitivity, and floaters are commonly reported adverse reactions and may occur while driving or operating machinery.”
> “Inform patients to avoid grapefruit or grapefruit juice while taking XALKORI.”
> “Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products [see Drug Interactions (7)].”
> “Advise patients to avoid prolonged sun exposure and to use sunscreen or protective clothing during treatment with XALKORI [see Adverse Reactions (6.1)].”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.2.2.4-4"></a>

###### Pharmacist-led interventions for oral anticancer therapy: systematic review and meta-analysis of 27 studies

> “A total of 27 studies evaluating pharmacist-led interventions in patients receiving oral anticancer therapy were identified through systematic searches, including randomized controlled trials, non-randomized controlled trials, and cohort studies.”
> “The study identified 11 pharmacist interventions distributed across four main domains, namely patient education and behavioral support, symptom and toxicity management, medication therapy management, and healthcare access support.”
> “The meta-analysis revealed that pharmacist interventions tend to improve medication adherence and treatment persistence.”
> “However, the impact on clinical endpoints and the incidence of drug-related problems remained heterogeneous.”

Source: [Liu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42152179/)

<a id="topic-2.2.2.4-5"></a>

###### Tebentafusp: expert recommendations on liver value monitoring and the two major toxicities

> “The safety profile of tebentafusp is manageable and includes two major pathologies: cytokine release syndrome (CRS) and skin-related events.”
> “The monitoring of liver values is crucial, as patients may experience an increase in transaminases, which can even manifest as tumour lysis syndrome.”

Source: [Hassel et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/37595494/)

<a id="topic-2.2.2.4-6"></a>

###### Tebentafusp: symptomatic management of cytokine release in a 2026 systematic review

> “Symptomatic management with antipyretics, glucocorticoids, and intravenous fluids is strongly recommended to mitigate these effects.”

Source: [Lanzafame et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984979/)

<a id="topic-2.2.2.4-7"></a>

###### Tebentafusp: structured adverse event monitoring in community oncology practice

> “In our practice, we utilize the EMR to embed drug-specific laboratory tests and AE monitoring guidance at appropriate time intervals in treatment order sets.”
> “This structured AE monitoring and management guidance is critical to ensuring that a patient safely remains on treatment and derives clinical benefit for as long as possible.”

Source: [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)

<a id="topic-2.2.2.4-8"></a>

###### Tebentafusp: management of skin reactions

> “Most cutaneous reactions are mild and can be effectively managed with emollients, topical corticosteroids, and antihistamines, while permanent discontinuation of therapy is uncommon.”

Source: [Koumprentziotis et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13664555/)

<a id="topic-2.2.2.4-9"></a>

###### Immune checkpoint inhibitors: management of immune-related adverse events by grade

> “The management of immune-related adverse events depends on their severity: in mild cases (grade 1), therapy can be continued with simple monitoring; in moderate cases (grade 2), therapy is temporarily suspended and oral corticosteroids are administered; in severe cases (grade 3 or 4), treatment is discontinued and high-dose corticosteroids are used, possibly with additional immunosuppressants such as infliximab for refractory colitis or mycophenolate for hepatitis.”

Source: [Lanzafame et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984979/)

<a id="topic-2.2.2.4-10"></a>

###### Response assessment with RECIST, tumor growth rate, and circulating tumor DNA

> “Treatment efficacy assessment includes response evaluation criteria in solid tumours (RECIST), tumour growth rate (TGR) analysis, and ctDNA dynamics.”

Source: [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/)

> “Faculty agreed on one clear use case for ctDNA: distinguishing true progression from the radiographic pseudoprogression and waxing-and-waning patterns characteristic of tebentafusp response.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.4-11"></a>

###### Early palliative and supportive care in the guideline

> “Early integration of palliative care is internationally recommended to facilitate the transition from curative to palliative care and to individualise the intensity of care for patients with cancer.”
> “It may include psychological support, nutrition and palliative care support.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.4-12"></a>

###### Surveillance for metastasis after treatment of the primary tumor at reference centers

> “Prognostication and surveillance should be led by a specialist MTB with UM expertise in ophthalmology, liver imaging, surgery, medical oncology and supportive care.”
> “Surveillance strategies should be managed at reference centres [III, A].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.4-13"></a>

###### Risk-based surveillance imaging after treatment of the primary tumor: North American Delphi consensus

> “Intermediate-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for 5 years, thereafter annually for at least 10 years from diagnosis.”
> “High-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for years 1–5 and every 6–12 months for years 6–10.”
> “In high-risk patients, the use of contrast-enhanced MRI abdomen is preferred over CT abdomen for surveillance of metastatic uveal melanoma.”
> “Although there was agreement that low-risk patients warrant surveillance, no consensus was reached on the optimal approach for this group.”

Source: [Alban et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784650/)

<a id="topic-2.2.2.4-14"></a>

###### Patient education and patient organizations

> “Patient education should be evidence-based, verifiable and accessible to enable patients to seek the right information to improve communication with their health care team.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Darovasertib plus crizotinib: response, duration of response, and overall survival trend in the OptimUM-02 topline results

> “The overall response rate (ORR) by BICR in the darovasertib combination and ICT arm was 37.1% and 5.8% (p-value: <0.0001), respectively.”
> “There were 5 complete responses by BICR observed in the darovasertib combination arm, and no complete responses observed in the ICT arm.”
> “The median duration of response (DOR) in the darovasertib combination arm was 6.8 months.”
> “However, in the OptimUM-02 study, there is an early trend in improvement in OS with the darovasertib combination arm versus the ICT arm.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-2.2.2.7-2"></a>

###### Darovasertib plus crizotinib: progressive disease as best response and discussant assessment against checkpoint inhibitor outcomes

> “Progressive disease as best response occurred in 6.2% of patients who received darovasertib plus crizotinib vs 28.2% of those assigned to investigator’s choice.”
> “In a disease where checkpoint inhibitors typically achieve response rates in the low teens and short progression-free survivals, these results clearly stand out,”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-2.2.2.7-3"></a>

###### Historical response, progression-free survival, and overall survival benchmarks cited by the sponsor

> “Based on data from large meta-analyses published by Khoja and Rantala it has been shown that mUM has an especially poor prognosis, with a reported median PFS of 2.8 months and median OS of ~12 months in the treatment-naïve setting.”
> “In the 2L setting, median PFS remains at ~2-3 months but median OS drops to ~8 months with a 1-year OS rate of ~37%.”
> “As shown in the table above the data from OptimUM-01 compares favorably to these historical PFS and OS benchmarks, as well as to historical ORR which is typically ~5%.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

> “Historical mOS of 10-12 months”
> “Median PFS and OS compared favorably to historical meta-analyses in first-line mUM”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.2.2.7-4"></a>

###### Historical 5-year survival in metastatic uveal melanoma

> “Metastatic uveal melanoma (mUM) carries a poor prognosis, with only an estimated 2% of patients historically surviving 5 years.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.7-5"></a>

###### Tebentafusp: median overall survival in the primary analysis and 5-year survival in HLA-A∗02:01-positive disease

> “The median OS was 21.7 months with tebentafusp versus 16.9 months with investigator’s choice.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Five-year overall survival (OS) data from the pivotal phase 3 IMCgp100-202 trial (NCT03070392), presented at the 2026 AACR Annual Meeting, demonstrated an OS rate of 16% with tebentafusp (n = 252) vs 8% with investigator's choice of therapy (n = 126) in patients with previously untreated HLA-A*02:01–positive metastatic uveal melanoma.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.7-6"></a>

###### Expert expectation of real-world overall survival with tebentafusp-based treatment

> “Real-world use of tebentafusp as a backbone with layered liver-directed therapy likely produces outcomes exceeding registrational data.”
> “The comparator bar was viewed as low, deep responses are uncommon, and the OS curves converge over time.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
